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ABSTRACT 
 
Androgen endocrine physiology is responsible for many processes in the body, 
from bone metabolism to skeletal muscle maintenance. Testosterone is one of the 
most potent androgens produced, with decades of research highlighting its 
androgenic-anabolic effect on skeletal muscle growth. The research has been 
further driven through the emergence of pharmaceutical derivates (steroids) of 
testosterone and their use in interventions for muscle wasting associated with 
disease and advancing age (sarcopenia). However, the molecular regulation of 
testosterone and the influence it has on cellular processes in promoting muscle 
development, hypertrophy and satellite cell activation (proliferation, 
differentiation) remain poorly understood.  
  In summary, this thesis has highlighted the impact of testosterone in 
rescuing an aged phenotype in myoblast cells (PD cells) displaying prior 
reductions in regeneration and hypertrophy vs. relevant ‘un-aged’ controls 
(Sharples et al., 2011, Sharples et al., 2012). Importantly, the results provide 
evidence towards the mechanisms for testosterone induced hypertrophy, where in 
the presence of testosterone and a functional androgen receptor (shown via AR 
antagonism/ flutamide administration) testosterone is fundamental in regulating 
appropriate myoD, myogenin and myostatin expression in the control of myotube 
differentiation and hypertrophy. Increases in androgen receptor protein levels in 
PD myoblasts under a testosterone stimulus highlight the intrinsic responsiveness 
of aged myoblasts to a hypertrophic stimulus which may somewhat explain the 
use of testosterone as an effective clinical treatment in muscle wasting disease. 
Finally, myotube hypertrophy occurred in both aged and un-aged myoblasts with 
testosterone administration even in the presence of an IGF-I receptor inhibitor 
(Picropodophyllin) suggesting a limited role of the IGF-IR and associated 
signaling in testosterones mediated increases in differentiation and hypertrophy.  
 Testosterone did appear however to increase Akt phosphorylation in cells 
that show a prior impaired regenerative capacity (PD cells), even in the presence-
IGF-IR inhibitor suggesting that testosterone can directly activate Akt 
independently of upstream IGF-IR a novel finding that is presented in chapter 5.  
This interaction maybe mediated by myostatin, where increases in myostatin has 
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been linked with directly inhibiting Akt (Dubois et al., 2014, Léger et al., 2008, 
Morissette et al., 2009), and in the present study we see an increase in myostatin 
mRNA and corresponding decrease in phospho-Akt when AR’s (via flutamide) 
action is inhibited and the protein level of AR is low (chapter 5). Furthermore in 
chapter 6 we further showed that inhibition of PI3K/AKT using LY294002 was 
sufficient to remove the prior rescuing of differentiation and hypertrophy in aged 
cells after testosterone administration. This was coupled with reductions in 
myostatin and increases in mTOR with testosterone administration. Overall AR 
seems to be the most fundamental pathway in testosterones induction of myotube 
differentiation and hypertrophy with important roles for myogenin, Akt, mTOR 
and myostatin in mediating these processes.  
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TNF-α Tumor necrosis factor-alpha 
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1. GENERAL INTRODUCTION 
Testosterone (17β-Hydroxyandrost-4-en-3-one: C19H2802) is a potent naturally 
occurring steroid hormone (androgen) produced from cholesterol. Within the 
body, testosterone (T) is responsible for regulating many physiological processes 
such as muscle maintenance, sexual and cognitive function, plasma lipids and 
bone metabolism (Bhasin et al., 1996, Evans, 2004). For decades, testosterone has 
been researched from the perspective of these physiological processes, with 
muscle growth, development and maintenance receiving predominant attention. 
Furthermore, such attention to muscle growth has been highlighted through the 
emergence of chemical and pharmaceutical derivates of T called Androgenic-
Anabolic Steroids (AAS) (Evans, 2004, Hartgens and Kuipers, 2004). The 
molecular regulation of T and its pharmaceutical derivatives remain poorly 
understood. Recent research however, has begun to delve into these mechanisms 
alongside the emergence of new cellular and molecular technologies.  
The aging process correlates with a gradual decline in the production of 
testosterone and a subsequent reduction in serum T levels (Dillon et al., 2010). In 
healthy young men, serum T levels range from 400-1000 ng/dl (Sinha-Hikim et 
al., 2003, Traish et al., 2011) whereas for elderly men, serum testosterone levels 
range from 150-550 ng/dl (Wierman, 2007). Any serum T levels below this range 
for elderly men are defined as hypogonadism (Dillon et al., 2010). Declining 
serum levels highlight the effects that T may have on peripheral tissues where 
sarcopenia and osteoporosis have been previously associated with the reduced 
levels (Dillon et al., 2010, Sattler et al., 2011). Testosterone administration has 
been utilised as a treatment for such conditions, and more importantly the 
development of T derivatives and selective androgen receptor modulators 
(SARMs) has provided a more specific target of action within the treatment of 
tissues (Dillon et al., 2010, Ting and Chang, 2008). However, due to its clinical 
importance it is fundamentally important to first understand the mechanisms and 
signalling pathways that T and androgens activate, to reduce the risk of cross talk 
with other signalling pathways and thus potential side effects that could be 
incurred with such pharmaceutical treatments (discussed below).  
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1.1 TESTOSTERONE PRODUCTION IN-VIVO 
 
Testosterone is produced predominately in the leydig cells located in the testes 
of males, with a small amount being additionally secreted from the adrenal cortex 
and ovaries in females. The nature of the hormone prevents it from being stored in 
the cells that produce it and thus on production it is immediately released from the 
cells. The signalling for the production of T within the gonads is through the 
hypothalamic-pituitary-gonadal-axis (Fig 1.1.) (Kim, 2007, Vingren et al., 2010). 
The signal originates in the hypothalamus by innervations of the Central Nervous 
System (CNS) which leads to specialized neurons secreting gonadotropin-
releasing hormone (GnRH). GnRH is then transported from the hypothalamus to 
the anterior pituitary gland and subsequently to the pituitary target cells, via the 
hypothalamic-hypophysical portal vein. At this location, GnRH activates the 
production and release of lutenizing hormone (LH) and follicle-stimulating 
hormone (FSH) from the gonadotropes, with both hormones consequently 
circulating to the gonads (Fig1.1).  
Lutenizing hormone is responsible for testosterone production in the leydig 
cells in men and in the theca calls of women. This production is brought about by 
LH binding to a G-protein coupled membrane receptor (Miller, 1988, Payne and 
Hales, 2004). Furthermore, the binding process initiates a rate-limiting step in 
testosterone production by way of cyclic adenosine monophosphate dependant 
protein kinase (protein kinase A) stimulation (Miller, 1988, Payne and Hales, 
2004). On the other hand, in terms of variations between men and women, FSH 
appears to have no direct effect on testosterone stimulation in men but stimulates 
production of pregnenolone in women. Pregnenolone is further processed into 
testosterone upon leaving the granuolsa cells. Another role of FSH, which appears 
in both men and women, is the stimulation of steroid binding proteins in the liver. 
These proteins (primary being sex-hormone binding globulin) are especially 
important for the T produced to be circulated within the body, due to 
testosterone’s hydrophobic nature and thus  not being readily dissolved in the 
systemic circulation (Vingren et al., 2010). Although this cascade of signalling 
events is the predominant source for T and androgen production, about 30 to 50% 
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of androgens are further produced in peripheral tissues (Labrie, 1991, Labrie, 
2010). 
 
 
Fig 1.1. Testosterone is produced through the signalling events of the Hypothalamus-pituitary-
gondal axis (A) and alternatively synthesised in target tissues via androgen metabolism (B). E, 
estrogen; P, progesterone; T, testosterone; E2, estradiol; AR, androgen receptor; DHEA, 
dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate. Adapted from (Vandenput 
and Ohlsson, 2010); (Wierman, 2007).  
 
1.1.2 Peripheral Tissue Expression  
 
Androgen production in peripheral tissue, such as bone and skeletal muscle, is 
synthesized locally from the sex steroid precursor’s dehydroepiandrosterone 
(DHEA) and DHEA sulphate (Fig 1.1) (Sato et al., 2008, Vandenput and Ohlsson, 
2010). The transformation of both steroid precursors involves steroidogenic 
enzymes to produce T and various other androgens (Fig 1.1). Of these 
steroidgenic enzymes, 5-α reductase is critical in converting T to 
dihydrotestosterone (DHT) (Labrie, 2010, Vandenput and Ohlsson, 2010). In both 
male and female rats, a single bout of exercise has been show to increase all of 
these metabolites and enzymes (DHEA, DHEAS, T, DHT and 5-α reductase type 
1 isoenzyme) and thus the activation of local bioactive androgen metabolism 
(Aizawa et al., 2010). Ultimately, the conversion creates a more potent androgen 
in DHT and is more readily available within the tissue compared to testosterone 
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(Bennett et al., 2010). A characteristic for DHT being more potent is the higher 
binding affinity to the androgen receptor within the cells (Bennett et al., 2010). 
Although within skeletal muscle, DHT levels are considerably low compared to T 
due to the low levels of 5-α reductase (Chen et al., 2005). Furthermore, it has 
recently been shown that the conversion of T to DHT is not a requisite for T to 
exert its anabolic effect, as suppressed levels of DHT still brought about changes 
in skeletal muscle strength with T administration (Bhasin et al., 2012).   
In bone tissue, bio-available testosterone is converted to estradiol through 
aromatization (Fig 1.1), with estradiol being observed to be important for 
regulation of bone loss and bone metabolism (Gennari et al., 2003, Khosla et al., 
2005, Vandenput and Ohlsson, 2010). Therefore, a reduced level with increasing 
age or even a testosterone/estradiol deficiency within individuals has been 
associated with rapid bone loss, in turn impacting on bone mineral content and 
density, leading to a more prevalent incidence of osteoporosis in elderly men and 
women (Fink et al., 2006). Estradiol has repeatedly been associated as the main 
predictor of bone morphology, with T frequently showing no association in bone 
structural parameters. Testosterones role within bone remodeling is believed to be 
primarily centered on its availability for conversion to estradiol (Ward et al., 
2011). Although, a recent study by Ward et al. (2011) suggests that bio-available 
T may influence bone health through its effect on skeletal muscle mass reducing 
mechanical load inducing bone remodeling. For a more detailed review on sex 
steroid metabolism and influences on bone, refer to Vandenput and Ohlsson 
(2010) or Callewaert, Boonen and Vanderschueren (2010).  
 
1.2 TESTOSTERONE AND SKELETAL MUSCLE 
 
Testosterone is thought to elicit an anabolic effect on skeletal muscle via 
increases in protein synthesis and decreases in protein degradation (Ahtiainen et 
al., 2011, Brodsky et al., 1996, Sheffield-Moore et al., 1999). These adaptations 
culminate in a hypertrophic (increased size via increased protein synthesis) 
response occurring in skeletal muscle. Indeed, a dose dependant increase in the 
size of skeletal muscle, shown by increases in cross sectional area (CSA), is 
observed following administration of testosterone enanthate at doses of 25-600 
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mg (Bhasin et al., 1996, Bhasin et al., 2001, Sinha-Hikim et al., 2002). Another 
form of growth within skeletal muscle, besides hypertrophy, is muscle cell 
hyperplasia. Skeletal muscle fibre number is set at gestation (in-utero) due to 
mature fibres that are unable to divide (i.e. terminally differentiated or post 
mitotic). Skeletal muscle’s change in size occurs as a result of a specialised cell 
type (the satellite cell) that resides underneath the basal lamina. These cells can 
undergo hyperplasia (cell division/ mitosis) and fuse to the existing fibres to 
increase size or repair damage from trauma, injury or exercise. Testosterone has 
been shown to increase satellite cell number and increase activation and fusion of 
these cells indicated by an increase in myonuclear incorporation in skeletal 
muscle in-vivo following testosterone administration (100-600 mg) (Chen et al., 
2005, Kadi and Thornell, 2000). The analysis of skeletal muscle morphology in 
power lifters demonstrates significant positive correlations between the number of 
myonuclei per area and fibre area size (Eriksson et al., 2005). Indeed, with the use 
of androgenic-anabolic steroids, muscle hypertrophy adaptations in power lifters 
are amplified compared to non-users (Eriksson et al., 2005). Despite these 
intriguing physiological observations, the molecular mechanisms by which 
testosterone initiates anabolic processes for a hypertrophic response remain poorly 
understood.  
To investigate androgen signalling, various experimental approaches have 
been utilized. Commonly, the administration of exogenous T (Ferrando et al., 
2002) is implemented, employed in either an in vivo or in vitro model. 
Alternatively the suppression of endogenous testosterone within in vivo models, 
via injections (goserelin), are performed (Kvorning et al., 2007). Other molecular 
techniques have enabled research to gain an insight into T’s mechanisms using 
androgen receptor antagonists (Inoue et al., 1994, Masiello et al., 2002) and 
transgenic or knock out animal models (MacLean et al., 2008, Ophoff et al., 
2009). Another approach within in vivo studies is the elevation in endogenous 
serum T levels (up to 38 nmol.L
-1 
(1100 ng/dl)) through resistance training 
(Spiering et al., 2009). This response is commonly elicited through a high volume 
and high intensity program (Spiering et al., 2009, Vingren et al., 2010). Although, 
recent evidence would suggest post-exercise elevations in T have no causal effect 
on muscle hypertrophy and myofibrillar protein synthesis rates, likely due to 
exercise inducing only small and transient increases in free testosterone compared 
to pharmacological administration (West et al., 2009, West et al., 2010, West and 
Phillips, 2010, Wilkinson et al., 2006). The use of human muscle biopsies can be 
taken pre and post resistance training to enhance our understanding of molecular 
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events associated with this specific stimulus and the role of T. However, due to 
ethical considerations, assessing the role of T in the activation of satellite cells is 
difficult with the processing and sampling of biopsies, as such this particular 
approach has been relatively unavailable in human studies. Therefore, animal and 
in vitro models currently allow for the most in depth investigation of the 
molecular targets involved in androgen signalling, with the identification of 
potential target pathways to be triggered through a T stimulus. Below are some of 
the mechanisms indicated by these models.  
T(Brodsky et al., 1996, Ferrando et al., 1998, 2002, Smith et al., 2013, Urban 
et al., 1995)et al.et al.Tet al.(Ferrando et al., 2002)(Vingren et al., 2010)(Kraemer 
and Ratamess, 2005, McCall et al., 1999, McCaulley et al., 2009, Rønnestad et 
al., 2011)(Mitchell et al., 2013, West et al., 2009, 2010, Wilkinson et al., 
2006)(Wilkinson et al., 2006)et al(2012)(2012)(Atkinson et al., 2010, Ferrando et 
al., 2002)(Bhasin et al., 2001, Basaria et al., 2010, Fernandez-Balsells et al., 
2010)(Basaria et al., 2010)(Bhasin et al., 2001)(Atkinson et al., 2010, Bhasin et 
al., 2001, Sinha-Hikim et al., 2002) 
1.3 DIRECT PATHWAY (TESTOSTERONE-AR COMPLEX) 
 
Androgens interact with muscle tissue via the androgen receptor (AR), a 
member of the steroid receptor superfamily and nuclear transcription factors 
(Chen et al., 2005, Kadi, 2008). The AR is detectable within hormone-sensitive 
cells e.g. bone and muscle cells (Gentile et al., 2010). Within target cells, un-
ligand bound AR is located in the cytoplasmic compartment of the cell, in the 
form of a multi-complex protein consisting of heat shock proteins and 
immunophilins (Fig 1.2.) (Bennett et al., 2010, Gobinet et al., 2002). Once 
testosterone is bound to AR, a conformational change occurs leading to AR 
dissociating from its multi-protein complex and recruiting co-activators such as 
importin-α, androgen receptor-associated protein-70 (ARA70) and filamin-α, 
enabling the ligand-bound AR to translocate to the nucleus (Figure 2.) (Bennett et 
al., 2010, Wannenes et al., 2008). In the nucleus, AR acts as a transcription factor 
and thus interacts with androgen responsive elements (ARE) within the genome 
(Ahtiainen et al., 2011) e.g. specific target genes such as insulin-like growth 
factor I, MyoD, myosin heavy chains (Gentile et al., 2010). As these specific gene 
targets described above have fundamental functions in muscle cell proliferation, 
differentiation, maturation, and survival. The activation of the AR has been 
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proposed to mediate fundamental processes in  skeletal muscle cells (Bennett et 
al., 2010).  
 
 
Fig 1.2. Overview of the human androgen receptor gene, protein and the conformational 
change once bound to an androgen. The gene consists of 8 exons which code for a functional 
protein (approx. 920 amino acids) with four domains. Exon 1 encodes for the N-terminal 
transactivation domain (NTD); Exon 2-3 encodes the DNA-binding domain (DBD); Exon 4 
encodes the small hinge region, finally exons 5-8 encode for the C-terminal ligand-binding domain 
(LBD). The LBD represent the domain where androgens bind to the receptor protein, resulting in 
the release of heat shock proteins (HSP) and immunophilins plus the recruitment of co-activators, 
ARA70 and filamin-α, thus enabling translocation to the nucleus. Adapted from Bennett et 
al.(2010) and Chen et al.(2005).  
 
Satellite cells (discussed above) within skeletal muscle provide the 
predominant location for AR expression and thus androgens can act directly 
through these cells (Chen et al., 2005, Lee, 2002, Sinha-Hikim et al., 2004). 
Satellite cells once activated are termed myoblasts and can proliferate, enter 
differentiation or even return to quiescence (Fig 1.3.) (Chen et al., 2005, 
Cornelison and Wold, 1997, Kadi et al., 2005, Sinanan et al., 2006, Smith et al., 
1994). In addition, as mentioned satellite cells provide a major source for the 
addition of new myonuclei within the skeletal muscle (Kadi, 2008) and thus the 
myonuclei addition increases the focal points for AR expression as well as helping 
maintain nuclear-to-cytoplasmic balance (Kadi et al., 1999). In terms of muscle 
hypertrophy, the differentiation/fusion of cells into the existing fibres allows for a 
further increase in size (Fig 1.3.). Plus the addition of more satellite cells, as 
previously mentioned, leading to an increased in myonuclei would aid in the 
availability of androgen receptors to interact with testosterone more readily 
(Sinha-Hikim et al., 2003). The availability of the androgen receptor and 
testosterone levels is highlighted by gender differences, as males produce ten 
times more testosterone and equally have an increased AR protein content than in 
females (Vingren et al., 2009). 
 
 
Fig 1.3. Location of the Satellite cell and its involvement in muscle fibre modeling. Adapted 
from Kadi et al.(2005). 
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In mediating T’s effects, the increase (up-regulation) or decrease (down-
regulation) in AR mRNA expression is an important consideration (Ratamess et 
al., 2005, Vingren et al., 2009). Commonly with resistance exercise, where acute 
elevations in testosterone levels are observed, there is an initial stabilisation of the 
AR, followed by a down-regulation (1hr post exercise) (Ratamess et al., 2005) 
before finally an up-regulation (3hr post exercise (Spiering et al., 2009)). This 
type of phase response is further highlighted by Ferrando et al. (2002) where the 
(6 months) administration of exogenous T produced a significant increase in AR 
protein expression after 1 month, yet after 6 months of administration, AR protein 
expression levels returned to near baseline values. Additionally, in females, this 
phase response occurs more quickly than in males (Vingren et al., 2009). The 
phase response or paradigm was suggested to be the result of a steady-state 
adaptation with the administration of T. Interestingly though, Insulin-Like Growth 
Factor I (IGF-I) protein expression, remained elevated for the same time frame 
after exogenous T administration. Thus, posing the question; does T’s interaction 
revolve predominately around the AR or an indirect pathway, for which; in the in 
vivo environment, the administration of T may be more beneficial to patients in a 
cycling pattern (Ferrando et al., 2002)?  
Two more recent in vivo studies investigated the role of androgen receptor 
expression by suppressing endogenous T (by injecting goserelin) (Kvorning et al., 
2007) or applying a resistance training stimulus to elevate endogenous T 
(Ahtiainen et al., 2011). Through the implementation of a 21 week resistance 
training program (60-90% of 1 RM, 5-12 reps per set, 5 sets total), Athtianen et 
al. (2011) observed no statistically significant changes in AR mRNA expression 
and AR protein content between young and old training groups. However, when 
individual changes within groups were further analysed, significant relationships 
were observed in AR protein concentrations and training-induced changes (1 
repetition maximum, fibre CSA) within the skeletal muscle i.e. increased AR 
protein concentration with increase in fibre CSA. Thus, AR protein concentrations 
may have a role training induced skeletal muscle adaptations. Contrary to this, 
Korvning et al, (2007) suppressed testosterone (administration of goserelin) which 
limited the increase in muscle strength being observed post-strength training but 
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more importantly endogenous testosterone did not appear to be involved in the 
regulation of AR mRNA expression as similar expression was observed in 
suppressed verses placebo groups. Indeed, recent research has suggested that 
testosterone may influence skeletal muscle growth via a different pathway to AR 
interaction (Gentile et al., 2010, Kovacheva et al., 2010, Ratamess et al., 2005). 
From the perspective of in vitro studies, the androgen receptor has commonly 
been inhibited using either flutamide or biclutamide (AR antagonist) (Basualto-
Alarcón et al., 2013, Sculthorpe et al., 2012, Serra et al., 2011, Wannenes et al., 
2008). Certain studies in particular have highlighted the variation of levels in AR 
expression within mouse C2C12 skeletal muscle cells (Altuwaijri et al., 2004, 
Sheppard et al., 2011). Recently Sheppard and colleagues (2011) demonstrated 
the affect of sequence variation within the AR receptor on C2C12 cell 
development. They addressed the polyglutamine repeat for AR 14, 24 and 33 CAG 
repeats involvement in cell proliferation and differentiation. The transcriptional 
activity increased with repeating CAG length, and in response to T administration. 
Furthermore, ligand activation was increased for AR33 compared to AR 14 and 24. 
These alterations resulted in reduced cell proliferation in AR33 transfected cells, 
reduced creatine kinase activity in AR14 cells and myonuclear fusion index being 
lower in AR14 and AR33 cells compared to wild type (non-transfected) cells. 
Sheppard and colleagues highlight the role which this polymorphism plays in 
altered growth and development, but most importantly, their observations show 
that within mouse C2C12 cells (wild type) there is a low expression of AR as 
previous studies have adopted a similar technique of AR transfection to address 
the role of androgen treatment where total AR expression appears low (Lee, 2002, 
Wu et al., 2010a) compared to various species and muscle groups (De Naeyer et 
al., 2014, Kadi et al., 2000). 
Contrary to these previous studies though, Wannenes et al. (2008) used 
multiple techniques (western blotting, immunofluorescence and polymerase chain 
reaction (PCR)) to demonstrate that the cellular model of C2C12 cells implemented 
clearly expressed the androgen receptor within their study. The authors 
highlighted the translocation of the AR from the cytoplasm to the nucleus, which 
was accompanied by increases in myogenin, myosin heavy chain isoforms and 
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GRIP-1 (steroid receptor coactivator) expression, supporting T’s role in driving 
muscle differentiation (Lee, 2002, Sculthorpe et al., 2012). The expression levels 
of AR would suggest the importance of AR in skeletal muscle development and 
mediating T’s action. Indeed, between muscle groups in vivo, the expression of 
AR differs between the upper and lower limbs of the body (Kadi et al., 2000). 
However, it may be that where AR expression levels are low, T’s action is 
mediated via another signaling cascade which is more prominent (White et al., 
2012). Most recently in C2C12 muscle cells, it has been observed that with 
incremental increases in T doses, there is indirect activation of the Akt/mTORC1 
pathway in stimulating muscle protein synthesis, a potential T-mediator which is 
discussed below.           
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Fig 1.4. Two potential pathways testosterone may use to interact with skeletal muscle cells. 
Testosterone can act directly via the AR pathway (right side) or indirectly through the IGF-I 
signalling pathway (left side). Akt, protein kinase B; AR, Androgen receptor; ARE, Androgen 
response elements; DHT, dihydrotestosterone; ERK, extracellular signal-regulated kinase; eiF2B, 
the guanine nucleotide-exchange factor for eukaryotic initiation factor 2; 4E-BPP-1, eukaryotic 
translation initiation factor 4E binding protein 1; FOXO, forkhead homebox type O; GSK-3, 
Glycogen Synthase Kinase-3; HSP, Heat shock proteins;  IGF-I, insulin-like growth factor-I; IRS-
1, insulin receptor substrate-1; MAFbx, Muscle atrophy f-box; MAPK, mitogen activated protein 
kinase; mTOR, mammalian target of rapamycin; MuRF1, muscle RING-finger protein-1; P70S6K, 
P70S6 Kinase- a serine/threonine kinase (phosphorylation of S6 induces protein synthesis at the 
ribosome); Ras, Ras Protein; Raf, MAP Kinase Kinase Kinase (MAP3K). Adapted from Bennett et 
al (2010); (Sharples and Stewart, 2011).  
 
1.4 INDIRECT PATHWAYS  
 
1.4.1 Role of IGF-I and Its Downstream Pathways 
 
IGF-I regulates several biochemical pathways (Fig 1.4.), involved in protein 
synthesis within skeletal muscle cells (Rommel et al., 2001, Yin et al., 2009). The 
downstream pathways of Pi3K/Akt/mTOR play a fundamental role in myotube 
hypertrophy (Fig 1.4.) (Rommel et al., 2001), with recent evidence that mTOR 
can be also activated independently of IGF-I through mechanical stimulation and 
amino acid supplementation (Miyazaki et al., 2011, Spangenburg et al., 2008). 
The binding of IGF-I to its receptor, activates a cascade of signalling, initiated 
with the activation of Pi3K. The release of a phosphate group by Pi3K allows for 
the phosphorylation and activation of Akt. Once at this step in the pathway, Akt 
mediates the phosphorlaytion of mTOR. Through mTOR, protein synthesis is 
promoted through mitigating eukaryotic initiation factor 4E– binding protein 1 
(4E-BP1)-mediated inhibition of eukaryotic initiation factor 4E (eIF-4E) (Rommel 
et al., 2001, Yin et al., 2009). Supplementary to mTOR promoting protein 
synthesis through eIF-4E, the activation of mTOR further promotes protein 
synthesis via the phosphorylation of p70S6k and subsequent S6K downstream 
target (Yin et al., 2009). Another downstream target, GSk-3β is a substrate of Akt 
and thus once Akt is phosphorylated, GSk-3β becomes phosporylated and 
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inhibited. This inhibition of GSk-3β in turn activates eukaryotic translation factor 
eIF-2B leading to further increases in protein synthesis (Fig 1.4.). There is 
evidence that testosterone mediates its androgenic effects through Insulin-like 
growth factor (IGF-I) and its associated downstream signaling (Serra et al., 2011). 
For example, with a T deficiency, a reduced level of IGFI in humans has been 
observed which may suggest an activation/synergistic behaviour by testosterone 
on IGF-I (Bhasin et al., 2001, Yin et al., 2009). The suggested synergistic 
behaviour is further supported through T supplementation, where the addition of 
exogenous androgens is accompanied by an increase in IGFI protein and mRNA 
expression (MacLean et al., 2008, Sculthorpe et al., 2012, Serra et al., 2011). 
Furthermore, IGFI and its splice variants, IGFIEa and MGF, stimulate both 
satellite cell proliferation and differentiation with a unique temporal expression 
following resistance exercise (Ates et al., 2007, Hill and Goldspink, 2003, 
Hameed et al., 2003). There is emerging evidence within skeletal muscle cells for 
IGF-I activation of the AR through a ligand-independent mechanism (Kim and 
Lee, 2009a, Kim and Lee, 2009b, Lee, 2009).  
The androgen receptor is considered a ligand dependant receptor, yet recent 
research by Kim and Lee (2009a; 2009b) suggests that total AR and increases in 
AR mRNA expression can be induced through the addition of endogenous IGF-I 
in C2C12 skeletal muscle cells. These investigators observed (through 
immunocytochemistry fluorescence staining) an increase in AR DNA binding 
activity in murine skeletal muscle cells (C2C12) in a time-dependant manner after 
being treated with IGF-I.. Therefore, in the presence of IGF-I, it was observed that 
AR localization in the nucleus increased along with binding to ARE, in the 
absence of ligand. A follow up study by Kim and Lee (2009b) addressed the 
MAPK pathway (discussed in more detail below) as being a mechanism for AR 
activation and localization in the absence of the ligand. Through the use of MAPK 
pathway inhibitors (p38 MAPK, SB203580; ERK1/2 PD98059; JNK SP600125), 
total AR and AR phosphorylation response to IGF-I was blocked. Through a near 
identical approach, yet addressing the Pi3K/Akt pathway (inhibitor LY294002) 
similar results were seen by Lee (2009) suggesting that both MAPK and PI3K/Akt 
pathways stimulate AR activity and as these pathways have been shown to be 
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involved in proliferation (MAPK) and differentiation (PI3K/Akt) (Coolican et al., 
1997). Therefore, in conjunction with Testosterone binding to AR to initiate 
activation, IGF-I also activates AR through the MAPK and Pi3K/Akt pathways 
suggesting a dual regulation of AR through previously distinct pathways. The 
activation/synergist behaviour by testosterone on IGF-I may facilitate competition 
between T binding directly to AR or increased IGF-I levels activating the AR 
first, in a ligand-independent manner.  
The utilization of animal models has further allowed research to address the 
role which T may play in the activation/mediation of IGF-I and its downstream 
pathways (Wu et al., 2010a, Yin et al., 2009). Yin et al.(2009) employed a 
catabolic mouse model (dexamethasone administration) to investigate the effect of 
T on reversing muscle atrophy. It was observed that T reversed the effects of 
atrophy via the activation of the IGF-I downstream targets, Akt, GSk-3β and 
p70S6K (Table 1.1). The activation of downstream target p70S6K has further 
been associated with androgen-mediated muscle hypertrophy in castrated rats (Xu 
et al., 2004). The role of T supplementation in reversing muscle wasting/loss was 
further supported by Kovacheva et al.(2010), in similar findings to Yin et 
al.(2009) in using a mouse model, T supplementation reversed muscle loss via 
activation of Akt signalling pathway.  
The exact mechanisms for T-induced hypertrophy to occur through IGF-I 
remain controversial due to recent research suggesting that the IGF-I/Growth 
hormone axis is not necessary to mediate the effects of T on skeletal muscle in 
vitro (Serra et al., 2011). Testosterone was observed by Serra et al. (2011) to 
rescue muscle-specific mass in the absence of both GH and IGF-I, through use of 
GH-deficient rats that also show suppressed IGF-I levels. A possible explanation 
for this observation may be due to mTOR, a key regulator of satellite cell growth 
and proliferation (Sarbassov et al., 2005). Previously the use of rapamycin, an 
inhibitor of mTOR, blocked overload-induced and IGF-I induced skeletal muscle 
hypertrophy in vivo and in vitro respectively (Bodine et al., 2001, Rommel et al., 
2001). The activity of mTOR has been observed to play a key role in mediating 
the effects of T-induced muscle hypertrophy, independently of IGF-I and Akt 
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after mechanical stimulation (Miyazaki et al., 2011, Spangenburg et al., 2008, Wu 
et al., 2010a).  
In rat L6 myoblasts, Wu et al.(2010a) utilized various inhibitors for mTOR, 
AR, IGF-I and its receptor (IGF-IR) as well as inhibitors for Akt and Erk to 
address their roles in T-induced hypertrophy. The authors observed that Erk and 
mTOR play an important role in hypertrophy occurring through T with both being 
activated under this stimulus. The activation of mTOR and Erk by T 
administration was observed independently of IGF-I, as the inhibition of IGF-I 
and IGF-IR still lead to the phosphorylation of mTOR and Erk. The increased 
activation of mTOR, may further be attributed to T’s action on REDD1 (inhibitor 
of mTOR) which has been observed to have reduced protein levels upon T’s 
administration (Wu et al., 2010b). Recently White and colleagues (2012) further 
supported the findings of Wu et al., showing that with testosterone administration 
there is a direct effect on mTOR activity. They observed an increase in 
phosphorylation of mTOR with increasing doses of T in C2C12 myotubes, 
highlighting the role of the AKT/mTOR pathway in T’s action. However, in slight 
opposition to the findings of Wu et al. (2010a), Brown et al. (2009) observed no 
activation within Erk in T supplementation of a mouse model, suggesting varying 
results between cell lines and in vivo models. Thus further investigation is 
warranted with other cell lines and in vivo experimentation to see if T-induced 
hypertrophy is dependent on Erk and mTOR activity. To note, Wu and colleagues 
observed no activation of IGF-IR or Akt with T, highlighted through no increases 
in expression and protein content in rat L6 myoblasts. The inactivation of IGF-IR 
may aid in the evidence for IGF-I not mediating the effects of T, as Wu et al. 
(2010a) observed unaltered changes in Igf1 mRNA levels with T administration.  
 Most recently, Basulto-Alarcon and colleagues (2013) have highlighted a 
link between mTOR and the androgen receptor in signaling the effects of a T-
stimulus. The authors used primary rat cultures in combination with various 
inhibitors for ERK1/2, PI3K/Akt, mTOR/S6K1 and the androgen receptor. They 
observed acute increases in ERK1/2, Akt and S6K1 with a T-stimulus. 
Additionally increases in myotube cross sectional area after 12 hours were 
abolished through inhibition of PI3K/Akt pathway (using LY294002) and the AR. 
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Their findings highlight the role of fast intracellular signaling and the role of the 
androgen receptor in T induced skeletal myotube hypertrophy.  Of course the 
interactions for how the cross talk occurs remain to be elucidated; however 
Basulto-Alcarcon and colleagues (2013) provide more evidence for the role of key 
proteins and signals which T stimulates to promote muscle hypertrophy.  
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Table 1.1 Various androgen treatments and their interactions with the downstream targets of IGF-I 
signalling pathway 
Signalling 
Proteins 
Published Papers Androgen 
Treatment 
Activation 
Level  
Target Cells 
IGF-IR Wu et al. 2010a 100 nM T No effect. Rat L6 myoblasts 
MAPK Kovacheva et al. 
2010 
Brown et al. 
2009 
0.5cm or 1.0cm T 
Implant 
2cm T Implant 
(supraphysiologial 
dose) 
No effect. 
  
Young vs. Old 
Mice 
Mouse Model. 
     
ERK1/2 Wu et al. 2010a 
Brown et al. 
2009 
100nM T 
2cm T Implant 
(supraphysiologial 
dose) 
  
No effect. 
Rat L6 myoblasts 
Mouse Model 
     
Akt Yin et al. 2009 
Wu et al. 2010 
Kovacheva et al. 
2010 
0.5 mg/100g/day T 
100 nM T 
0.5 or 1.0cm T 
implant 
  
No effect. 
 
Rat Model 
Rat L6 myoblasts 
Young vs. Old 
Mice 
mTOR Wu et al. 2010a 100 nM T   Rat L6 myoblasts 
     
p70s6k Yin et al. 2009 
Xu et al. 2004 
 
Wu et al. 2010a 
0.5 mg/100g/day T 
0.3mg/kg or 
3.0mg/kg DHT 
100nM T 
No effect. 
 
  
Rat model 
Rat model 
(Castrated) 
Rat L6 myoblasts 
     
GSk-3β Yin et al. 2009 
 
Gentile et al. 
2010 
0.5 mg/100g/day T 
 
3mg/kg per day 
DHT 
  
 
Rat model 
 
Rat model 
(Castrated) 
 
 
1.4.2 MAPK/JNK/Notch Signalling 
 
As previously mentioned, mitogen-activated protein kinases (MAPK’s) are 
another family of downstream proteins activated by IGF-I (Fig 1.4.) and consists 
of three subfamilies, ERK (1/2), p38 MAPK and JNK (Brown et al., 2009, Kim 
and Lee, 2009b). ERK (1/2) is activated in response to a growth stimuli and thus 
involved in promoting cell growth where as p38 MAPK and JNK are involved in 
growth inhibition and promoting apoptosis (cell death) through either 
inflammatory or environmental signals (Brown et al., 2009). However, p38 
MAPK has dual roles and has been implicated as a differentiation regulator with 
different isoforms having distinct functions. Where p38-α promotes differentiation 
and inhibis proliferation where as p38-β has the opposite actions on activated 
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satellite cells (Lassar, 2009). Testosterone supplementation has been observed to 
influence all these proteins in inducing muscle fibre hypertrophy and rescuing 
muscle mass size in an aging model (Brown et al., 2009, Kovacheva et al., 2010). 
More specifically, Brown et al. (2009) utilised a mouse model of T-induced 
hypertrophy where it was observed that after 2-4 weeks of T supplementation 
(Table 1.1 and 1.2), p38 MAPK was activated (high levels of phosphorylated p38 
MAPK) and JNK inhibited (decreased levels of phosphorylated JNK). Kovacheva 
et al. (2010) further supported these observations using the same mouse model. 
Notch signalling represents another alternative pathway as the pathway is 
responsible for the activation, proliferation and the myogenic progression of 
satellite cells (Conboy et al., 2003, Sinha-Hikim et al., 2006). Thus testosterone 
supplementation may increase satellite cell number via the activation of this 
pathway. T has indeed been observed to increase the expression of Delta, the 
ligand which binds to activate the Notch receptor (Brown et al., 2009). Notch 
signalling is mediated via the activation of p38 MAPK, which has been observed 
to be induced through a T stimulus in young mice (Brown et al., 2009). Using 
inhibitors for p38 MAPK Brown and colleagues (2009) highlighted a reduction in 
the activation of Notch signalling in the presence of T. The impact of reduced 
Notch signalling resulted in decreased expression of Notch 1 and Notch 2 as well 
as decreased expression of myogenin (muscle specific transcription factor and 
promoter of expression of creatine kinase and cytoskeletal proteins e.g. titin and 
desmin). As the increase in all these factors resulted in muscle fibre hypertrophy, 
it may be suggested that p38 MAPK can activate Notch signalling contributing to 
hypertrophy via a T stimulus. In comparison, T appeared not to activate p38 
MAPK in aged mice. However, through the increased expression of Notch 1, T 
still reversed age-related effects on skeletal muscle i.e. decreased the levels of 
myostatin and increased inhibition of JNK contributing to rescuing muscle mass 
size (Kovacheva et al., 2010). Therefore, it may be suggested that the signalling 
pathways mediating this process may vary with age per se or p38 MAPK is not 
fundamental in T action which may suggest an alternative mechanism maybe 
more important.  
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1.4.3 Myostatin/TGF-β Signalling  
 
The molecular mechanism for how T-induces the promotion of muscle growth 
and hypertrophy is one aspect considered so far. An alternative aspect to consider 
is the possible role of action testosterone exerts on pathways (see table 1.2.) 
involved in growth inhibition, protein degradation and programmed cell death 
(apoptosis). Transforming growth factor-β (TGF-β) signalling pathway is 
responsible for the inhibition of myogenic differentiation (Beggs et al., 2004). 
Follistatin is a Wnt target gene, expressed following β-catenin nuclear localisation 
and subsequently plays a role in binding to TGF-β family members. One such 
family member is myostatin and thus Follistatin inhibits the activity of myostatin 
(endogenous inhibitor of growth) (Amthor et al., 2004). Myostatin is responsible 
for the up-regulation of p21, an inhibitor of cyclin-dependant kinase (CDK) and 
subsequently cell cycle withdrawl in G1 and thus differentiation with the 
subsequent inhibition of cell proliferation (Kovacheva et al., 2010, McCroskery et 
al., 2003). In addition, myostatin has been observed to reduce myotube size and 
differentiation of myoblasts via Akt/mTOR and p70S6K signalling (pathways 
suggested to be activated by T) (Trendelenburg et al., 2009).  
Testosterone supplementation has been observed to down-regulate the 
expression of myostatin (Kovacheva et al., 2010, Mendler et al., 2007). Through 
the suggested AR/β-Catenin cross talk leading to the expression of Wnt target 
genes, follistatin is up-regulated following T administration and thus the 
regulation of TGF-β signalling (Brown et al., 2009). Most recently, Braga and 
colleagues (2012) have highlighted the potential role of follistatin in mediating 
testosterone’s action in mice. They assessed growth and differentiation on satellite 
cells which had been isolated from the levator ani muscle of mice. T up-regulated 
follistatin expression which resulted in TGF-β induced inhibition of growth and 
differentiation being blocked and thus highlighting T’s role in inhibiting this 
particular pathway via increased follistatin expression. Furthermore, T inhibits 
JNK (Brown et al., 2009), which besides MAPK interaction with T, is a possible 
consequence of the reduction in myostatin expression. The inactivation of JNK 
may further play a role through stimulating cellular proliferation by reducing the 
up-regulation of p21 (Huang et al., 2007). These potential events influenced by T 
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may offer a potential mechanism of action for T through a reduction in cell 
apoptosis causing increased cell growth instead. Therefore with age, T’s action 
may be a protective function (Qin et al., 2010, Zhao et al., 2008), that is more 
specific towards sarcopenia and muscle wasting diseases, where metabolites 
associated with grown inhibition, reduced regenerative capacity and cell apoptosis 
are highly expressed (Degens, 2010). 
 
Table 1.2. The interaction of Androgens with alternative (growth inhibition/cell development) 
signalling pathways  
Proteins Published 
Paper 
Androgen treatment Activation Level Target Cells 
Myostatin Mendler et 
al. 2007 
T propionate 
100ug/100g body 
weight for 4 weeks 
 Male Wister rats 
(Castrated) 
JNK Brown et al. 
2009 
Kovacheva 
et al. 2010 
2cm T Implant 
0.5cm/1.0cm T 
Implants 
 
 
 
Mouse Model 
 
Young vs. Old 
Mice 
 
Notch 1 
and 2 
Brown et al. 
2009 
2cm T Implant 
(supraphysiologial 
dose) 
Increased 
expression after 1 
and 8 weeks  
Mouse Model 
Delta Brown et al. 
2009 
2cm T Implant Increased 
expression after 2 
and 8 weeks  
Mouse Model 
β-Catenin Singh et al. 
2009 
Gentile et 
al. 2010 
100nM T and 10nM 
DHT 
3mg/kg per day 
DHT. 
Plus translocation 
to the nucleus. 
Acute increase  
after 1-7 days 
treatment. 
Mouse C3H 
10T1/2 cells 
Rat Model 
(Castrated) 
 
Cyclin D1 McClung et 
al. 2005 
6mg/kg body 
weight, Nandrolone 
Decanoate 
mRNA levels. Rat soleus muscle 
REDD1 Wu et al. 
2010b 
 
28mg/kg/day and 
100-500nM T 
Protein and 
mRNA expession 
Dexamethasone -
treated Wister 
rats and rat 
L6.AR myoblasts 
4E-BP-1 Wu et al. 
2010b 
28mg/kg/day T   
FOXO1 Qin et al. 
2010 
   
 
MAFbx Zhao et al. 
2008 
 mRNA levels.  
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1.5 SKELETAL MUSCLE WASTING 
  
Muscle wasting occurs within many life-threatening diseases such as cancer 
(termed cancer cachexia), AIDS (Dudgeon et al., 2006), SEPSIS (Hasselgren et 
al., 2005), heart failure (Conraads et al., 2007) and ageing (sarcopenia) (Cruz-
Jentoft et al., 2010, Mitchell et al., 2012, Saini et al., 2009, Sharples et al., 2011). 
Individuals that experience muscle loss during these various disease states have a 
reduced physiological and functional capacity, altered metabolism (Russ and 
Lanza, 2011, Tisdale, 2009) and a reduction in circulating levels of growth 
hormone, insulin-like growth factor-I (IGF-I) and testosterone (Dudgeon et al., 
2006). These factors accumulate in increased frailty and morbidity and therefore 
reduced quality of life that subsequently leads to earlier mortality (Deans and 
Wigmore, 2005, Rantanen et al., 2000).  In the instance of cancer cachexia, 
muscle loss (also termed atrophy) can reach 75% at which point leads to fatality 
(Dillon et al., 2012, Muscaritoli et al., 2006). Furthermore this occurs in 50% of 
cancer patients, with cachexia alone causing 25% of cancer deaths (Argilés et al., 
2005).  
 Within the literature, the highlighted catabolic mediators of muscle loss in 
wasting diseases are tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) 
(Sakuma and Yamaguchi, 2013). There is an increase in systemic inflammation 
and the levels of IL-6 and TNF-α (Degens, 2010), with these levels correlating 
with weight loss and even a reduced survival in cancer cachexia patients (Argilés 
et al., 2005). Indeed the exogenous addition of both these cytokines in animal 
models has been observed to result in increased protein breakdown and reduced 
rates of protein synthesis (Li et al., 2003, Li et al., 2005b). The breakdown in 
protein has been observed in cultured myotubes to be mediated by the E3 ligase 
genes (e.g. MuRF-1 and MaFbx) in the ubiqutin-proteasome pathway (Frost et al., 
2007, Li et al., 2005b). The combination of these factors leads to an overall 
reduction in muscle strength and mass.  
 Using the example of the ageing process, the ability of skeletal muscle to 
regenerate becomes less efficient especially in response external stimuli such as 
exercise (Dreyer et al., 2006, Kadi et al., 2004), with several studies highlighting 
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the importance that the cell niche plays in the wasting phenotype (Chakkalakal et 
al., 2012, Carlson and Conboy, 2007, Conboy et al., 2003, 2005). Indeed, seminal 
work has shown that when aged mice undergo parabiotic sharing of their 
circulatory system with young mice, the activation of delta (notch ligand) is 
restored in association with the proliferative and regenerative capacity of the aged 
satellite cells (Conboy et al., 2005). The enhancement of muscle regeneration 
through a change in systemic environment suggests stem cells (satellite cells) 
retain regenerative potential (Conboy et al., 2005). Alternatively, the role of 
intrinsic alterations in the satellite cells ability to proliferate and differentiate in 
muscle wasting with age, have also been shown to be influential in contributing to 
the reduced capacity for regeneration (Beccafico et al., 2011, George et al., 2010, 
Pietrangelo et al., 2009).  
 T replacement therapy has been observed to increase muscle strength and 
mass in various clinical populations such as AIDS, COPD and sarcopenia (Bhasin 
et al., 2000, Casaburi et al., 2004, Dillon et al., 2012, Ferrando et al., 2002, Lewis 
et al., 2007, Sattler et al., 2011). In these clinical populations, the suggested 
mechanisms for skeletal muscle hypertrophy have focused on the expression of 
androgen receptor, IGF-I and myogenic regulatory factors, with increases being 
observed in proteins with testosterone administration (Casaburi et al., 2004, 
Ferrando et al., 2002, Lewis et al., 2007). There is however a limited number of 
studies which have investigated the role of T in restoring skeletal muscle atrophy 
at the cellular level (Serra et al., 2013, White et al., 2012, Wu et al., 2010a). 
1.5.1 Cellular Models to investigate ageing phenotypes 
 
In recent years, cell culture models have been implemented which are 
representative of the ageing process and atrophic phenotypes. These models have 
attempted to address the regulatory programme for myoblast proliferation and 
differentiation from the intrinsic perspective. Bigot and Colleagues  (2008) aged 
human satellite cells in vitro in order to address the effect of replicative 
senescence (terminal growth arrest) on the myogenic programme. They observed 
that senescent myoblasts were still able to form functional multinucleated 
myotubes, yet these were statistically smaller in size. These morphological 
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observations were explained by Bigot and colleagues to be due to the delay 
regulation of the myogenic program. For example, myogenin (terminal 
differentiation marker) had a 15 hour delayed expression which was accompanied 
by a 7-fold decrease. The observations of Bigot et al. contribute evidence towards 
the role intrinsic factors play in myotube formation/regeneration.        
Most recently, two myoblast models to study reduced differentiation 
capacity have been highlighted (Sharples et al., 2010, Sharples et al., 2011). The 
first investigated the parental mouse C2 myoblasts vs. their subclone, the C2C12 
cells. Despite their shared origins, we observed differences in morphological and 
biochemical responses between the C2 and C2C12 cells. The C2 cells displayed 
slower and diminished differentiation profiles compared to the C2C12 cells and 
were also more susceptible to TNF-α-induced inhibition of differentiation and 
induction of apoptosis. Because muscle wasting is associated with reduced muscle 
mass (Degens and Alway, 2003, Morse et al., 2005) and increased susceptibility 
to TNF-induced muscle protein degradation (Bruunsgaard et al., 2003, Lees et al., 
2009), this comparative model provides an excellent representation of muscle 
atrophy, hypertrophy and adaptability, thus, enabling the determination of 
potential regulators associated with muscle wasting. 
The second model utilises C2C12 cells that have undergone multiple 
population doublings (PD) vs. parental control cells (undergoing no doublings 
relative to the PD cells) (Sharples et al., 2011). These cells also display impaired 
differentiation in monolayer and in three dimensional culture systems (Sharples et 
al., 2012) verses their parental controls. It was reported that the MPD cells had 
significantly reduced numbers of cells exiting the cell cycle in G1, a prerequisite 
for fusion, with corresponding decreases in transcript expression of Igf1, myoD, 
myogenin and reduced activation of Akt with increases in Igfbp5 mRNA and JNK 
activation verses control cells (Sharples et al., 2011). Interestingly, similar 
morphology, transcript and signalling processes are also observed in cells isolated 
from elderly human muscle (Beccafico et al., 2011, Bigot et al., 2008, Pietrangelo 
et al., 2009) and in whole tissue biopsies (Cuthbertson et al., 2005, Léger et al., 
2008). Thus, these cells can be used as a representative model to investigate 
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mechanisms of atrophic phenotypes (PD) verses hypertrophic phenotypes (CON) 
(Sharples et al., 2011).  
1.6 AIMS AND OBJECTIVES 
 
Based on the review of the literature, the aims of this thesis are to: 1) 
investigate the role of testosterone in skeletal muscle cell differentiation and 
myotube hypertrophy in vitro; 2) investigate whether T administration can restore 
differentiation and myotube hypertrophy in population doubled skeletal muscle 
cells that show impaired differentiation and hypertrophy (ageing phenotypes). 3) 
Elucidate the most predominant molecular pathways in T’s action i.e. the 
androgen receptor and/or IGF-I and its associated cell signalling). Ultimate 
objectives and hence aims are to highlight key cellular and molecular mechanisms 
involved in testosterone-induced hypertrophy and regeneration in skeletal muscle 
cells with a view to enhancing future therapeutic interventions for clinical 
populations where muscle wasting is apparent. 
 
1.7 THESIS OVERVIEW 
 
To address our aims chapter 2 will define methodology undertaken in the 
following four data chapters; chapter 3 will determine a dose response of 
testosterone in skeletal muscle (C2C12) myoblasts. T will be administered to both 
proliferating and early differentiating cells as well as onto differentiated 
myoblasts (myotubes/myofibres). This chapter will thus help to establish a 
characterisation  of morphological adaptation of  C2C12 cells to T administration 
of differing doses vs. basal conditions i.e. myotube number, diameter, nuclei per 
myotube, myonuclear accretion) and transcript expression of key genes involved 
in differentiation and hypertrophy (myogenin, IGF-I, AR, myostatin etc)  in order 
to take the relevant dose forward to subsequent chapters. Chapter 4 will establish 
an effective dose to inhibit the AR (flutamide) and IGF-I receptor 
(Picropodophyllin: PPP) in order to determine their role in T’s molecular 
regulation of differentiation and hypertrophy in subsequent chapters. Here CON 
and PD cells will be incubated with T in the absence or present of flutamide or 
PPP with AR total protein and IGF-I signaling (pERK, pAKT) measured 
respectively to confirm inhibition. In Chapter 5 CON and PD cells will be 
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administered with testosterone, T plus AR inhibitors (flutamide), IGF-I receptor 
inhibitor (Picropodophyllin) (alone and in combination) dependant on dose 
determined in the above chapters) to address if whether the direct AR or indirect 
IGF pathways are the predominant routes for testosterone’s role in muscle cell 
differentiation and hypertrophy and whether this is altered/impaired in an aged 
muscle cell model (PD cells). Morphological analysis (desmin staining, myotube 
number and diameter, myonuclear accretion and nuclei per myotube), gene 
expression (myogenin, IGF-I receptor, AR, MyoD, myostatin) and key cell 
signaling (pERK, pAKT, p70S6K) processes will be investigated. Chapter 6 will 
finally investigate the IGF-I downstream target, Akt as this protein has recently 
been suggested to be involved in mediating testosterone induced-hypertrophy and 
low levels have been observed in aged mammals. Therefore this chapter will 
attempt to discover if Akt is involved in improving skeletal muscle regeneration 
when testosterone is administered.  Chapter 7 will provide a final summary, 
discussion of the work and future directions.
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2. MATERIALS AND METHODS 
 
2.1 GENERAL EQUIPMENT AND SPECIALISED SOFTWARE 
 
2.1.1 Cell Culture 
 
All cell culture was performed in a microbiological safety cabinet (Herasafe
TM
 
KS Class II, Thermo Fisher Scientific, Rosklide, Denmark). All cells were 
incubated in a Thermo scientific Hera Cell 150i CO2 Air Jacketed Incubator 
(Loughborough, UK). Liquid handling for cell culture was performed using an 
IBS Integra Biosciences Vacusafe Comfort (Chur, Switzerland). Distilled water 
from an Milli-Q intergral water purification system (Merck Millipore, Oxford, 
UK) was used in the preparation for all solutions.  
 
2.1.2. Biochemical Assays 
 
Total Protein assays were performed using a Thermo Labsystems Multiskan 
spectrum microplate reader (Franklin, MA, USA). Reagents for protein assays 
were purchased from Pierce (Division of Thermo Fisher Scientific, Rosklide, 
Denmark).  
 
2.1.3. Real Time PCR 
 
RNA concentration and purity were assessed by UV spectroscopy using a 
Nanodrop Spectrophotometer 3000 (Fisher, Rosklide, Denmark). Real-time PCR 
was performed using a Qiagility automated pipetting machine and Rotor-Gene Q 
PCR machine (Qiagen Inc, Valencia, CA, USA). Reagents for real time PCR (2x 
Quantifast SYBR Green RT-PCT master mix, 100 μl Quantifast RT mix) were 
supplied by Qiagen (Valencia, CA, USA). 
 
2.1.4 SDS page and Western Ligand Blotting 
 
Gels were prepared and run using a Mini-PROTEAN Tetra Cell 
Electrophoresis Unit (Bio-Rad Laboratories, Inc. Hercules, CA, USA; Figure 2.5). 
Transfer of proteins from gels to nitrocellulose membrane was performed using 
semi dry Trans Blot turbo transfer system (Bio-Rad Laboratories, Inc. Hercules, 
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CA, USA; Figure 2.6). Detection of proteins was achieved using enhanced 
chemiluminescence (ECL) with a West Pico Supersignal kit (Pierce, Rockford, 
IL, USA). Chemiluminescence detection was achieved using the Bio-rad Imaging 
System (Hercules, CA, USA) supported by Quantity One 4.6.2 (Bio-Rad 
Laboratories, Inc. Hercules, CA, USA ).  
 
2.2 PLASTICWARE 
 
Tissue culture flasks (T75) and 6 well plates for cell culture use were 
purchased sterile from Nunc Life Sciences, Thermo Fisher Scientific (Rosklide, 
Denmark). 96 well plates for protein assays from Nunc Life Sciences, Thermo 
Fisher Scientific (Rosklide, Denmark). 1 ml Cryogenic vials were originally 
produced by Biosigma (Venice, Italy) and purchased from Fisher Scientific UK 
(Loughborough, UK). Cell scrapers were also purchased from Fisher Scientific 
UK (Loughborough, UK). Syringe’s and syringe filters (0.20 M) were from 
Fisher Scientific UK (Loughborough, UK). 0.5, 1.5 and 2 ml tubes were 
purchased from Eppendorf (Hamburg, Germany) and 0.25, 0.5, 1.5 ml RNase 
Free Microfuge tubes for use in RNA extraction, isolation and Real-Time PCR 
were purchased from Ambion (Cheshire, UK). Pipette tips for tissue culture, 
biochemistry and aerosol resistant tips (ART
TM
) for use with RNA extraction, 
isolation and RT-PCR were purchased from Fisher Scientific UK (Loughborough, 
UK). 
 
2.3 TISSUE CULTURE REAGENTS 
 
Sterile cell and tissue culture media and supplements were purchased as 
follows: Dulbecco’s modified Eagle’s medium (DMEM, High glucose, with L-
glutamine Cat no. D6429) from Sigma-Aldrich (Poole, UK), foetal bovine serum 
(FBS) from PAA (Buckinghamshire, UK). The following supplements were 
purchased non-sterile and therefore sterilised through a syringe using a 0.20 µM 
filter: penicillin streptomycin solution and trypsin from Gibco (Paisley, UK) and 
Sigma-Aldrich (Poole, UK) respectively. Gelatin type A from porcine skin was 
purchased from Sigma-Aldrich (Poole, UK) and phosphate buffered saline (PBS) 
from Fisher Scientific UK (Loughborough, UK). The FBS, penicillin-
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streptomycin and trypsin were stored in -20°C in suitable aliquots until required to 
make up either growth media (GM) or differentiation media (DM). GM 
constituted: 395 ml bottle of DMEM plus 20% FBS (100 ml), and 1% penicillin -
streptomycin solution (5 ml). DM (50 ml) constituted; DMEM (48.5 ml) plus 2% 
FBS(1 ml), and 1% penicillin- streptomycin solution (500 μl). This sterile GM 
and DM were stored at 4C and used within 4 weeks. 
 
2.4 C2C12 SKELETAL MUSCLE MYOBLASTS 
 
The murine C2C12 cells are a subclone of the C2 line (Blau et al., 1985) where 
C2 cells were originally established by Yaffe and Saxel (Yaffe and Saxel, 1977) 
from adult C3H mouse leg muscle that was crush-injured to induce satellite cell 
proliferation. C2C12 cells are commercially available and were obtained from the 
American Tissue Culture Collection (ATCC; Rockville, MD, USA) and stocks 
were maintained and stored in liquid nitrogen (LN2) within our laboratories. These 
cells undergo spontaneous differentiation into myotubes on serum withdrawal, 
and do not require additional growth factors to stimulate the process (Blau et al., 
1985).   
 
2.4.1 Cell Culture of C2C12 skeletal muscle myoblasts 
 
C2C12 cells were brought up in 1.0 ml cryovials from LN2 at 1 × 10
6
 cells.ml
-1
. 
Once the cryovial contents had thawed, C2C12 cells were plated at 7-9 ×10
5
 cells 
(700-900 µl of total cell suspension in a cryovial) per T75 flask. T75s were pre-
gelatinised with 5 ml of 0.2% gelatin for 15 mins before aspirating off excess 
gelatin. GM was added to the cell suspension to make a total of 15 ml GM in T75 
flasks. Flasks were incubated in a humidified 5% CO2 atmosphere at 37°C, for 72 
hrs.  
Once the cells were ~ 80% confluent after a total of 72 hrs. Cells were washed 
twice with PBS to remove any serum (an inhibitor of trypsin) and trypsinised 
using 1 ml (per 75 cm
2
) 0.05% Trypsin/0.02% Ethylenediaminetetraacetic acid 
(EDTA) for 5 minutes at 37
o
C. Disassociation of the cells from the base of the 
flask was checked under the microscope (Phase contrast light microscope; CETI 
inverted light microscope, Thermo Fisher). 5 ml of GM was added (6 ml total, 
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including 1 ml trypsin) to inactivate the trypsin; this was collected into a test tube 
and gently dispersed using a 21 gauge needle and syringe to prevent cell 
clumping. The cell suspension was prepared in a 1:1 dilution in trypan blue stain 
(Gibco, Paisley, UK). Between 20 and 50 µl cell suspension was mixed with the 
equivalent amount of trypan blue stain and dispensed into a haemocytometer 
(Weber Scientific International, Hove, UK); for cell counting procedure see 2.6 
below. Cells were seeded at the required density (80,000/ml) in GM onto relevant 
pre-gelatinised (0.2%) 2 ml six well plates (total 160,000 cells per well) for 24 
hours to attach. Following washing, cells were further cultured until 80% 
confluency was attained (Fig 2.1). Any remaining cells from the original cell 
suspension were re-suspended at 1×10
6
 cells.ml
-1
 in growth medium and 10% 
dimethyl sulphoxide (DMSO; BDH, Poole, UK) for 24 hrs cold storage at -80
o
C 
before long term storage in liquid nitrogen (for cryopreservation see 2.7). 
 
 
Fig 2,1 The time course for C2C12 skeletal muscle cells from confluence (24hrs GM) to 
differentiating (72hrs) to myotube maturation (7 days DM). Cells were seeded at 80,000 per ml 
(0hrs) and cultured in growth media (GM) for 24hrs before being switched to differentiation media 
(DM) for 7 days.    
 
C2C12 skeletal muscle myoblasts were induced to differentiate by aspirating 
GM, washing with 1 ml of PBS and replacing with low serum media (DM). 2 ml 
of DM was added to each well. The cells were induced to differentiate for up to 
72 hrs and 7 days with morphological, biochemical, transcript and protein 
analyses taking place at 0, 72 hrs and 7 days, as detailed below. The media was 
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further topped up at 72hrs with 1 ml DM plus relative treatment (for treatments 
see below). 
 
2.4.2 Mean Population Doubled (PD) C2C12 myoblasts  
 
C2C12 mouse myoblasts (CON) were used fresh or had previously undergone 58 
population doublings (PD). (For a more detailed explanation, refer to Sharples et 
al. (2011)). In brief, cells had previously been doubled and numbers recorded 
throughout.  This cycle was repeated 20 times over 49 days, creating a stock of 
cells that had undergone population doublings, compared with the original stock 
that were retained in liquid nitrogen and had undergone no doublings (CON) 
relative to the PD cells and were used as the controls in all experiments reported 
here. Thus, the same ‘‘parental cells’’ that had produced their progeny were used 
as control cells. There was no observable cell death between cell expansions 
(determined upon counting by trypan blue exclusion) as previously reported 
(Sharples et al., 2011). Furthermore, the cells display an impairment in skeletal 
muscle regeneration due to an inability to exit the cell cycle (Sharples et al., 
2011). Overall, CON cells were used between passages 5-7 and PD cells were 
used between passages 25-27. Both cell types were resurrected as outlined in 
section 2.7 and cultured as detailed in section 2.4.1.  
  
2.5 CELL COUNTING BY TRYPAN BLUE EXCLUSION 
 
A haemocytometer was used for cell counting. This consists of a glass cover 
slip resting on a counting chamber. The cells were prepared as a 1:1 suspension in 
0.4% trypan blue stain and loaded into the haemocytometer. Cells in the four 
corner grids were counted under a microscope at × 10 magnification. Viable cells 
were identified as small, round and clearly visible, while non-viable cells were 
generally misshapen, slightly larger and had lost their membrane integrity and 
hence were trypan blue positive. If the standard deviation was high between the 
initial four counts, the same sample was loaded and counted on the opposite side 
of the haemocytometer and a further 4 grids used in the calculation. The resultant 
mean of 4 or 8 grids was calculated, which represented average cell numbers 
occupied 0.1 mm
3
. This value was then multiplied by 2 to take account of the 
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dilution factor of 1:1. A further multiplication by 10
4 
was undertaken to 
extrapolate the number of cells in 0.1 mm
3 
to 1 cm
3
 (equivalent to 1 ml of cell 
suspension) (Equation 2.1). The total number of cells contained in the cell 
suspension could be calculated by multiplying by the total volume of cell 
suspension (ml).  
 
Cells.ml
-1
  = Average 4-8 grids × dilution factor (2) × 10
4
 cells.ml
-1 
Equation 2.1 Calculation of viable and dead cell number following haemocytometer counting.  
 
2.6 CELL CRYOPRESERVATION AND RESURRECTION  
 
Viable cells that had been passaged were preserved in Liquid Nitrogen (LN2) 
by supplementing GM with 10% Dimethyl sulphoxide (DMSO), a cryoprotectant 
that penetrates the cell membrane and functions by replacing part of the cells 
water and subsequently reducing ice crystal formation that can cause damage to 
the cells (Lovelock and Bishop, 1959, Rubinsky, 2003). Once cells were 80% 
confluent in T75 flasks they were trypsinised and counted (as above 2.5). The cell 
suspension was then supplemented with additional GM to ensure the density of 
cells was 1×10
6
 cells.ml
1
, or if the cells suspension was populated with less than 
1×10
6
 cells.ml
1
 they were centrifuged for 5 minutes at 2500 rcf and then re-
suspended with the correct amount of GM to ensure density of 1×10
6
 cells.ml
-1
. 
The cell suspension was dispersed using a 21 gauge needle and syringe to avoid 
cell clumping. 10% DMSO was added in a drop-wise manner and slowly agitated 
up and down using a pipette. 1 ml of this cell suspension was transferred to a 1.0 
ml cryovial labeled with cell type, passage number upon resurrection, treatment 
condition (if any), and date of storage. The vials were then placed into freezing 
chamber “Mr Frosty” purchased from Fisher Scientific (Loughborough, UK) 
containing isopropyl alcohol and placed into a freezer at -80C. This chamber is 
designed to cause a rate of freezing of -1C.minˉ1 which slowly allows the 
reduction in metabolism of the cells and thus enhanced survival. After 24 hrs the 
cells were transferred into a liquid nitrogen storage tank, Biostore (Tyne & Wear, 
UK). For resurrection, frozen vials containing cells were obtained from LN2 and 
the exterior cleaned with 70% industrial methylated spirits (IMS). Cells were 
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placed inside a flow hood and thawed at room temperature. Cells were then plated 
onto plasticware as described in section 2.4.1 for initiation of specific 
investigations.  
 
2.7 DOSING CELLS 
 
2.7.1 Reconstitution of Testosterone 
 
50 mg Testosterone (Tocris Bioscience, Bristol, UK) was purchased and 
initially prepared by adding 5 ml of DMSO to 7.2 mg T making a 5 mM stock 
solution (0.0072 g (1 mol/288.42 g)/ 0.005 L= 0.00499 M) in DMSO. The stock 
was aliquoted into 200 μl eppendorfs. These were frozen at -20oC in 20 µl 
aliquots for storage. The working stock was kept for a month until a fresh stock 
was made.  Concentrations of 50, 100 and 500nM were used on mouse C2C12 
cells, with 100 nM being used in CON and PD myoblasts.  
 
2.7.2 Reconstitution of Flutamide (AR inhibitor) 
 
1g of flutamide (Tocris Bioscience, Bristol, UK) was purchased and initially 
prepared as a 10 mg.ml
-1
 stock in 1ml of DMSO. The stock was aliquotted into 
200 μl eppendorfs. These were frozen at -20oC in 50 µl aliquots for storage until 
use. Concentrations of 20 and 40 μM were used on CON and PD cells (see 
Chapter 4 & 5).  
 
2.7.3 Reconstitution of Picropodophyllin (IGF-IR inhibitor) 
 
1mg of Picropodophylin (Calbiochem, Nottingham, UK) was purchased and 
initially prepared as a 1 mg.ml
-1
 stock in 1ml of DMSO. The stock was aliquotted 
into 200 μl eppendorfs. These were frozen at -20oC in 50 µl aliquots for storage 
until use. Concentrations of 30, 90 and 150 nM were used on CON and PD cells 
(see Chapter 4 & 5).  
 
2.7.4 Reconstitution of LY294002 (Pi3K/Akt inhibitor) 
 
1mg of LY294002 (Calbiochem, Nottingham, UK) was purchased and 
initially prepared as a 20 mg.ml
-1
 stock in 1ml of DMSO. The stock was 
aliquotted into 200 μl eppendorfs. These were frozen at -20oC in 20 µl aliquots for 
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storage until use. A concentration of 5 μM was used on CON and PD cells (see 
Chapter 6). The LY294002 inhibitor has been extensively shown to be highly 
specific and effective in C2C12 cells in inhibiting PI3K and downstream Akt (Al-
Shanti et al., 2011, Coolican et al., 1997, Frost et al., 2009, Lee, 2009, Li et al., 
2005a, Zeng et al., 2012).  
 
2.7.5 Reconstitution of IGF-I  
 
50 ug of recombinant human insulin-like growth factor I (IGF-I) was 
purchased from Sigma Aldrich (Poole, UK) and reconstituted in 100 mM 
hydrochloric acid to generate a 10 ng.ml
-1
 useable stock. The stock was aliquoted 
into 200 μl eppendorfs. These were frozen at -20oC in 20 µl aliquots for storage 
until use. A 10 ng.ml
-1
 concentration was used in experiments described in 
Chapter 3 and 4. 
 
2.7.6 Procedure for dosing cells  
 
For experimental protocols involving the dosing of CON and PD C2C12 
skeletal myoblasts (prior to the induction of differentiation by placing cells in 
DM) the DM was pre-dosed with testosterone 50, 100 and 500 nM, Flutamide at 
20 and 40 μM, Picropodophylin  at 30, 90 and 150 μM and LY294002 at 5 μM. 
For small quantities as highlighted in the example below, then serial dilution was 
performed. The following equation was used to determine amount of the stock 
solutions required: 
Amount of stock required (µl) = (RC ÷ SC) × DM required (ml) 
Where: RC = Required Concentration 
        SC = Stock Concentration 
e.g.   
Amount of Stock Required (µl)= 100 nM Testosterone ÷ 5000000 nM
 
× 50 ml 
Amount of Stock Required (µl) =  1 µl of Testosterone stock to be added to 50 
ml of DM. 
Equation 2.2. An equation to calculate amount of stock required when dosing skeletal muscle 
cells with testosterone and inhibitors in DM.  
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2.8 LYSING CELLS FOR USE WITH TOTAL PROTEIN ASSAY 
 
Cells were induced to differentiate for up to 72 hrs and 7 days in DM ± dosing 
conditions detailed above. At the relevant time points cells were washed twice in 
1 ml/well PBS and lysed in 300 µl.well
-1
 for 6 well plates using 10 mM TrisHCl, 
5mM EDTA, 50 mM sodium chloride, 30 mM sodium pyrophosphate, 50 mM 
sodium fluoride, 100 µM sodium orthovanadate, 1 mM PMSF and 1% Triton X-
100 (Cell lysis buffer). Cells were lysed at room temperature for 10 minutes, and 
lysates were scraped and collected into 1.5 ml eppendorf tubes. Tubes were 
labelled with cell type, condition, time point and date, and subsequently stored at -
20
o
C for at least 24 hrs prior to protein assays (see below 2.9). Protein assays 
were all completed within 2 weeks of the sample being obtained.  
 
2.9 TOTAL PROTEIN ASSAY 
 
2.9.1 Principle 
 
The total protein that was present in a single well of  6 well plates was 
determined using a highly sensitive reagent for dilute aqueous solutions; 
Bicinchoninic acid (BCA), which detects Cu
+1
, and is created when Cu
+2
 is 
reduced by protein in an alkaline environment (Smith et al., 1985). When the 
reagent was mixed with a sample; two molecules of BCA join with one cuprous 
(Cu
+1
) molecule and the reaction becomes purple coloured. This purple colour is 
due to the macromolecular structure of protein, the number of protein bonds and 
the presence of the four amino acids: Cysteine, Cystine, Tryptophan and Tyrosine 
(Wiechelman et al., 1988). The darker the colour the more protein present. The 
absorbance of this complex was measured between 540 and 590 nM which is 
linear with increasing protein concentrations (Equation 2.3). 
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1.  Protein (peptide bonds) + Cu
2+
 → tetradentate-Cu+  
         complex 
 
2.  Cu
+
 complex   + Bicinchoninic Acid (BCA) → BCA-Cu+                
                           
complex        
 (Purple Coloured) 
         ↓  
Read at absorbance 540 nM-
590nM 
Equation 2.3. Chemical reactions underlying the protein assay (Smith et al., 1985). 
 
2.9.2 Procedure 
 
Standards made with bovine serum albumin (BSA) were used to determine the 
concentration of protein (mg.ml
-1
) based on standard curve generated using a Bio-
Tek ELISA plate reader (Winooski, VT, USA). BSA protein standards were 
prepared at 4, 2, 1, 0.5, 0.25, 0.125, 0.0625 and 0 mg.ml
-1
 initially by diluting 200 
mg BSA (in 0.9% sodium chloride and sodium azide a preservative; Pierce, 
Rockford, IL, USA) with 4.8 ml cell lysis buffer (detailed in section 2.8) 
providing a working stock solution (× 10) at 40 mg.ml
-1
 of BSA. 200 µl of stock 
solution was then diluted with 1.8 ml cell lysis buffer providing the first standard 
of 4 mg.ml
-1
 BSA. All subsequent standards were prepared by mixing 1 ml of the 
previous standard with 1 ml cell lysis buffer, apart from the preparation of the 0 
standard, which was the cell lysis buffer alone.   
 
BCA reagents A & B were purchased from Pierce (Rockford, IL, USA). 
Reagent B was made up of 4% cupric sulphate and was mixed thoroughly in a 
multichannel trough with reagent A (sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1 M of sodium hydroxide) at a ratio of 
1:50. 10 l of standard, sample and a blank (distilled water) were pipetted in 
duplicate into a 96 well plate. 200 l of the working reagent was added to all 
wells using a multichannel pipette (excluding the blank), and the plate was 
incubated at 37C for up to 60 mins. Following background subtraction, the 
absorbance was recorded at 30 and 60 minutes at 630 nM using a Thermo 
Chapter 2: Methodology 
36 | P a g e  
 
Labsystems Multiskan spectrum microplate reader. The standard curve was 
generated by plotting the average blank-corrected 630 nM measurement of each 
BSA standard against its pre-programmed known concentration in mg.ml
-1
. 
Sample concentrations were calculated from the standard curve. 
 
2.10 IMMUNOCYTOCHEMISTRY AND MICROSCOPY 
 
2.10.1 Principal 
 
Antibodies can be used to probe and detect specific molecules of interest in 
cells. This is achieved by the antibodies being specific for antigens which are 
present on the protein of interest. The addition of fluorescent dyes allows for these 
proteins to be visualised by fluorescence microscopy.  
Firstly, the cells must be fixed. Two types of fixatives can be used- organic 
solvents and cross-linking agents. For this thesis, an organic solvent is used. This 
type works by dehydrating the cells and removing lipids, yet the cell architecture 
remains intact. Alternatively, the cross-linking agent such as paraformaldehyde 
allows for a network of linked antigens to be created via intermolecular bridges 
and thus preserves the cell structure. In order for the antibodies to infiltrate the 
cell and access the intracellular protein of interest, the cell membranes need to be 
first permeablised. This is normally achieved using a detergent such a Triton. In 
unison with permeablisation being performed, blocking is performed. This step is 
necessary in order to prevent the binding of the primary antibody to non-specific 
sites with the cell structure. Serum is used for the blocking of non-specific binding 
as this also allows for the avoidance of background fluorescence when image 
collection is performed (detailed in 2.10.3). Subsequently, after the steps of 
fixation, permablisation and blocking, the cells can be incubated with the desired 
antibodies. There are two types of antibodies which can be used in ICC and IHC: 
i) Polyclonal antibodies- These are produced from the sera of animals, by 
injecting the antigen of interest into the animal. The animal’s B-
lymphocytes produce an antibody specific to the protein of interest. 
These antibodies are then harvested and purified for subsequent use in 
ICC/IHC.   
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ii) Monoclonal antibodies- These antibodies are more expensive and take 
longer to produce. A similar procedure occurs to the polyclonal 
antibodies where the animal is injected again with the antigen of 
interest, however this time; the B-lymphocytes are fused in vitro with 
myeloma cells to form hydrodimas. These hydrodimas are isolated and 
allowed to multiply, formulating a large stock of identical antibodies to 
the antigen of interest.  
 
Therefore, the process of indirect immunofluorescence was utilised in this thesis, 
which required the use of an initial primary antibody to bind to the protein of 
interest within the cell. This followed by a secondary antibody against the IgG of 
the animal in which the primary antibody was raised. The conjugation of the 
secondary antibody with a fluorescent dye (e.g. TRITC or FITC) allows for 
visualisation upon excitation at the correct wavelength.     
 
2.10.2 Procedure  
 
Cells were fixed by first, media being aspirated from the wells and 
replaced with PBS (1ml per Well) and 1ml of methanol/acetone (50:50mix) ice-
cold. The mix was incubated in the wells for 10mins. Upon the incubation time 
being complete, this mix was aspirated and a further 2ml methanol/acetone was 
added carefully to each well and incubated for another 10mins. Finally PBS 
(2ml/well) was added after removal of the methanol/acetone mix and plates were 
stored in 4
o
c until further analysis. The process of immunofluorescence was 
performed directly in the wells of 6 well plates or on glass cover slips.  In general, 
cover slips/wells were stained for desmin and nuclei using 1:200 desmin primary 
antibodies (Abcam, Cambridge, UK), 1:200 TRITC secondary antibody (Sigma, 
St Louis, USA) and 1:2000 Sytox Green (Life Technologies, CA, USA) nuclei 
stain using the protocol illustrated in fig 2.2. The blocking/permeabilisation 
solution consisted of 1x TBS (pH 8.5), 5% goat serum (Sigma Aldrich, Poole, 
UK) and 0.2% Triton-X 100 (Fisher Scientific, Loughborough, UK) with 100 and 
500 μl added to cover slips and wells respectively. The antibody solutions 
consisted of 1x TBS, 2% goat serum and 0.2% Triton-X100 plus either the 
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primary or secondary antibody at concentrations highlighted above.  Cover slips 
were mounted on to slides using Mowiol and left in the dark, overnight to dry. 
Wells were covered in 2 ml of 1x TBS and stored in 4
o
C until fluorescent 
microscopy was performed. All incubation periods were performed at room 
temperature.  
 
 
 
Fig 2.2 Immunocytochemistry protocol implemented for cover slips and wells. 
 
2.10.3 Image Quantification  
 
A total of 30 fields per condition for each time point were captured with a cell 
imaging system at x10 magnification for light microscope (Inverso-TC, CETI, 
Medline Scientific Limited, Oxon, UK) and x40 (chapter 3) and x 20 (chapter 5) 
fluorescent microscopy (DM6000 FS, Leica, Germany). Images were analysed 
using Image J (Java) software (National Institutes of Health, USA). Morphology 
was assessed by determination of myotube diameter, number of myotubes per 
view, mean number of nuclei per myotube per field of view, fusion index (cell 
fusion) and total nuclei counts (changes in total cell number and therefore an 
indices for proliferation). A myotube was defined as containing 3
+
 nuclei 
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encapsulated within cellular structures, so to avoid counting of single cells 
undergoing mitosis. Myotube diameter (μm) was determined by measuring the 
diameter of 3 equidistant points on each myotube (left end, middle, right end) and 
determining the mean of the 3 values as previously described (Stevenson et al., 
2005, Trendelenburg et al., 2009). An indicator of myonuclear accretion (fusion 
index) was calculated by dividing myotubes into two classes; myotubes which 
expressed 3-4 nuclei or myotubes which expressed 5+ nuclei, with the data 
expressed as percentages. 
 
2.11 RNA EXTRACTION  
 
2.11.1 Procedure 
 
Following the required experimental incubation period, murine C2C12 
myoblasts had their existing media aspirated, were washed with PBS and lysed for 
5 min at RT in 300 µl TRIZOL reagent/well (Sigma-Aldrich, Poole, UK). 
TRIZOL is a mono-phasic solution of phenol guanidine isothiocyanate that 
disrupts cells and dissolves all cell components other than RNA and DNA and 
protein. 2 wells of a 6 well plate per condition were harvested using a scraper and 
then collected into 1.5 ml RNase free tubes. Samples were agitated by vortexing 
for 10 seconds to ensure cells were totally lysed and were then stored at -20ºC for 
up to 1 week before homogenates were supplemented with 0.1 ml chloroform per 
0.5 ml of TRIZOL reagent prior to vigorous mixing for 15 seconds. Resulting 
mixtures were kept at room temperature for 10 minutes then centrifuged at 12000 
g for 15 mins at 4˚C. Following centrifugation the mixture separates into a lower 
red phenol-chloroform phase containing cell debris and components of TRIZOL, 
a milky-coloured interphase containing DNA and protein, and a colourless 
aqueous upper phase that houses the RNA and chloroform. The colourless 
aqueous phase was carefully extracted into new RNase free tubes, without 
disturbing the interphase. RNA was precipitated from the aqueous phase by 
mixing with isopropanol at a ratio of 1:2 (with the starting amount of 300 μl 
TRIZOL). Samples were stored at room temperature for 5-10 mins and 
centrifuged at 12000 g for 10 minutes at 4 °C. Supernatant was removed and the 
RNA pellet washed by adding 1 ml of 75% ethanol. The samples were centrifuged 
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at 7500 g for 5 minutes at 4 ˚C. Ethanol was removed and the RNA pellet air-
dried until it was invisible in the tube. RNA was dissolved in 30-50 µl RNA 
storage solution (Ambion- The RNA Company, Cheshire, UK) and vortexed for 
10 seconds. All procedures above were carried out using RNA-free pipette tips 
and pipettes that were handled for RNA use only. A different tip was used for 
every sample to ensure no cross contamination. All work surfaces and equipment 
were sprayed with 70% IMS and then RNase ZAP (Ambion- The RNA Company, 
Cheshire, UK) before commencing work with RNA. The samples were either 
stored in -80°C or analysed immediately for RNA concentration (see section 
2.12.2.).   
 
2.11.2 RNA Concentration   
 
         RNA concentration and purity were assessed through UV spectroscopy at 
ODs of 260 and 280 nm, using the Nanodrop spectrophotometer 3000 (Fisher, 
Rosklide, Denmark). Only samples with a 260:280 ratio of between 1.9 and 2.15 
were carried forward for reverse transcription and PCR amplification (detailed in 
section 2.13).   
 
2.12 ONE STEP, REAL TIME POLYMERASE CHAIN REACTION (PCR) 
USING SYBR GREEN DYE  
 
2.12.1 Principal  
 
The use of real time PCR allows for gene expression levels to be quantified. 
This molecular biology technique allows for the amplification of specific gene 
sequences in order to quantify the original amount of starting material e.g. RNA 
or DNA. Therefore, a sequence of RNA expression can be targeted to see if it is 
up or down regulated with a particular treatment e.g. testosterone administration. 
The first initial step is to extract RNA from the sample (see section 2.12). The 
isolated RNA can then be reverse transcribed into complimentary DNA (cDNA). 
The reverse transcription is achieved by oligo primers binding to the poly-A tail at 
the 3’ end of the mRNA molecule, and the enzyme reverse transcrisptase 
generates the complimentary sequence. The process of reverse transcription 
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usually occurs between 40 to 60
o
C and in this thesis, 50
o
C. The following three 
steps of PCR occur:  
 
i) Denaturation: This step involves the heating of reaction tubes to 95oC, 
allowing for the disruption of hydrogen bonds on the complementary 
DNA strands.    
ii) Annealing: Specific primers which are complementary to the sense and 
anti-sense strands of the DNA, bind (anneal) to the sequence of 
interest. A reduction in temperature occurs at this stage, which is 
optimal for the primers that were designed (See table 2.1 )   
iii) Extension: A Taq polymerase enzyme is used to synthesize a new 
strand of the target DNA sequence. The enzyme achieves synthesis of 
new DNA by attaching to the primary sites on the primers and uses 
dNTP’s to extend the target sequence. The process generally occurs at 
an optimal temperature of 72
o
C, and in this thesis was performed at 
60
o
C.     
 
The completion of all three steps combined indicates one cycle has been 
performed. Generally, PCR is carried out for 40 cycles, generating millions of 
copies of specific gene sequence that is of interest for quantification. Finally, the 
technique uses fluorescence in order to detect the amount of cDNA which has 
been amplified in real-time. Particular to this thesis, SYBR green was used as the 
fluorescent dye which binds to double stranded DNA and the subsequent 
fluorescence is detected by the PCR machine. The amount of fluorescence is 
measured at the end of the extension step for each cycle, and thus as the number 
of cycles increases and the products is amplified, then the level of fluorescence 
will increase accordingly. The quantification of fluorescence and relative gene 
expression is outlined in section 2.13.4.    
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2.12.2 Primer Design 
 
Primer sequences were identified using Gene (NCBI, 
www.ncbi.nlm.nih.gov/gene) and designed using both web-based OligoPerfect™ 
Designer (Invitrogen, Carlsbad, CA, USA) and Primer-BLAST (NCBI, 
http://www.ncbi.nlm.nih.gov/tools/primer-blast). Sequence homology searches 
ensured specificity. Three or more GC bases in the last 5 bases at the 3’ end of the 
primer were avoided. Secondary structure interactions (hairpins, self-dimer and 
cross dimer) within the primer were avoided. All primers ranged between 18 and 
23 bp and amplified a product between 173 and 197 bp. GC content was between 
36.3 and 60%. Primers without the requirement of further purification were 
purchased from Sigma (Suffolk, UK).  
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Table 2.1 Primer Sequences for Genes of interest  
 
 
2.12.3 Procedure 
 
PCR reaction tubes were prepared using the QIAGility automated pipetting 
system (Qiagen, Crawley UK). Reactions (20 μl) were made up in transparent, 
optically clear RNA free tubes which consisted 0.15 μl of both forward and 
Gene Primer Sequence (5’-3’) Ref. Sequence 
Number 
Amplicon 
Length (bp) 
GC% 
Content 
AR F:GCCTCCGAAGTGTG
GTATCC 
R:CCTGGTACTGTCCA
AACGCA 
NM_013476.3 138 60 
55 
IGF-IR F:CTACCTCCCTCTCTG
GGAATG 
R:GCCCAACCTGCTGT
TATTTCT 
NM_010513 185 47.4 
47.4 
IGF-I F:ATCAGCAGCCTTCC
AACTC 
R:AAGGTGAGCAAGCA
GC 
NM_010512 116 45 
47.4 
MyoD F:CATTCCAACCCACA
GAAC 
R:GGCGATAGAAGCTC
CAA 
NM_010866 125 59.7 
50 
MAFbx F:GTCGCAGCCAAGAA
GAGAA 
R:CGAGAATCCAGTCT
GTTGAA 
NM_026346.3 155 52.7 
47.7 
Myostatin F:TACTCCGAATAGAA
GCCATAA 
R: 
GTAGCGTGATAACGTCAT
C 
NM_010834 194 36.3 
45 
mTOR F: 
CACTCCACTATCCT
GTTACCT 
R: 
GAGATCCTTGGCAC
ACCT 
 NM_020009  190 47.6 
55.5 
Myogenin F:CCAACTGAGATTGT
CTGTC 
R: 
GGTGTTAGCCTTATGTGA
AT 
NM_031189 173 47.3 
40 
RP-IIβ F:GGTCAGAAGGGAA
CTTGTGGTAT 
R:GCATCATTAAATG
GAGTAGCGTC 
NM_153798.1 197 50 
44.4 
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reverse primers at 100 μM concentration (sigma), 0.2 μl of Quantifast reverse 
transcription kit (Qiagen), and 10 μl of SYBR green dye (Qiagen) plus 9.5 μl of 
70 ng RNA/Sample (concentrated at 7.3 ng.ul
-
1). Upon completion, reaction tubes 
were loaded into a Rotogene 3000 (Qiagen, Crawley, UK). RT-qRT-PCR was 
performed as follows: 10 min, 50
o
C (reverse transcription), 5 min 95
o
C 
(transcriptase inactivation and initial denaturation), Followed by: 10 secs, 95
o
C 
(denaturation), 30 secs, 60
o
C (annealing and extension) for 40 cycles (see section 
2.12.1). Following completion, melting curve analyses were performed to exclude 
primer-dimer and non-specific amplification (Fig 2.3).  
 
 
Fig 2.3 Melt curve analysis showing peak confirms primer set specificity. The melt curve shown is 
from primers designed for mouse (mus musculus) mTOR.  
 
2.12.4 qPCR analysis  
 
Relative mRNA expression was quantified by using the comparative CT 
method (also known as the 2
-ΔΔCT
 method) as described previously (Livak and 
Schmittgen, 2001, Schmittgen and Livak, 2008). The cycle threshold (CT) for an 
individual sample is defined as the cycle at which the sample’s fluorescence 
produced by the reaction exceeds the background fluorescence (Fig 2.4). 
Therefore, the numerical value of the CT inversely represents the amount of 
amplicon in the reaction i.e the lower the CT value, the greater amount of gene 
expression. Subsequently, gene expression can be normalised to the CT value for 
a housekeeping gene (e.g. RP-IIβ) which is selected based on being stable under 
all conditions in the experiment. Finally, this methods requires that the data is 
made relative to a control condition (e.g. CON DM 0hrs).  The following equation 
was implemented: 
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e.g. 2
-ΔΔCT
 = [(CT gene of interest – CT internal  control) Treatment sample – 
(CT gene of interest - CT internal control) Untreated sample)]  
 
Equation 2.4  The comparative CT method used to quantify relative mRNA expression 
(Adapted from Schmittgen and Livak (2008)) 
 
 
Fig 2.4 The determination of the threshold cycle (CT) for gene expression quantification. 
Identification of the threshold cycle is used to quantify the starting expression level for the gene of 
interest. For example, the brown line (above) has a lower CT value compared the blue line, 
meaning heightened expression.     
 
2.13 SDS-PAGE (SODIUM DODCEYL SUPLHATE- 
POLYACRYLADMIDE GEL ELECTROPHORESIS) AND 
IMMUNOBLOTTING  
 
2.13.1 Principal  
 
Separation of complex protein structures is performed using discontinuous 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
according to their molecular weight in kilo Daltons (kDa) (Laemmli, 1970). 
Different concentrations of acrylamide can be used for polymerisation depending 
on the size of interest e.g. 12% gel for proteins of low molecular weight vs. 7% 
gels for a protein of high molecular weight. The use of bis-acrylamide allows for 
the polymerisation of the gel by forming cross-links between the acrylamide 
polymers. The process of polymerisation is catalysed by mixing ammonium per 
Chapter 2: Methodology 
46 | P a g e  
 
sulphate (APS) and N, N, N’, N’-Tetramethylethylenediamine (TEMED). Two 
discontinuous gels are generated: i) the resolving gel (10%) which separates the 
protein by size and ii) the stacking gel (5%) which enables large volume of dilute 
sample to be loaded in to lanes and thus align at the gel interface, prior to 
separation occurring in the resolving gel.   
 
2.13.2 Sample preparation 
 
After transfer to DM or relevant dosing conditions cell monolayers were 
washed twice in PBS and lysed in 200 µl/ well of a 6 well plate in cell lysis buffer 
containing: 10 mM TrisCl, 5mM EDTA, 50 mM sodium chloride, 30 mM sodium 
pyrophosphate, 50 mM sodium fluoride, 100 µM sodium orthovanadate, 1 mM 
PMSF and 1% Triton X-100 and 1 cOmplete Protease Inhibitor cocktail tablet 
(Roche, Hertfordshire, UK). After 5 minutes on ice, the cells were scraped with a 
cell scraper, transferred to a 1.5 ml eppendorf tubes and stored at -80˚C until 
required. Protein concentrations were assessed using methodology in Section 2.9 
above prior to preparation for loading.  
5X Sample buffer (Laemmili Buffer) was prepared (3 ml 1M Tris-HCl pH 6.8, 
0.5 g SDS, 5 ml Glycerol, 2 ml dH2O, gel loading solution (Sigma Aldrich, Poole, 
UK) and 2 ml β-mercaptoethanol. 30 µg of protein per cell lysate was added to 
sample buffer. Approximately 60 µl of supernatant sample per condition was 
loaded with 8 µl of loading buffer.  Molecular weights were determined by the 
incorporation of 10 µl rainbow molecular weight protein standards. Rainbow 
marker was purchased from Sigma-Aldrich (Color Burst Electrophoresis Marker, 
Sigma, Poole, UK). Containing myosin (violet; 200 kDa), BSA (red; 100 kDa), 
GDH (blue; 60 KDa), ADH (red; 45 kDa), Carbonic Anhydrase (orange; 30 kDa), 
200 mM Tris, SDS and formamide (amount not specified). The samples were 
boiled at 90˚C for 5 minutes in a beaker of water placed on a hotplate (to reduce 
disulphide bonds) before loading onto the gel with a 20 μl loading tip (Fisher 
Scientific, Loughborough, UK).  
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2.13.3 Gel preparation  
 
Gels were prepared using a Mini-PROTEAN Tetra Cell Electrophoresis Unit 
(Bio-Rad Laboratories, Inc. Hercules, CA, USA; Fig 2.5). The glass plates were 
assembled as per manufacturer’s instructions. The resolving gel (30% acrylamide 
1% BIS, 1.5M Tris base pH 8.9, 0.1M EDTA pH 7.4, 10% SDS, 0.1% (w/v) APS 
and 0.1% (v/v) TEMED) was poured between the clamped plates in the Tetra Cell 
unit (Fig 2.5). Ethanol: dH2O (1:1) gel overlay buffer, was poured over the top of 
the gel which enables uniform polymerisation by preventing air from inhibiting 
the process at the surface of the gel. Once polymerized, the ethanol was 
thoroughly washed away with dH2O and the stacking gel (30% acrylamide 1% 
BIS, 54mM Tris HCl pH 6.8, 0.1M EDTA pH 7.4, 0.1% (w/v) SDS, 0.1% (w/v) 
APS and 0.1% (v/v) TEMED) was over-layed. A 10 well-comb was inserted into 
the stacking gel whilst un-polymerised to ensure loading of samples could take 
place. The combs were removed once the staking gel had polymerized and the 
gels were transferred the gel running tank (shown in Fig 2.5). The upper and 
lower chambers were filled with 1X running buffer (25 mM Tris base, 192 mM 
glycine, 2 mM EDTA and 0.1% (w/v) SDS in dH2O pH 9.65).  
 
2.13.4 Electrophoretic separation 
 
Samples subjected to 10% SDS-PAGE were electrophoresed at 200 volts 
using a PowerPac
TM
 HC high-current power (Bio-Rad Laboratories, Inc. Hercules, 
CA, USA) until the sample buffer tracking dye reached the bottom of the gel. 
 
2.13.5 Transfer of proteins to Nitrocellulose Membrane  
 
The glass plates (Fig 2.5) were carefully disassembled without ripping the 
gels. The stacking gel removed using a scraper leaving the resolving gel. 
Meanwhile, a piece of Hybond-C nitrocellulose and 4 sheets of Whatman filter 
paper (Bio-Rad Laboratories, Inc. Hercules, CA, USA) were cut to the size of the 
gel (7.5 x 8 cm) and immersed in transfer buffer final pH 8.3 (114 nM glycine, 19 
mM Tris base and 33% methanol). Two sheets of pre-immersed Whatman filter 
paper were placed on the green semi dry trans blot turbo transfer system (Bio-Rad 
Laboratories, Inc. Hercules, CA, USA; Fig 2.6), the gel was placed on top of the 
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filter paper followed by the nitrocellulose membrane paper and a further 2 layers 
of pre-immersed Whatman filter paper added. Finally, the combined layers were 
rolled to ensure no air bubbles were retained between each layer. The lid of the 
electrode cell was placed on top of the gel sandwich stack. The proteins were 
transferred to the nitrocellulose membrane support for use in western ligand 
blotting for 30 minutes at 25 V using a PowerPac
TM
 HC high-current power (Bio-
Rad Laboratories, Inc. Hercules, CA, USA).  
 
2.13.6 Ponceau S staining  
 
It is possible to view the transfer efficiency of the proteins and view any 
unstained molecular weight markers by staining the membrane with a non-
permanent dye called Ponceau S. Membranes were incubated in 0.1% Ponceau S 
solution in 5% acetic acid (Sigma, Poole, U.K) for 5 minutes, washed with dH2O 
and the markers marked with a soft pencil. Membranes were completely de-
stained following prolonged washing with dH2O and 1 × TBS (containing 1% 
Tween-20).  
 
2.13.7 Immunoblotting 
 
Immunoblotting was performed using a fast western supersignal west pico 
rabbit substrate kit (Pierce, Rockford, IL, USA). The western blotting was 
performed based on manufacturer’s instructions. Initially, the nitrocellulose 
membranes were soaked in wash buffer (containing blocking solution twice) for 
10 minutes. Next, membranes were sealed in plastic bags containing primary 
antibodies (1:1000-2000) in an antibody diluent liquid for 1 hour incubation at 
room temperature. Primary antibodies (rabbit polyclonal) were purchased from 
New England Bio labs (Santa Cruz, USA) (Table 2.2). Post primary antibody 
incubation, membranes were washed in 1 x TBS (containing 0.05% Tween). 
Then, membranes were incubated for 30 minutes in HRP-conjugated secondary 
antibody (1ml in 10ml) at room temperature. Then membranes were washed with 
1 x wash buffer supplied in the kit for 5 minutes each. All washes and incubations 
were performed on a rocking platform in boxes and sealed bags respectively.   
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Table 2.2 Primary antibodies for proteins of interest and loading control 
Protein Cat no. Concentration Molecular Wt. 
(kDa) 
Androgen receptor Sc-816 1:500 110 
IGF-I receptor Sc-713 1:500 97 
Total Akt 9272 1:1000 60 
Akt
ser473
 4058 1:1000 60 
Total ERK ½ 9102 1:1000 42, 44 
ERK 1/2
thr202/tyr204
 9101 1:1000 42, 44 
Total p70S6K 9202 1:1000 70 
p70S6K
thr389
 9205 1:1000 70 
GAPDH 5174 1:4000 37 
 
 
2.13.8 ECL detection  
 
Detection of proteins was achieved using enhanced chemiluminescence (ECL) 
with a West Pico Supersignal kit (Pierce, Rockford, IL, USA). The ECL substrate 
was made up from reagent A and B in a ratio of 1:1 (2.5 ml each) and incubated 
for 5 minutes (Supersignal kit) with gentle agitation according to manufacturer’s 
instructions. Membranes were drained bags resealed and light emission captured 
using the Biorad Imaging System (Hercules, CA, USA). Briefly, reagent A decays 
to H2O2, the substrate for peroxidase. Reduction of the enzyme HRP is coupled to 
a light producing reaction by detection with reagent B. This contains luminol, 
which upon oxidation, produces blue light that can be detected on an imaging 
system.  
 
2.14 Statistical Analysis       
 
All statistical analysis performed in this thesis was done using SPSS version 
19 (IBM, Armonk, NY, USA) and Graph Pad Prism Software (San Diego, USA). 
All data was checked for normal distribution and being parametric. The statistical 
tests performed will be detailed in the methods section of each results chapter. 
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3. THE DOSE EFFECTS OF TESTOSTERONE ADMINISTRATION 
IN C2C12 SKELETAL MUSCLE CELLS 
 
3.1 INTRODUCTION 
 
Testosterone elicits an anabolic effect on skeletal muscle via increases in 
protein synthesis, decreases in protein degradation and the reutilization of amino 
acids (Ahtiainen et al. 2011; Brodsky et al. 1996; Sheffield-Moore et al. 1999). 
These adaptations culminate in a hypertrophic (increased size via increased 
protein synthesis) response occurring in the skeletal muscle. An increase in size of 
skeletal muscle, shown by increases in cross sectional area (CSA) has been 
observed following administration of testosterone enanthate (derivative of T 
through the addition of an ester) at doses of 25-600 mg, with corresponding 
strength increases being dose dependant (Bashin et al. 1996; Bashin et al. 2001; 
Sinha-Hikim et al. 2002). Testosterone has been shown to increase satellite cell 
number and increase activation and fusion of these cells indicated by an increase 
in myonuclear incorporation in skeletal muscle in vivo following testosterone 
administration (100-600 mg) (Chen et al. 2005; Kadi & Thornell, 2000).  Power 
lifters known to be users of androgenic-anabolic steroids demonstrate an 
amplified muscle hypertrophy response (Eriksson et al. 2005). However, the 
molecular mechanisms by which testosterone stimulate anabolic processes for 
hypertrophic responses remain poorly understood. 
 
3.1.1 Molecular targets from human studies involved in Testosterone-induced 
muscle hypertrophy 
 
In the last decade, human studies have investigated potential molecular and 
cellular targets which may mediate the effects of testosterone administration in 
enhancing skeletal muscle mass. Ferrando and colleagues (2002) observed 
increases in AR protein expression after 1 month administration of testosterone 
enanthate (dose adjusted to maintain individuals within 17-28 nmol.l
-1
 range), but 
these levels reduced to pre-treatment after 6 months treatment in elderly men. 
Furthermore, IGF-I protein expression increased after 1 month, and continued to 
increase following continued 6 month administration. The alterations in AR and 
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IGF-I protein levels accompanied increases in leg lean body mass, muscle volume 
and muscle strength (leg and arm). In a study using graded doses (25, 50, 125, 300 
and 600 mg) of testosterone, Sinha-Hikim and colleagues (2006) investigated 
testosterone induced hypertrophy looking specifically at satellite cell influence. 
They observed doses from 125 mg and above, increased satellite cell number 
(PCNA+), along with activation of Notch and increased myogenin expression. 
The authors providence evidence for testosterone restoring skeletal muscle mass 
in elderly individuals, with a dose effect above 125 mg. To note, AR was not 
measured within this cohort, although the satellite cell is the main location for AR 
expression in humans (Kadi et al., 2000, Kadi, 2008).  
 
3.1.2 Molecular targets investigated in animal/in-vitro studies with 
testosterone administration. 
 
In-vitro studies have further enhanced our understanding of potential 
molecular targets which may be involved in testosterone induced hypertrophy. 
The majority of testosterone related studies have centered around the AR, IGF-I, 
myostatin and myogenin expression (marker of terminal differentiation) in 
relation to myotube differentiation and hypertrophy (Kovacheva et al., 2010, 
Braga et al., 2012, Singh et al., 2009, Sculthorpe et al., 2012, Wannenes et al., 
2008, Lee, 2002, Serra et al., 2011). In human craniofacial muscle cells, 
Sculthorpe and colleagues (2012) observed significant increases in Igf1 mRNA 
expression with 500 nM T compared to 100 nM T, with this observation being 
abrogated through AR inhibition using flutamide. In comparison, Wannenes et al. 
(2008) used 0.1, 1 and 10 nM testosterone on C2C12 skeletal muscle cells, to 
investigate the role of the AR in muscle cell differentiation. The authors observed 
a dose-response increase in AR (protein and mRNA expression), myogenin, 
myosin heavy chains (MyHC: IIb, IIx/d and I) and GRIP-1 (co-regulator of the 
AR) expression. These observations provide evidence towards testosterone and 
the AR role in myogenesis, even at a low dose.  
Further studies have addressed the role of IGF-I and its downstream 
pathways in mediating the effects of testosterone (Serra et al., 2011, Wu et al., 
2010a). Serra and colleagues utilized both a knock out (IGF-I receptor/IGF-IR) 
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animal model and primary human myoblasts to address the impact of circulating 
IGF-I and associated signaling in testosterone mediated processes. IGF-I receptor 
knock outs were treated with a GnRH antagonist to suppress endogenous T. The 
administration of exogenous testosterone enanthate enhanced body weight and 
levator ani muscle weight (androgen-responsive which is due to abundance of AR 
expression present). Furthermore, testosterone treatment enhanced primary human 
myotube morphology through myonuclear accretion, diameter and increased 
MyHC expression in the presence of small interference RNA for IGF-I receptor. 
The author’s observations highlight variables (morphological and biochemical) 
which testosterone can enhance in vitro and potentially how these effects are 
mediated.  
Therefore, based on literature above, the temporal action of testosterone on 
pre-existing myotubes verses differentiating myoblasts is yet to be investigated 
along with the impact of high and low doses in C2C12 muscle cells. By addressing 
these two factors, the findings will inform a suitable dose to be used later in the 
thesis as well as the impact of testosterone on muscle differentiation and 
hypertrophy.  
   
3.1.3 Aims and Objectives 
 
Therefore in light of the literature discussed above, the aims of this chapter 
were to characterize high and low testosterone doses (50 and 500 nM) in C2C12 
skeletal muscle myoblasts, with administration at two points in time: 
differentiating (myoblast pre-fusion/upon transfer to low serum media/ denoted 
0hrs) vs. differentiated (pre-existing myotubes/72 hrs in low serum media) 
defined as T1 and T2 respectively. The investigation of  both dose and time point 
administration would allow for the determination of the effects of testosterone on 
myotube formation (differentiation) and hypertrophy as well as a suitable dose for 
subsequent experiments (chapter 5 and 6). Thus morphological (myotube number, 
myotube diameter, myonuclear accretion) and transcriptional (myogenin, AR, 
IGF-I and myostatin) alterations to testosterone administration were measured. It 
was hypothesized that there would be dose responsive increase in morphological 
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and transcriptional differentiation and hypertrophy as well as myotube 
hypertrophy and differentiation.    
 
3.2 METHODOLOGY 
 
3.2.1 Cell Culture 
Mouse C2C12 skeletal muscle myoblasts were resurrected as described in 
section 2.6 and cultured as outlined in section 2.4.1. Once cells were ~80% 
confluence, they were seeded at 80,000 cells per ml in 2 ml of growth media 
(GM) per well onto 0.2% porcine gelatin-coated 6-well plates and grown in a 
humidified 5% CO2 atmosphere at 37
o
C. Once confluent, the myoblasts were 
changed from growth media to low serum media/differentiation media (DM), 
which promotes the fusion of the myoblasts into multinucleated myotubes. C2C12 
myoblasts undergo spontaneous differentiation into myotubes on serum 
withdrawal, and do not require growth factor addition to stimulate the process 
(outlined in section 2.4.1). Cells were incubated in DM for 30 minutes at 37
o
C in 
a 5% CO2 atmosphere with this period of equilibration denoted as the 0 hour time 
point.  
For T1 experiments, cells at the time points of 0, 72 hrs and 7 days were fixed 
and isolated for RNA (outlined in sections 2.10.2 and 2.12). For T2 experiments, 
cells were cultured in DM for 72 hrs (defined as 0hrs for T2) and then transferred 
to treatments as described below. Extraction and fixation for T2 was performed at 
24hrs and 72hrs post administration to analyze morphology and transcriptional 
changes using reverse transcription quantitative real-time polymerase chain 
reaction (RT-PCR) (described in sections 2.10.2 and 2.12 respectively).  
Due to observations from investigations into 50 nM and 500 nM (detailed 
below) a further dosing condition (100 nM) was investigated, primarily in CON 
myoblasts, and then this dose was taken forward to characterize the basal 
adaptation in cells that display prior reductions in regeneration/ageing phenotypes, 
the PD myoblasts. In brief, population doubled  (PD) myoblasts have previously 
undergone 58 doublings and the process results in impaired regeneration (Sharples 
et al., 2011), where as CON myoblasts have undergone relatively few population 
doublings vs. the daughter population doubled cells (See section 2.4.2 for more 
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detail). Cell culture was performed as outlined in section 2.4.1 (same as the T1 
methodology) and myotube morphology (myotube number, nuclei per myotube, 
myotube diameter) was reported in this chapter (with transcriptional and signaling 
data reported in chapter 5 and 6). It should be noted that for 100 nM conditions 
different microscopes, and therefore microscope objectives were used for 
morphological images (detailed in 3.2.5 section). Therefore, absolute numbers for 
100 nM dosing conditions were unable to be directly compared to 50 and 500 nM, 
however, we were able to be compare to the DM control ran in the same 
experiments.  
 
3.2.2Cell Treatments 
All treatments were administered in DM described above (detailed in section 
2.7.6). The treatments comprised of a vehicle control (DMSO at a concentration 
of 0.01%), Testosterone doses (T) 50, 100 nM and 500 nM i.e. DM + T (outlined 
in section 2.7).  DMSO was used as the solvent for T reconstitution at the same 
concentration as the vehicle (0.01%). For results and figure legends the following 
nomenclature will be used control (DM) (50 nM T, 100 nM T, 500 nM T. All 
treatments were added at 0 hrs and existing media was further supplemented at 72 
hrs for T1 and only at 72 hrs for T2.  
 
3.2.3 RNA Isolation 
6 well plates for each time point (T1: 0hrs, 72hrs, 7 days; T2: 0hrs, 24hrs, 
72hrs) were washed with 1 ml per well of Phosphate Buffer Saline (PBS) and 
extracted for RNA by placing 300 μl of TRIzolTM Reagent (Sigma, St Louis) in 
each well. Total RNA was extracted as outlined in section 2.12.1. RNA 
concentration and purity were assessed through UV spectroscopy at ODs of 260 
and 280 nM, using the Nanodrop spectrophotometer 3000 (outlined in section 
2.11.2).  
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3.2.4 Real time, Reverse Transcriptase Polymerase Chain Reaction (rt-RT-
PCR) 
Seventy nanograms of RNA was taken from each sample and real time, 
reverse transcription polymerase chain reaction (RT-rt-PCR) was performed as 
detailed in section 2.12.3. Primer sequences for genes of interest are shown in 
table 2.1 and were checked for specificity according to section 2.12.2. The 
relative mRNA expression  of  AR, IGF-I, myogenin and myostatin  was 
quantified using the comparative Ct (
ΔΔ
ct) Method against a reference gene of RP-
IIb and calibrator of control treatment (after 72hrs exposure in both T1 and T2 
(72hrs = 0hrs in T2) experiments). Raw CT for qPCR conducted in this chapter of 
work can be viewed in appendix 1 (Table 9.1).  To note, for the T2 experiment, 
gene expression was made relative to reference point of 0hrs (time of 
administration on pre-cultured myotubes) and thus value equals ~1 (not shown in 
figures for Fig 3.6). 
 
3.2.5 Immunocyctochemistry Analysis 
For 50 and 500 nM doses, cells were fixed and immunocytochemistry was 
performed as described in section 2.10.2. Myotubes were stained for desmin 
(intermediate filament found in skeletal muscle near Z line of sarcomeres) and 
images captured on x40 oil magnification confocal microscopy. Quantification of 
morphology was performed as outlined in section 2.10.3. For 100 nM dosing, 
cells were fixed and immunocytochemistry was performed as outlined in section 
2.10.2. Images were captured on x20 magnification fluorescence microscope (due 
to a laboratory move) and are presented in Chapter 5. 
 
3.2.6 Statistical Analysis  
Experiments were performed 3 x (n=3) in triplicate. Data are presented as 
Mean + S.D unless stated otherwise. Shapiro-Wilk and Levenes tests were used to 
test for normal distribution and homogeneity of variation respectively. A two way 
mixed ANOVA was performed (for main effects and interactions for time, dose 
and cell type) with subsequent bonferonni post-hoc test to determine where 
significant differences lay. Subsequently, Gene expression data was assessed 
using a (2x4) mixed two-way factorial ANOVA for interactions between time 
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(72hrs and 7 days) and treatments (Control, 50 nM T, 500nM T and IGF-I). 
Morphology data was assessed using a one-way ANOVA for interactions between 
time (7 days) and treatments. For 100 nM dose experiment, Morphology was 
assessed using a two way mixed (2x2) ANOVA was performed in CON 
myoblasts for interactions between time (72hrs and 7 days) and treatments (DM 
and 100 nM T). In PD myoblasts, Independent T-tests were performed to compare 
treated vs. untreated cells in myotube morphology variables. A p-value of ≤0.05 
was considered statistically significant. All statistical analyses were performed 
using SPSS version 19 and GraphPad Prism Software (detailed in section 2.14).   
 
3.3 RESULTS  
3.3.1 The effects of testosterone treatment on myotube morphology at 
different administration points 
In the T1 experiment, the administration of testosterone at 0hrs and 72hrs lead 
to both doses of testosterone significantly increasing myotube diameter (50 nM T 
20.7 ± 5.9μm; 500 nM T 20.4 ± 4.9 μm (P ≤ 0.001 respectively)) compared to 
control (17.5 ± 3.4 μm) treatment (Fig 3.1A) after 7 days exposure. Interestingly, 
there was no significant difference observed between the two testosterone doses 
for the increased myotube diameter. To note, in cover slips fixed at 72hrs there 
was no quantifiable myotubes present in any of the treatments for the T1 
experiment. No statistical differences were observed for mean number of nuclei 
per myotubes in any of the treatments (control 5.08 ± 1.89; 50 nM 5.66 ± 2.00; 
500 nM 5.89 ± 2.08; P=N.S.). Testosterone induced (50 nM 3.53 ± 2.34; 500 nM 
3.10 ± 1.24) increases in myotube number were not significantly different from 
the control treatment (2.89 ± 1.71), shown in Fig 3.1B.  
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Fig 3.1 The effects of 50 and 500 nM testosterone doses on morphological parameters. Myotubes 
stained for desmin (red) and nuclei (green) in the T1 experiment after 7 days culture. A) Doses of 
50 and 500 nM testosterone significantly increased myotube diameter compared to control. B) 
Testosterone doses (50 and 500 nM) did not significantly increased the number of myotubes per 
image compared to control treatment (P=N.S).  
 
However, when myotubes in the T1 experiment were analysed for variation in 
number of nuclei per myotube (myonuclear accretion) and expressed as a 
percentage, both testosterone treatments (50 nM 62.0 ± 4.6%; 500 nM 59.8 ± 
4.7%) had significantly increased the percentage of myotubes expressing 5+ 
nuclei (Fig 3.2) verses control (39.3 ± 4.8%). Whereas the control (60.7 ± 4.8%) 
treatment had a significantly higher percentage of myotubes with 3-4 nuclei 
incorporated (P ≤ 0.05) (Fig 3.2) compared to 50 nM (38.0 ± 4.7%) and 500 nM 
(40.2 ± 4.7%) testosterone.  
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Fig 3.2 The effect of testosterone administration (T1) after 7 days exposure on the incorporation of 
nuclei into myotubes. Testosterone doses significantly increased the percentage of myotubes 
expressing 5+ nuclei (p ≤ 0.05). Data represented as Mean ± S.E.M.    
 
In the T2 experiment, increases in myotube size of pre-existing myotubes (T2 = 
72hrs in DM after transfer into low serum media) after 24hrs testosterone 
administration vs. the control treatment (50 nM 16.80 ± 2.22 μm; 500 nM 16.58 ± 
2.17 μm vs. control 14.54 ± 1.64 μm; P ≤ 0.001, Fig. 3.3A). Additionally, the 
testosterone-induced increases in myotube diameter were observed after 72 hrs 
exposure (50 nM 16.99 ± 3.00 μm; 500nM 16.54 ± 2.07 μm vs. control 14.87 ± 
1.44 μm; P ≤ 0.001, Fig. 3.3A), although there was no significant main effect for 
time (P= N.S). To note again, opposite to the original hypothesis, there was no 
difference observed between a low and high dose as testosterone doses resulted in 
similar increases in myotube diameter. In terms of mean nuclei per myotube, 
testosterone induced an increase in myonuclei compared to control treatment after 
24 hours exposure (T2) (50 nM 4.94 ± 1.32; 500 nM 4.32 ± 0.83 vs. control 3.76 ± 
0.67; P ≤ 0.001, Fig. 3.3B). As for myotube number, there were no alterations 
after 24hrs exposure, but 500 nM testosterone did increase moytube number after 
72hrs exposure compared to the control treatment (500 nM T 2.82 ± 1.02 vs. 
control 2.00 ± 0.64; P ≤ 0.02, Fig 3.3C).   
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Fig 3.3 The effects of testosterone administered to pre-existing myotubes (T2 experiment) on 
myotube morphology. A) A Significant increase in myotube diameter was observed with the 
administration of testosterone (50 and 500 nM) compared to the control treatment after 24 and 
72hrs (P ≤ 0.0001) B) At 24hrs, both testosterone doses increased the number of nuclei per 
myotube compared to the control treatment (P ≤ 0.0001) C) There were no significant differences 
in myotube number after 24hrs exposure. 500 nM testosterone only increased myotube number 
compared to the control treatment after 72hrs (P ≤ 0.02).  
 
Interestingly and in comparison to the T1 experiment, the addition of 
testosterone on to differentiated myoblasts (T2) didn’t lead to an increase in 
myonuclear accretion as the percentage of myotubes expressing 3-4 and 5+ nuclei 
was similar after 24 hrs and 72 hrs for all treatments (Fig 3.4). 
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Fig 3.4 The addition of treatments to pre-existing myotubes for 24 hrs (A) and 72hrs (B) exposure 
(T2 experiment) on myonuclear accretion. There were no significant differences in the alterations 
of myotubes expressing 3-4 nuclei vs. 5+ nuclei for all treatments at both time points.  
 
3.3.2 The effect of Testosterone doses on gene mRNA expression levels at 
different administration time points.    
In order to assess the effects of testosterone on differentiation, the steroid was 
added to confluent C2C12 cells after transfer to low serum media (T1). After 72 
hrs exposure, a significant increases in myogenin were observed in 50 and 500 
nM testosterone treatments compared to control (50 nM 1.27 ± 0.36; 500 nM 1.16 
± 0.40 vs. control 0.97 ± 0.40; P ≤ 0.01, Fig 3.5A). However, there was no 
statistical difference between the two T treatments suggesting no further increases 
in myogenin at the higher dose of 500 nM vs. 50 nM. No statistically significant 
changes occurred in myogenin mRNA levels after 7 days exposure in any of the 
treatments (P=N.S, Fig 3.5A), which is not surprising seen as myogenin is 
involved in myoblast fusion not maturation of existing myotubes. 
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Fig 3.5 The effect of testosterone doses on selected gene transcripts in differentiating myoblasts 
(T1 experiment). A) Both *50 and *500 nM testosterone increased myogenin expression after 72 
hrs exposure compared to control treatment (P ≤ 0.01). B) Exogenous λIGF-I significantly 
increased AR mRNA expression after 72 hrs (P ≤ 0.01). Testosterone doses did not significantly 
alter AR expression levels at any time point. C) Testosterone doses also did not significantly alter 
IGF-I mRNA expression after 72 hrs and 7 days exposure. The addition of exogenous 
#
IGF-I 
significantly down regulated IGF-I mRNA after 72 hrs exposure (P ≤ 0.01) D) The 50 nM 
testosterone significantly down regulated myostatin expression after 7 days exposure compared to 
the control treatment (*P ≤ 0.001).     
 
After 7 days exposure, the largest increase in Igf1 mRNA expression was 
observed in the 50 nM T condition, although no statistical differences were 
observed between treatments in IGF-I expression (P=N.S, Fig 3.5C). As for AR 
mRNA expression (Fig 3.5B), there were no significant changes between 
testosterone doses at either time points (P=N.S). In terms of myostatin mRNA 
expression, the 50 nM testosterone treatment significantly down regulated 
myostatin levels compared to the control treatment after 7 days exposure (50nM 
1.18 ± 0.45 vs. control 2.04 ± 0.68; P ≤ 0.001, Fig 3.5D)  
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In comparison to the T1 observations, the administration of testosterone on 
pre-existing myotubes (T2) resulted in slightly different results. Only the 50 nM 
dose of testosterone had an effect on myogenin mRNA expression (Fig 3.6A). 
After 24 hours exposure, myogenin expression remained significantly elevated 
compared to the control treatment (50 nM 0.90 ± 0.09 vs. control 0.67 ± 0.20; P ≤ 
0.01, Fig 3.6A). However, after 72 hrs exposure, there was a significant reduction 
in myogenin expression with 50nM testosterone compared to the control treatment 
(50nM 0.60 ± 0.19 vs. control 0.87 ± 0.12; P ≤ 0.01, Fig 3.6A). In terms of the 
500 nM dose, there were no significant alterations in myogenin expression at 
either time point (24 hrs control 0.67 ± 0.20 vs. 500 nM 0.80 ± 0.14; 72hrs control 
0.87 ± 0.12 vs. 500 nM 0.75 ± 0.22; P=N.S. Fig 3.6A). Interestingly, there were 
no alterations in AR mRNA expression levels between treatments (Fig 3.6B). 
However, a main effect for time was observed, where a reduction in AR mRNA 
significantly decreased after 24 hrs to 72 hrs culture time (P ≤ 0.001, Fig 3.6B).  
For Igf1 mRNA expression, 50 nM testosterone maintained levels after 24 
hours exposure compared to the control treatment (50 nM 0.86 ± 0.17 vs. Control 
0.62 ± 0.20; P ≤ 0.05, Fig 3.6C). After 72 hrs exposure, 500 nM testosterone 
administration resulted in statistically significant reductions in Igf1 mRNA 
expression (500 nM 0.98 ± 0.11 vs. control 1.29 ± 0.32; P ≤ 0.01, Fig 3.6C). 
Finally, for myostatin mRNA expression, testosterone doses administered to pre-
existing myotubes had no significant effect on reducing levels in comparison to 
the results observed in differentiating myoblasts in the T1 experiment (P=N.S, Fig 
3.6D).   
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Fig 3.6 The effect of testosterone administration on mRNA expression levels in pre-existing 
myotubes (T2). A) *50 nM testosterone significantly increased myogenin mRNA expression after 
24hrs exposure (P ≤ 0.01). However after 72 hrs exposure myogenin was significantly down 
regulated in the 50 nM testosterone treatment compared to other treatments (**P ≤ 0.01). B) 
Treatments administered to pre-existing myotubes did not alter AR mRNA expression levels. 
However, with time, there was a significant decrease in AR mRNA in all treatments at 72 hrs 
compared to 24 hrs (P ≤ 0.001). C) *50 nM testosterone statistically elevated IGF-I expression 
after 24 hrs exposure compared the control treatment (P ≤ 0.05). There was a significant reduction 
observed with 500 nM after 72 hrs exposure (**P ≤ 0.01).  D) There were no alterations in 
myostatin expression levels after 24 and 72 hrs with any treatments administered (P=N.S).  
 
3.3.3 The effect of a 100 nM dose in CON and PD myoblasts on myotube 
morphology 
As there was little difference between the high and low dose testosterone with 
respect to a hypertrophic response an intermediary 100 nM dose was implemented 
(similar to T1) firstly in the CON myoblasts as this dose has previously been 
extensively used in myoblast in vitro studies in the literature ((Basualto-Alarcón 
et al., 2013, Serra et al., 2011, White et al., 2012, Wu et al., 2010a), then 
subsequently in the PD myoblasts to characterise their response to testosterone 
administration. The 100 nM dose had a significant effect on myotube 
hypertrophy. After 7 days exposure, testosterone increased myotube number in 
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CON myoblasts (CON 3.27 ± 0.72 vs T 4.73 ± 0.87; P ≤ 0.0001, Fig 3.7A). In 
terms of myotube diameter, testosterone significantly increased size after 72 hrs 
(CON 16.18 ± 1.57 μm vs T 19.04 ± 2.07 μm; P ≤ 0.05, Fig 3.7B) and 7 days 
(CON 16.34 ± 1.11 μm vs T 19.54 ± 1.77 μm; P ≤ 0.05, Fig 3.7B) exposure. In 
CON myoblasts, increases nuclei number per myotube were observed after 72 hrs 
(CON 3.38 ± 0.50 vs. T 4.68 ± 0.92; P ≤ 0.05, Fig 3.7C) and 7 days (CON 4.93 ± 
0.92 vs. T 6.80 ± 1.51; P ≤ 0.05, Fig 3.7C) exposure.   
 
 
Fig 3.7 The effect of 100 nM T dose on myotube morphology in CON myoblasts. A) Testosterone 
significantly increased myotube number compared to basal conditions (*P ≤ 0.0001). B) 
Testosterone significantly increased myotube diameter in CON (*P ≤ 0.05) myoblasts after 72 hrs 
and 7 days compared to untreated cells. C) Testosterone increased nuclei per myotube after 72 hrs 
and 7 days culture (*P ≤ 0.05).  
 
As the 100 nM dose elicited a positive hypertrophic response in CON 
myoblasts, it was carried forward and investigated in the PD myoblasts. The 
amount of myotubes present at 72 hrs was sparse and thus myotube number and 
nuclei number per myotube were not quantified after 72 hrs culture. There were 
no alterations in myotube number after 7 days testosterone treatment compared to 
basal conditions (PD vs. T; P=N.S, Fig 3.8A). Testosterone significantly 
increased myotube diameter after 72hrs (PD 13.40 ± 0.37 vs. T 17.57 ± 1.28; P ≤ 
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0.05) and 7 days (PD 15.52 ± 1.89 vs. T 18.79 ± 2.10; P ≤ 0.05) exposure 
compared to untreated PD myoblasts (Fig 3.8B). Finally, testosterone increased 
the number nuclei per myotube in both CON and PD myoblasts. After 7 days 
exposure, 100 nM testosterone significantly increased nuclei per myotube 
compared to un-treated PD myoblasts (PD 4.14 ± 0.79 vs. T 6.58 ± 1.54; P ≤ 0.05, 
Fig 3.8C). Overall, the 100 nM T dose appear to have a positive hypertrophic 
response in both cell types.  
 
Fig 3.8 The effect of 100 nM testosterone dose on myotube morphology in PD myoblasts A) 
Testosterone had no significant impact on myotube morphology after 7 days culture (P=N.S) B) 
Increases in myotube diameter was observed in testosterone treated PD myoblasts after 72 hrs and 
7 day culture compared to untreated cells (*P ≤ 0.05) C) Testosterone significantly increased the 
number of nuclei per myotube in PD myoblasts after 7 days treatment (*P ≤ 0.05).  
 
3.4 DISCUSSION 
 
3.4.1 Characterization of testosterone on myogenesis and hypertrophy 
 
In the present study, the use of testosterone significantly enhanced myotube 
hypertrophy when administered to both differentiating and differentiated 
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myoblasts. These observations support in-vitro and in-vivo data which has 
repeatedly shown the hypertrophic effect of testosterone administration on 
skeletal muscle (Sculthorpe et al., 2012, Bhasin et al., 2001, Sinha-Hikim et al., 
2002, Sinha-Hikim et al., 2006, Serra et al., 2011, Wannenes et al., 2008). The 
administration of testosterone to differentiating myoblasts increased myonuclear 
accretion (myotubes expressing 5+ nuclei) in the T1 experiment only, highlighting 
the steroids role in differentiation (cell fusion) and contribution towards myotube 
hypertrophy. In the T1 experiment, the significant increase in myogenin (promotes 
differentiation/cell fusion) expression with testosterone at 72hrs provides evidence 
towards confirmation of testosterone’s role in enhancing muscle differentiation 
and myonuclear accretion, resulting in enhance myotube hypertrophy. Further, 
this pattern of heightened myogenin expression was observed in the T2 
experiment after 24 hrs exposure of testosterone. These observations are 
supported by earlier studies in C2C12 muscle cells, although their focus was on the 
androgen receptor itself, instead the role of a testosterone stimulus (Lee, 2002, 
Wannenes et al., 2008).  
  Contrasting to previous studies, testosterone administration did not  
significantly increase endogenously expressed  IGFI mRNA when exposed to 
differentiating myoblasts (Sculthorpe et al., 2012). In the T2 experiment, 50 nM 
testosterone maintained local IGFI expression after 24 hrs exposure, a factor 
which might help explain the enhanced myotube hypertrophy, without increased 
myonuclear accretion, as T has been observed to enhance muscle protein synthesis 
(Brodsky et al., 1996, Ferrando et al., 2002, Urban et al., 1995). Another 
possibility where testosterone may interact with the IGF-I/Pi3K/Akt pathway is 
through myostatin, as decreases were observed with 50 nM testosterone in the T1 
experiment after 7 days exposure. In vitro myostatin has been observed to inhibit 
IGF-I induced myotube hypertrophy through Akt (myostatin inhibited Akt 
phosphorylation). Plus myostatin appears to reduce Akt/TORC1/p70S6K 
signaling, myoblast differentiation and myotube size (Morissette et al., 2009, 
Trendelenburg et al., 2009). Thus the reductions in myostatin mRNA expression 
under a testosterone stimulus may have contributed to the enhanced myotube size 
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observed.(Léger et al., 2008)(Aversa et al., 2012)(Atkinson et al., 2010, Bhasin et 
al., 2005, Dillon et al., 2012)  
 
3.4.2 The effect of low and high doses towards testosterone-induced 
hypertrophy  
 
Interestingly, there was no difference between high and low dose 
responses in mRNA expression changes and morphological parameters between 
testosterone treatments. A low level of AR in C2C12 cells has previously been 
reported (Altuwaijri et al. 2004) and thus no dose response may likely be due to 
androgen receptor saturation. Within the C2C12 cell line, previous literature has 
reported low endogenous levels of AR expression (Altuwaijri et al., 2004). To 
overcome this factor, the AR has been over expressed (transfection) to address the 
action of testosterone (Altuwaijri et al., 2004, Lee, 2002, Sheppard et al., 2011) 
due to these potential low levels. Recently Sheppard et al. (2011) illustrated the 
variability in AR level in C2C12 cells with a low expression in single myoblasts 
cells and heightened expression in formed myotubes, where the expression 
decreased with time (myotube maturation).   
Indeed, the T2 experiment provides evidence towards a decrease in AR 
expression, as the mRNA level significantly reduced with myotube maturation 
(independent of treatment condition between 24 hrs to 72 hrs). Wannenes et aland 
Colleagues (2008) exposed wild type C2C12 cells (no AR transfection performd) 
to low doses of T (1-10 nM) for 0,2,4 days and observed a dose-response in the 
activation of AR mRNA expression plus the translocation of AR from the 
cytoplasm to the nucleus, while investigating T’s role in muscle differentiation. 
Thus the differing results between the current study and Wannenes et al (2008), 
maybe due to the different dose exposures, the length of exposure time and 
possibly the variability in AR expression levels. Overall, these two experiments 
(T1 and T2) and the 100 nM dose in CON and PD myoblasts, provide an indication 
for a suitable dose to be used in subsequent experiments as in-vitro testosterone 
administrations have ranged from low dose (1-100 nM) (Basualto-Alarcón et al., 
2013, Wannenes et al., 2008, Wu et al., 2010a) to high dose (400-500 nM) 
(Sculthorpe et al., 2012, Serra et al., 2011). 
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3.4.3 Chapter Summary 
 
In summary, this chapter of work has characterized the cellular and 
transcriptional effects of testosterone-induced hypertrophy in skeletal muscle 
C2C12 myoblasts and myotubes. Furthermore, a temporal response has been 
observed by administrating testosterone on to differentiating myoblasts vs. pre-
existing myotubes. Testosterone induced hypertrophic alterations in myotube 
morphological characteristics such as diameter and myonuclear accretion. These 
alterations were accompanied by the up regulation of myogenin, Igf1 mRNA and 
the down regulation of myostatin mRNA expression levels, although these 
changes were dependant on the point of testosterone administration. Commonly, 
increases in muscle mass and myotube size with testosterone administration are 
observed with a dose response effect. However within this cell type, there was no 
difference between the 50 and 500 nM testosterone, a factor potentially explained 
by previously reported low levels of androgen receptor expression. Due to this 
observation, a 100 nM dose was administered to the CON myoblasts and carried 
forward into PD myoblasts to characterize this dose in cells that display impaired 
regeneration. A hypertrophic response (myotube number and diameter) was 
observed in both cell types with the 100 nM dose. Overall, this chapter provides 
evidence of the cellular and molecular targets involved in testosterone-induced 
hypertrophy, indicating a suitable dose for use in subsequent experiments, as well 
as targets which may mediate this action.       
 
3.4.4 Linking Summary 
In order to investigate the role of direct AR verses indirect IGF-I signaling, a 
dose response of AR inhibitors and IGF-IR inhibitor was needed to be established. 
Although an increase in local IGF-I expression did not occur compared to 
previous literature (Sculthorpe et al., 2012, Serra et al., 2011), a mean increase 
with testosterone administration was observed. Furthermore, the decrease in 
myostatin levels with testosterone administration in the current chapter, and 
potential activation of downstream IGF-I signalling (i.e. via Akt), make it  
pertinent to investigate if IGF-I signalling as such signalling may still be involved 
in mediating testosterone-induced muscle hypertrophy. 
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4. THE CHARACTERIZATION OF INHIBITOR DOSES FOR THE 
ANDROGEN RECEPTOR AND IGF-I RECEPTOR  
 
4.1 INTRODUCTION 
There are two potential pathways which may mediate the action of 
testosterone induced skeletal muscle hypertrophy; binding to the androgen 
receptor (direct) and the IGF-I/Akt/mTOR/p70s6k pathway (indirect). In vivo, 
androgen receptor expression has been investigated in numerous studies 
implementing resistance exercise to mechanically overload skeletal muscle 
(Spiering et al., 2009, Ratamess et al., 2005, Vingren et al., 2009, Hulmi et al., 
2008). Resistance exercise elicits an increase in circulating levels of anabolic 
hormones such as IGF-I and testosterone, which may contribute to muscle 
hypertrophy (Borst et al., 2001, Kraemer and Ratamess, 2005, Spiering et al., 
2009). Although the recent evidence casts doubt on the importance of post-
exercise circulating in muscle hypertrophy (West et al., 2009, West et al., 2010, 
Wilkinson et al., 2006), yet increases in androgen receptor protein content have 
been correlated with muscle hypertrophy, specifically mean fibre cross-sectional 
area (Mitchell et al., 2013). In comparison, IGF-I has been extensively shown to 
stimulate muscle protein synthesis and enhance muscle hypertrophy (Rommel et 
al., 2001, Sacheck et al., 2004, Kalista et al., 2011).  Although it may still be 
under debate as to whether  IGF-I receptor is/is not required  for load induced 
hypertrophy ((Spangenburg et al., 2008), it does, however, appear critical in 
skeletal muscle development (Fernández et al., 2002, Philippou et al., 2007) 
satellite cell activation and differentiation (Crown et al., 2000, Heron‐Milhavet et 
al., 2010, Lawlor et al., 2000, Sharples et al., 2010).  
 
4.1.1 The role of the androgen receptor in skeletal muscle differentiation and 
hypertrophy 
 
Testosterone is a ligand of the androgen receptor and thus binds to the 
receptor to form a complex which binds promoter or androgen response elements 
(ARE) of target genes to regulate their transcription (Chen et al., 2005). The 
classical view is that un-ligand bound receptor resides in the cytoplasm, once 
bound it translocates to the nucleus (Bennett et al., 2010). Most recently in C212 
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muscle cells, the AR has been observed to be sub-localized in the mitochondria 
and microsomal (Pronsato et al., 2013).  The satellite cell is the predominant 
location for AR expression and thus the AR may contribute to muscle hypertrophy 
via differentiation and/or proliferation of these cells (Doumit et al., 1996, Lee, 
2002, Wannenes et al., 2008, Sinha-Hikim et al., 2004). The AR and IGF-I both 
have androgen response element present upon their promoter regions (Grad et al., 
1999, Wu et al., 2007). Interestingly, myogenin does not have an response 
element present but has been observed to have increased expression following 
testosterone-administration and subsequent binding to the AR (Lee, 2002). This 
factor is highlighted in a study by Lee (2002), where AR transfection into C2C12 
muscle cells, lead to enhance muscle differentiation under a testosterone stimulus.   
The effects on skeletal muscle by inhibiting the AR have been investigated in 
vitro using chemical inhibitors (flutamide & bicalutamide) (Sculthorpe et al., 
2012, Wannenes et al., 2008, Basualto-Alarcón et al., 2013)  and animal knockout 
models (MacLean et al., 2008, Ophoff et al., 2009). Animal knockout models 
illustrate the importance of the androgen receptor in skeletal muscle development 
as these models exhibit decreases in muscle mass and impairment i.e. reduced 
muscle force production (Chambon et al., 2010, MacLean et al., 2008, Ophoff et 
al., 2009). The uses of flutamide and bicalutamide in vitro cell culture are 
designed as substrate competitors (AR antagonists) and thus compete with 
Testosterone for binding to the androgen receptor (Bennett et al., 2010, Singh et 
al., 2003). Indeed the co-incubation of testosterone and an AR antagonist in vitro 
leads to reduced muscle differentiation and hypertrophy (Basualto-Alarcón et al., 
2013, Sculthorpe et al., 2012, Wannenes et al., 2008).  
 
4.1.2 The role of the IGF-I receptor and downstream signaling in skeletal 
muscle. 
The binding of IGF-I to its receptor, activates a cascade of signalling, initiated 
with the activation of Pi3K. The release of a phosphate group by Pi3K allows for 
the phosphorylation and activation of Akt. Once at this step in the pathway, Akt 
mediates the phosphorylation of mTOR. The activation of mTOR promotes 
protein synthesis via the phosphorylation of p70S6k and S6K targets (Yin et al., 
Chapter 4: Characterization of Inhibitor doses for the Androgen receptor and IGF-I 
receptor 
73 | P a g e  
 
2009). The activation of this signaling cascade leads to increased muscle protein 
synthesis and subsequently muscle/myotube hypertrophy (Bodine et al., 2001, 
Rommel et al., 2001). Similar to the AR, the inhibition of IGF-IR has been 
performed using substrate competitors (Picropodophyllin) (Girnita et al., 2004, 
Duan et al., 2009), small interference RNA and animal knockout models 
(Deldicque et al., 2007, Galluzzo et al., 2009, Heron‐Milhavet et al., 2010, Liu et 
al., 1993, Serra et al., 2011, Spangenburg et al., 2008). IGF-I stimulates both 
proliferation and differentiation via the IGF-I receptor and mice lacking the IGF-I 
receptor have diminished muscle size (Clemmons, 2009, Liu et al., 1993).   
 
4.1.3 Aims and Objectives 
 
Therefore in light of the literature discussed above, the aims of this chapter 
were to characterize doses for inhibitors of the AR (20 and 40 μM) and IGF-IR 
(30, 90 and 150 nM) in C2C12 skeletal muscle myoblasts, specifically utilizing the 
population doubling (PD) model (Sharples et al., 2011). The investigation of all 
the inhibitor doses will allow for the determination of an effective dose to be 
identified for use in a subsequent chapter (5). Thus morphological (myotube 
diameter and number) and transcriptional (myogenin, AR and IGF-I) and 
biochemical (Akt and ERK1/2) alterations to these doses were measured. It was 
hypothesized that a detrimental dose response effect would be observed towards 
cellular and molecular signalling involved in myotube differentiation and 
hypertrophy.      
 
4.2 METHODOLOGY 
 
4.2.1 Cell Culture 
Mouse C2C12 skeletal muscle myoblasts (CON and PD; outlined in 2.4.2) were 
resurrected as described in 2.6 and cultured as outlined in 2.4.1. Cells were 
cultured as detailed in section 2.4 and chapter 3. Cells at the time points of 0, 72 
hrs and 7 days were fixed for histology, isolated for RNA (outlined in 2.12.2 and 
2.12) for rt-PCR and lysed for protein analysis (western blots, as outlined in 2.9). 
For the IGF-I receptor stimulation experiment, cells were stimulated for 15 
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minutes in treatments detailed below (4.2.2) and then lysed for protein analysis 
(detailed in 2.9).  
 
4.2.2Cell Treatments 
All treatments were administered in DM described above (detailed in 2.7.6). 
The treatments comprised of a vehicle control (DMSO at a concentration of 
0.01%), Flutamide doses (F) 20 and 40 μM, Picropodophyllin (PPP) 30, 90 and 
150 nM i.e. DM + PPP and DM + F. For the IGF-I receptor stimulation study to 
address downstream signalling of the receptor, exogenous IGF-I (10 ng.ml
-1
) and 
PPP were incubated alone and together i.e. DM + IGF-I and DM + PPP (outlined 
in section 2.7). The IGF-I stimulation was conducted to address whether PPP was 
still effective in the presence of exogenous IGF-I. The exogenous IGF-I dose was 
selected based on previously published work (Saini et al., 2008). DMSO was used 
as the solvent for flutamide and picropodophyllin reconstitution at the same 
concentration as the vehicle (0.01%). For results and figure legends the following 
nomenclature will be used Control, F, PPP and IGF-I respectively. All treatments 
were added at 0 hrs and existing media was further supplemented at 72 hrs for 
flutamide and Picropodophyllin experiments.   
 
4.2.3 RNA Isolation 
6 well plates for each time point (0hrs, 72 hrs and 7 days) were washed with 1 
ml per well of Phosphate Buffer Saline (PBS) and extracted for RNA by placing 
300 μl of TRIzolTM Reagent (Sigma, St Louis) in each well. Total RNA was 
extracted as outlined in section 2.12.1. RNA concentration and purity were 
assessed through UV spectroscopy at ODs of 260 and 280 nM, using the 
Nanodrop spectrophotometer 3000 (outlined in 2.11.2).  
 
4.2.4 Real time, Reverse Transcriptase Polymerase Chain Reaction (rt-RT-
PCR) 
Seventy nanograms of RNA were taken from each sample and real time, 
reverse transcription polymerase chain reaction (RT-rt-PCR) was performed as 
detailed in section 2.12.3. Primer sequences for genes of interest are shown in 
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table 2.1 and were checked for specificity according to 2.12.2. The relative 
mRNA expression of AR, IGF-I, myogenin was quantified using the comparative 
Ct (
ΔΔ
ct) Method against a reference gene of RP-IIb and calibrator of Control 
treatment (after 0hrs in all experiments). Raw CT for real time qPCR conducted in 
this chapter of work can be viewed in appendix 2 (Table 9.2).   
 
4.2.5 Immunoblotting 
Samples were prepared as outlined in 2.13.2. Gels were made up of a 10% 
resolving gel and a 5% stacking gel. Samples were electrophoresed at 200 volts 
until the sample buffer tracking dye reached the bottom of the gel (detailed 
in2.13.4). The proteins were transferred to the nitrocellulose membrane for use in 
Immunoblotting for 30 minutes (described in 2.13.5). The western blotting was 
performed based on manufacturer’s instructions (described in 2.13.7). Membranes 
were sealed in plastic bags containing primary antibodies for Akt (total and 
phosphorylation (Ser473)), ERK ½ (total and phosphorylation (Thr202/Tyr204)) 
at a concentration of 1:1000, and GAPDH (loading control; 1:4000) in an 
antibody diluent liquid for 1 hour incubation at room temperature. Detection of 
proteins was achieved using enhanced chemiluminescence (ECL) with a West 
Pico Supersignal kit as described in 2.13.8.  
 
4.2.6 Microscope Analysis  
Cells were fixed using the protocol detailed in 2.10.2. PBS (2ml/well) was 
added after removal of the methanol/acetone mix and plates were stored in 4
o
c 
until further analysis. Quantification of myotube diameter and myotube number 
was captured using an x10 light microscope (Inverso-TC, CETI, Medline 
Scientific Limited, Oxon, UK). In total 30 fields per condition for each time point 
were acquired and analyzed using image J (Java) software (National Institutes of 
Health, USA) as detailed in section 2.10.3.   
 
4.2.6 Statistical Analysis  
Experiments were performed in triplicate, with 3 separate repeats (n=3). Data 
are presented as Mean + S.D unless stated otherwise. Gene expression data was 
assessed using a mixed three-way factorial ANOVA for interactions between time 
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(72 hrs and 7 days), treatments (DM, 40μM F; DM, 150nM PPP) and cell types 
(CON and PD). Morphology data was assessed using an ANOVA for interactions 
between time (72 hrs and 7 days), treatments and cell types. If significant 
interactions were present, independent t-tests were conducted to confirm statistical 
significance between variables of interest. For the IGF-I stimulation experiment, a 
one way ANOVA was performed for western blots analyses. A p-value of <0.05 
was considered statistically significant. All statistical analyses were performed 
using SPSS version 19 and GraphPad Prism Software (detailed in 2.14).   
 
4.3 RESULTS  
4.3.1 The impact of flutamide doses on myotube morphology 
There was a significant difference between the CON and PD cell types for 
myotube diameter and number after 7 days culture (Fig 4.1). After 72hrs, there 
were no visible myotubes observed in the PD myoblasts for all treatments 
highlighting basally impaired regeneration as previously described by Sharples et 
al., 2011; 2012. The CON myoblasts resulted in a significantly greater number of 
myotubes (CON 4.29 ± 0.77 vs. PD 2.29 ± 0.61, P ≤ 0.001) and increased 
myotube size (CON 16.69 ± 1.09 μm vs. PD 12.94 ± 1.04 μm, P ≤ 0.001) verses 
PD myoblasts (Fig 4.2) after 7 days.     
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Fig 4.1 Light microscope images (10x magnification) of CON and PD myoblasts administered 20 
and 40 μM doses for 72 hrs and 7 days. The administration of both flutamide doses resulted in 
decreases in differentiation (72hrs) and hypertrophy (7 days) in CON and PD myoblasts.  
 There was a detrimental impact on myotube morphology in a dose 
response manner in the presence of flutamide (Fig 4.1) in both cell types. In CON 
myoblasts, there was a significant reduction in myotube number (CON DM 2.46 ± 
0.66 vs. 40 μM F 1.22 ± 0.44; P ≤ 0.01, Fig 4.2A) and diameter (CON DM 15.20 
± 0.85 μm vs. 40 μM F 12.67 ± 1.27 μm; P ≤ 0.01, Fig 4.2B) with the highest 
flutamide dose after 72hrs exposure. After 7 days exposure, the reduction in 
myotube number (CON DM 4.29 ± 0.77 vs. 40 μM F 1.93 ± 0.59; P ≤ 0.01) and 
diameter (CON DM 16.69 ± 1.09 μm vs. 40 μM F 14.78 ± 1.12μm; P ≤ 0.01) with 
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40 μM flutamide was still observed (Fig 4.2). In PD myoblasts, a similar trend 
was observed after 7 days exposure as 40 μM flutamide was detrimental to the 
myotube formation and hypertrophy with no measurable myotubes being 
observed vs. DM conditions and 20 μM flutamide that did have measurable 
myotubes (7 days myotube diameter: PD 12.94 ± 1.04 vs 20 μM F 10.89 ± 1.64; 
Fig 4.2B). Overall in terms of PD myoblasts, there was a ~45% decrease in 
myotube number and ~16% in diameter with the presence of 20 μM flutamide 
alone. Subsequently the 40 μM dose was carried forward for AR gene expression 
and total AR protein analyses.  
    Fig 4.2. The quantification of myotube morphology with flutamide administration in CON and 
PD myoblasts after 72 hrs and 7 days exposure. A) The administration of flutamide had a 
detrimental effect on myotube number after 72 hrs and 7 days in CON cells (*P ≤ 0.001). In the 
PD cells, flutamide was detrimental to myotube formation with 40 μM inhibiting myotube 
formation after 7 days exposure  B) Myotube diameter was significantly reduced at 72hrs (*P ≤ 
0.001) and 7days (**P ≤ 0.001) with flutamide administration in CON cells. In PD cells, the 
addition of 40 μM flutamide resulted in no myotubes being formed after 7 days exposure. 
Furthermore, at 7 days there was a significant difference in basal CON and PD mean myotube 
diameter (**P ≤ 0.001).  
4.3.2 Androgen receptor protein and related gene transcript alterations with 
flutamide administration 
 
In basal conditions between CON and PD cells, myogenin mRNA expression 
was significantly down-regulated in PD cells after 72 hrs (CON DM 28.94 ± 3.28 
vs. PD DM 8.12 ± 1.33; P ≤ 0.05, Fig 4.3A) and 7 days (CON DM 29.37 ± 3.04 
vs. PD DM 17.78 ± 1.78; P ≤ 0.05, Fig 4.3A). Similarly IGF-I mRNA expression 
was down-regulated in PD cells compared to CON basal conditions after 72 hrs 
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(CON DM 3.14 ± 0.68 vs. PD DM 0.62 ± 0.27; P ≤ 0.05, Fig 4.3B) and 7 days 
(CON DM 7.10 ± 3.10 vs. PD DM 3.94 ± 1.61; P ≤ 0.05, Fig 4.3B). Finally, 
androgen receptor mRNA expression exhibited the same pattern of down-
regulation after 72 hrs (CON DM 1.51 ± 0.76 vs. PD DM 0.64 ± 0.12; P ≤ 0.05, 
Fig 4.3C) and 7 days (CON DM 1.39 ± 0.38 vs. PD DM 0.81 ± 0.39; P ≤ 0.05, 
Fig 4.3C) between PD and CON myoblasts. The AR mRNA observations 
highlight that in basal conditions, PD myoblasts have a lower expression of AR 
initially compared to CON myoblasts.   
The administration of the 40 μM flutamide dose significantly reduced 
myogenin expression in both CON and PD cells after 72 hrs (CON DM 28.94 ± 
3.28 vs. 40μM F 19.44 ± 1.99; PD DM 8.12 ± 1.33 vs. 40 μM F 1.17 ± 0.52; P ≤ 
0.05, Fig 4.3A) and 7 days (CON DM 29.37 ± 3.04 vs. 40 μM F 18.22 ± 6.12; PD 
DM 17.78 ± 1.78 vs. 40 μM F 0.39 ± 0.18; P ≤ 0.05, Fig 4.3A). In comparison, 
Igf1 mRNA expression with only significantly reduced in PD cells after 7 days 
exposure (PD DM 3.94 ± 1.61 vs. 40μM F 0.74 ± 0.26; P ≤ 0.05, Fig 4.3B). There 
were no significant alterations in AR mRNA expression in the presence of 
flutamide at either time points in CON and PD myoblasts (P=N.S, Fig 4.3C). 
However, there was a reduction in total androgen receptor protein with flutamide 
in both cell type at72 hrs and 7 days (Fig 4.3D).     
 
 
 
 
 
 
 
 
Chapter 4: Characterization of Inhibitor doses for the Androgen receptor and IGF-I 
receptor 
80 | P a g e  
 
 
Fig 4.3. The effects of flutamide administration on specific gene transcripts and total 
androgen receptor protein levels after 72 hrs and 7 days exposure. A) Myogenin mRNA expression 
was significantly down regulated in PD cells after 72 hrs and 7days compared to basal CON cells 
(*P < 0.05). The addition of flutamide significantly decreased myogenin levels in both CON (*P < 
0.05) and PD (**P < 0.01) cells at both time points. B) IGF-I expression was significantly lower in 
basal PD cells compared to CON cells at both time points (*P < 0.05). Flutamide significantly 
reduced IGF-I expression in the PD cells after 7 days exposure (**P < 0.05). C) There was a 
significant decrease between CON and PD myoblast basal AR levels after 72hrs (*P < 0.05) and 7 
days (**P < 0.01) culture. D) Interestingly, flutamide appeared to reduce total AR protein levels in 
both cell types for both time points (Flutamide +; DM -). Images are representative blots (n=3).  
 
4.3.3 Alterations in myotube morphology with the addition of 
Picropodophyllin 
The IGF-I receptor inhibitor (PPP) was administered to both CON and PD 
myoblasts for 72 hrs and 7 days. With increasing doses, there appeared to be a 
detrimental effect on myotube morphology in both cell types (Fig 4.4).  At 72 hrs, 
similar to the flutamide experiment, there were no quantifiable myotubes present 
in the PD cell type. The following absolute data is different as different samples 
were generated for the PPP dose experiment. There were significant differences 
between basal CON and PD myoblasts for myotube number (CON DM 4.18 ± 
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0.61 vs. PD DM 2.54 ± 0.66; P ≤ 0.01, Fig. 4.5A) and diameter (CON DM 16.06 
± 0.65μm vs. PD DM 13.24 ± 0.59μm; P ≤ 0.01, Fig. 4.5A) after 7 days culture.  
There was a significant detrimental effect with increasing doses of PPP on 
CON myoblasts after 72 hrs (CON DM 2.30± 0.73 vs. 30 nM 1.92 ± 0.67; 90 nM 
1.38 ± 0.51; 150 nM 1.33 ± 0.49; P ≤ 0.01, Fig. 4.5A) and 7 days (CON DM vs. 
30 nM 3.32 ± 0.61; 90 nM 3.21 ± 0.57; 150 nM 2.46 ± 0.58; P ≤ 0.01, Fig. 4.5A) 
in mean myotube number. The same pattern was evident in the PD myoblasts after 
7 days culture (PD DM 2.54 ± 0.66 vs. 30 nM 1.68 ± 0.65; 90 nM 1.59 ± 0.59; 
150 nM 1.50 ± 0.58; P ≤ 0.01, Fig. 4.5A). In terms of myotube diameter, the 
increasing doses reduced the diameter in CON myoblasts after 72 hrs (CON DM 
15.11 ± 0.81 vs. 30 nM 14.09 ± 1.02; 90 nM 13.77 ± 1.34; 150 nM 13.37 ± 0.62; 
P ≤ 0.01, Fig. 4.5B) and at 7 days (CON DM 16.06 ± 0.65 vs. 30 nM 15.32 ± 
0.73; 90 nM 15.38 ± 0.71; 150 nM 15.17 ± 0.65; P ≤ 0.01, Fig. 4.5B). In the PD 
cell type, myotube diameter was also significantly reduced with increasing PPP 
dose at 7 days (PD DM 13.24 ± 0.59 vs. 30 nM 12.92 ± 1.11; 90 nM 12.81 ± 0.59; 
150 nM 11.54 ± 1.08; P ≤ 0.01, Fig. 4.5B). The alterations in myotube 
morphology provides evidence towards the PPP inhibiting the IGF-I receptor, 
highlighted by the reduction in muscle differentiation (myotube number ~41% 
decrease) and hypertrophy (myotube diameter ~7% reduction). Subsequently, 
IGF-I signalling and gene transcripts involved in muscle differentiation are 
investigated below.   
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Fig 4.4 Representative light microscope (x10 magnification) images of CON and PD myoblasts 
administered with 30, 90 and 150 nM doses of PPP for 72 hrs and 7 days culture. The 150 nM 
dose of PPP appeared to have the most detrimental effect on cell differentiation and hypertrophy in 
both cell types at each time point.   
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Fig 4.5 The effect of Picropodophyllin (PPP) doses on CON and PD myotube morphology 
after 72 hrs and 7 days. A) A detrimental effect in myotube number was observed with increasing 
doses of PPP in CON myoblasts after 72hrs (*P < 0.01) and 7 days (**P < 0.01). In PD myoblasts, 
PPP was also detrimental to myotube formation after 7 days culture (***P < 0.01).  B) 
Additionally PPP reduced myotube diameter in both CON and PD myoblasts after 72hrs and 7 
days culture (P < 0.05). To note, no quantifiable myotubes were observed in PD myoblasts after 
72hrs culture hence no data presented for the above morphological analyses.  
 
4.3.4 No effect of Picropodophyllin administration on IGF-I receptor protein 
and gene expression  
Interestingly, compared to the alterations in myotube morphology, the 
addition of 150 nM PPP resulted in no differences between DM and treatments in 
either cell type for myogenin, MyoD, Igf1 and the Igf1 receptor (Fig 4.6). 
Furthermore, similar to the flutamide experiment, there were significant 
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differences between basal CON and PD myoblasts for myogenin mRNA 
expression (CON DM 65.85 ± 29.14 vs. PD DM 23.52 ± 9.89; P ≤ 0.01 Fig 4.6A) 
and MyoD mRNA expression (CON DM 5.67 ± 2.04 vs. PD DM 2.79 ± 1.16; P ≤ 
0.01 Fig 4.6A) after 72 hrs cell culture. Furthermore, Picropodophyllin 
administration had no effect on total protein levels for the IGF-IR in either cell 
type at 72 hrs and 7 days (Fig 4.7).  
 
 
Fig 4.6  The effect of Picropodophyllin (PPP) on myogenin (A), MyoD (B) IGF-I (C) and 
IGF-IR (D) in CON and PD myoblasts. A) There was a significant decrease in myogenin 
expression between basal CON and PD cells after 72 hrs (*P < 0.01). B) A significant decrease in 
MyoD expression between CON and PD cells was observed after 72 hrs as well (*P < 0.01). C & 
D) Similar to myogenin and MyoD, there were no effects of PPP administration on IGF-I and its 
receptor in either cell type during culture time (P=N.S.).    
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Fig 4.7 Representative western blots for the IGF-I receptor (β sub-unit) (n=3) in CON and PD 
myoblasts after 72 hrs and 7 days exposure with (+) and without (-) the inhibitor, Picropodophyllin 
(150 nM). GAPDH (37kda) was blotted as a loading control. There appeared to be no alterations in 
IGF-IR protein levels in either cell type with administration of the inhibitor.  
 
4.3.5 Effects of exogenous IGF-I stimulation in combination with 
Picropdophyllin on downstream protein signalling.  
Due to the no changes observed in gene transcripts and IGF-IR protein levels 
in the presence of the IGF-IR inhibitor (PPP) the downstream signalling 
(pERK1/2 and pAkt) of IGF-IR was investigated in order to confirm that PPP was 
impacting on the function of the receptor to relay to intracellular signalling. We 
also included the addition of exogenous IGF-I in the presence of the PPP in order 
to further substantiate its role in the inhibition of IGF-IR function. The addition of 
exogenous IGF-I for 15 minutes in PD myoblasts lead to a statistically significant 
increase (~90%) in Akt phosphorylation levels compared basal PD myoblasts (PD 
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DM 9.0 ± 1% vs. PD IGF-I 102.5 ± 12.5%; P ≤ 0.01, Fig 4.8C). The co-
incubation of PPP with exogenous IGF-I abrogated the effect of IGF-I alone (PD 
IGF-I 102.5 ± 12.5% vs. IGF-I+PPP 41 ± 9%; P ≤ 0.01, Fig 4.8C). However, 
there was no significant effect observed between basal PD and PPP alone. In CON 
myoblasts, a similar trend was observed for exogenous IGF-I alone (CON DM 1 ± 
1% vs. CON IGF-I 31.5 ± 3.5%; P ≤ 0.05, Fig 4.8C) increasing Akt 
phosphorylation. However, the PPP inhibitor when co-incubated with IGF-I did 
not abrogate the exogenous IGF-I stimulation of Akt (CON IGF-I 31.5 ± 3.5% vs. 
CON IGF-I+PPP 25.5 ± 5.5%; P ≤ 0.05, Fig 4.8C). The ineffectiveness of the 
PPP in combination with exogenous IGF-I may be due to IGF-I being having a 
higher affinity to the receptor than PPP, although in the PD myoblasts, the Akt 
response is blunted. There were no changes in Akt total protein levels in either 
cell type for any of the treatments administered. 
 
 
Fig 4.8 Immunoblots for Akt (total and phosphorylation (Ser473)) after 15 minutes exposure to 
various treatments in CON (A) and PD (B) myoblasts. C) Exogenous IGF-I stimulated Akt 
phosphorylation in CON (*P < 0.05) and PD (*P < 0.01) myoblasts after 15 minutes. The effect of 
exogenous IGF-I was reduced in the PD myoblasts only when co-incubated with PPP (**P < 
0.01).  Values expressed as Mean ± S.E.M. Samples are duplicates for one experiment (n=1)   
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Furthermore, the activation of ERK1/2 was investigated after exogenous IGF-I 
stimulation for 15mins in PD and CON myoblasts. In both CON and PD 
myoblasts, exogenous IGF-I significantly increased ERK1/2 phosphorylation 
compared to basal treatments (CON IGF-I 86 ± 2% vs. CON DM 48 ± 13%; PD 
IGF-I 61 ± 0% vs. PD DM 30.5 ± 0.5%; P ≤ 0.01, Fig 4.9C). The co-incubation of 
IGF-I and PPP, reduced ERK1/2 phosphorylation significantly compared to IGF-I 
alone in both cell types (CON IGF-I 86 ± 2% vs. CON IGF-I+PPP 38.5 ± 12.5%; 
PD IGF-I 61 ± 0% vs. PD IGF-I+PPP 45 ± 1%; P ≤ 0.01, Fig 4.9C). However, 
PPP alone had no significant effect on ERK 1/2 phosphorylation compared to DM 
alone in CON and PD myoblasts (P=N.S.), although there was a mean reduction 
observed. There were no alterations in ERK1/2 total protein levels in either cell 
type. Overall, the abrogation of pAkt and pERK 1/2 phosphorylation with PPP in 
combination of exogenous IGF-I provides evidence for 150 nM dose being 
sufficient to inhibit the function of the IGF-I receptor and its downstream 
intracellular signalling.   
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Fig 4.9 Immunoblots for ERK1/2 (total and phosphorylation (Thr202/Tyr204)) after 15 minutes 
exposure to various treatments in CON (A) and PD (B) myoblasts. C) Exogenous IGF-I 
significantly increased ERK1/2 phosphorylation in CON and PD myoblasts after 15 minutes 
exposure (*P < 0.01). The co-incubation of IGF-I and PPP lead to reduced levels in ERK1/2 
phosphorylation in both cell types (**P < 0.01). There was a mean reduction in PPP alone in 
ERK1/2 phosphorylation in CON and PD myoblasts, although this observation was not 
statistically significant. Values expressed as Mean ± S.E.M. Samples are duplicates for one 
experiment (n=1)    
 
4.4 DISCUSSION 
   
The androgen receptor and IGF-I receptor have been linked to play roles in 
muscle mass and development (Fernández et al., 2002, MacLean et al., 2008, 
Philippou et al., 2007). The current chapter of work investigated the effects of two 
inhibitors, one for each receptor; flutamide and Picropodophyllin respectively. 
Furthermore, the doses for the inhibitors were characterized in cells which display 
hypertrophic (CON) and aged/reduced differentiation (PD) phenotypes, as these 
cells will be used in chapter 5 and 6 in order to address the role of testosterone in 
a model of ageing muscle cells. In PD myoblasts, reductions in myotube number 
and diameter for morphology and myogenin and MyoD for gene transcripts were 
observed compared to CON myoblasts, confirming previously published 
observations (Sharples et al., 2011, Sharples et al., 2012).  
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4.4.1 The impact of Flutamide on the androgen receptor and muscle 
differentiation 
Flutamide is an anti-androgen drug which competes with testosterone and its 
derivative, DHT for the binding to the androgen receptor (AR) (Bennett et al., 
2010). Flutamide has been used in numerous studies to investigate the impact of 
the AR on muscle differentiation and hypertrophy (Singh et al., 2003, Diel et al., 
2008, Sculthorpe et al., 2012).  In the current study, an increasing flutamide dose 
resulted in reduced myotube formation and hypertrophy in both CON and PD 
myoblasts. The 40 μM dose resulted in alterations in myogenin and IGF-I mRNA 
expression, for which IGF-I has been reported to have an androgen response 
element in the promoter region of the gene (Grad et al., 1999, Wu et al., 2007).   
There appeared to be a reduction in total AR protein levels with flutamide 
administration, although there were no alterations at the mRNA level. These 
observations combined provide evidence for the inhibition of the androgen 
receptor and thus a dose to be used the later experiment (Chapter 5). To note, the 
detection of the androgen receptor at the protein level (although the mRNA being 
lowly expressed (i.e. low Ct values of 28.45 ± 2.20) the use of the C2C12 muscle 
cell line, as earlier studies have occasionally transfected in AR due to previously 
reported  low levels in this cell type (Altuwaijri et al., 2004, Lee, 2002, Sheppard 
et al., 2011). Overall, despite low mRNA levels, inhibiting the AR appeared to 
have catastrophic effects on morphological and transcriptional markers of 
differentiation and hypertrophy, eluding to the importance of a functional AR in 
myotube formation and hypertrophy in skeletal muscle (Mitchell et al., 2013, 
Sheppard et al., 2011)   
 
4.4.2 The effect of Picropodophyllin on the IGF-I receptor and muscle 
differentiation 
There is limited evidence on the impact of Picropodophyllin in skeletal muscle 
differentiation (Deldicque et al., 2007, Galluzzo et al., 2009). In the current study, 
the 150 nM dose was detrimental to myotube formation and hypertrophy in both 
cell types. These alterations in the muscle phenotype were accompanied by 
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decreases in IGF-I downstream signalling (pAkt and pERK1/2) as 
picropodophyllin acts a substrate competitor for the IGF-IR to inhibit tyrosine 
phosphorylation of the receptor (Vasilcanu et al., 2004). Both ERK ½ and Akt 
and ERK1/2 downstream of the IGF-I receptor have been highlighted to 
contribute towards muscle proliferation and differentiation respectively (Adams, 
2002, Al-Shanti and Stewart, 2008, Coolican et al., 1997, Sarbassov and Peterson, 
1998) and thus the ~40% (pERK ½)  and ~60% (pAkt) decreases in signalling 
with the administration of PPP in the presence of  exogenous IGF-I may explain 
the reductions in myotube number and diameter.  
Previous doses of Picropodophyllin used in C2C12 muscle cells have ranged 
from 1-100 nM (Deldicque et al., 2007, Galluzzo et al., 2009), although the effect 
on muscle cellular process such as differentiation were not reported. The 
inhibition of the IGF-IR has previously been observed to delay skeletal muscle 
differentiation in myoblasts in vitro and mice lacking a functional IGF-I receptor 
have diminished muscle size and development (Cheng et al., 2000, Clemmons, 
2009, Fernández et al., 2002, Heron‐Milhavet et al., 2010, Liu et al., 1993, Kim et 
al., 2005). Alternatively small interference RNA has been used to inhibit the 
function of the IGF-I receptor, with a reduction in myotube area being observed in 
cultured human muscle cells (Serra et al., 2011). Overall, the administration of 
Picropodophyllin at a 150 nM dose is detrimental to myotube formation and 
hypertrophy, providing evidence for effective inhibition of the IGF-I receptor 
through alterations in the downstream signalling cascade.       
 
4.4.3 Chapter Summary 
 
In summary, this chapter of work has investigated the use of two inhibitors 
for the androgen receptor (Flutamide) and IGF-I receptor (Picropodophyllin) on 
skeletal muscle differentiation and hypertrophy in both control and population 
doubled cells that show a prior aged phenotype. These two receptors, as eluded to 
previously are suggested to mediate testosterone-induced muscle hypertrophy. 
The administration of flutamide (40 μM) significantly reduced myotube 
hypertrophy and differentiation in cells expressing hypertrophic CON and 
atrophic (PD) phenotypes. The detrimental effect was accompanied by alterations 
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in gene transcripts for muscle differentiation, IGF-I and the androgen receptor 
itself. In the instance of Picropodophyllin administration, a 150 nM dose had a 
negative effect on muscle differentiation and hypertrophy in both cell types. There 
were no alterations in gene transcripts or IGF-I receptor protein levels. However, 
close inspection highlighted reductions in Akt and ERK1/2 phosphorylation with 
Picropodophyllin treatment. Therefore, the 40 μM of flutamide and 150 nM doses 
were carried forward for co-incubation experiments with testosterone.    
 
4.5 THESIS DIRECTION 
 
In the current chapter and previous (chapter 3), both testosterone and 
inhibitors for AR and IGF-IR have been characterized in mouse C2C12 skeletal 
muscle cells and cells that show prior impaired reductions in regenerative capacity 
(aged phenotype/PD cells). Subsequently, going forward, a 100 nM testosterone 
dose will be used (highlighted in section 3.3.3) as this has been utilized in other 
cell lines/primary cultures (Basualto-Alarcón et al., 2013, Serra et al., 2011, Wu 
et al., 2010a). The evidence reported in the current chapter has identified 
appropriate doses which will be carried forward in the co-incubations of 
testosterone (100 nM) with flutamide (40 uM) and Picropodophyllin (150 nM) in 
order to elucidate the most predominant pathway (direct AR vs. indirect IGF-IR) 
in testosterones role in increasing differentiation and hypertrophy in muscle cells 
(Chapter 5). As testosterone administration has been implemented in ageing 
populations to enhance muscle mass, (Atkinson et al., 2010, Bhasin et al., 2000, 
Lewis et al., 2007, Sinha-Hikim et al., 2006), chapter 5 will also focus on the 
restoration of a hypertrophic phenotype in cells that show prior impaired 
regeneration/differentiation and the mechanisms controlling this process. Chapter 
6 will investigate the role of Akt in the restoration in the ageing phenotype 
observed in chapter 5.
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5. TESTOSTERONE ACTS VIA THE AR AND NOT THE IGF-IR 
IN THE INDUCTION OF DIFFERENTIATION AND 
HYPERTROPHY AND RE AN AGED PHENOTYPE IN 
MYOBLASTS.  
 
5.1 INTRODUCTION 
  The regulation of skeletal muscle mass is reliant on the balance between 
hypertrophy (e.g. protein synthesis/anabolism) and atrophy (e.g. protein 
breakdown/catabolism). A potential clinical intervention for promoting a positive 
net balance in the favour of protein synthesis is Testosterone administration 
(Brodsky et al., 1996, Sheffield-Moore et al., 1999). Testosterone replacement 
therapy has been observed to increase muscle strength and mass in various clinical 
populations including patients with AIDS, COPD and sarcopenia (Bhasin et al., 
2000, Casaburi et al., 2004, Dillon et al., 2012, Ferrando et al., 2002, Sattler et 
al., 2011). However, a limited number of studies have investigated the role of 
testosterone in skeletal muscle hypertrophy and during periods of atrophy i.e. 
following ageing (Serra et al., 2013, Wu et al., 2010a, White et al., 2012) at the 
cellular level. Recently, Serra and colleagues (2013) observed increases in skeletal 
muscle regeneration in young and aged rats post injury, which culminated in 
increased satellite cell activation and proliferation under a testosterone stimulus. 
These observations highlight the potential of testosterone administration in 
rescuing aged muscle mass and ageing phenotypes, with the mechanisms 
remaining to be elucidated.   
 
5.1.1 Myoblast models to investigate skeletal muscle hypertrophy and 
atrophy. 
 Recent studies have highlighted two myoblast models to study reduced 
differentiation capacity (Sharples et al., 2010, 2011, 2012). The first investigated 
the parental mouse C2 myoblasts vs. their subclone, the C2C12 cells. Despite their 
shared origins, we observed differences in morphological and biochemical 
responses between the C2 and C2C12 cells. The C2 cells displayed slower and 
diminished differentiation profiles compared to the C2C12 cells and were also 
more susceptible to TNF-α-induced inhibition of differentiation and induction of 
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apoptosis (Sharples et al., 2010). Because muscle wasting is associated with 
reduced muscle mass (Degens and Alway, 2003, Morse et al., 2005) and increased 
susceptibility to TNF-induced muscle protein degradation (Bruunsgaard et al., 
2003, Lees et al., 2009), this comparative model is an excellent representation of 
muscle atrophy, hypertrophy and adaptability, thus, enabling the determination of 
potential regulators associated with muscle wasting. The second model utilised 
C2C12 cells that had undergone multiple population doublings (PD) verses parental 
control cells (CON), which have undergone no doublings relative to the PD cells 
(Sharples et al., 2011). These cells also display impaired differentiation in 
monolayer (Sharples et al., 2011) and in three dimensional culture systems 
(Sharples et al., 2012) verses their parental controls. 
 
5.1.2 Potential mediators of testosterone-induced muscle hypertrophy  
Commonly in studies, testosterone has been co-incubated with inhibitors for 
the AR, IGF-IR, Akt, mTOR in a multitude of cell lines and primary cultures to 
investigate testosterone-induced hypertrophy (Basualto-Alarcón et al., 2013, Serra 
et al., 2011, Sculthorpe et al., 2012, Wannenes et al., 2008, Wu et al., 2010a). The 
AR, Akt, ERK1/2 and mTOR have all been observed to be involved in 
testosterone-induced hypertrophy in rat L6 myoblasts and primary cultures (Wu et 
al., 2010a, Basualto-Alarcón et al., 2013), however these pathways are usually 
studied in isolation and there is no information about the most 
predominant/important pathway in testosterone induced hypertrophy. Indeed, in-
vivo the AR and p70S6K (downstream of IGF-I/mTOR), measured by increases in 
protein expression, have been correlated with increased muscle hypertrophy (Baar 
and Esser, 1999, Mitchell et al., 2013). Furthermore, Akt and mTOR have been 
observed to prevent muscle atrophy (highlighted by using genetic activation 
animal models) (Bodine et al., 2001). However there is limited data on the 
potential role of upstream factors (IGF-IR) and the AR in mediating testosterone 
rescuing muscle atrophy. Studies which have investigated both these receptors in 
relation to myotube hypertrophy, predominately inhibit the pathways 
independently, and there is controversy around the most important pathway in 
testosterones action via the indirect IGF-I pathway (Serra et al., 2011, White et 
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al., 2012) or the direct AR pathway (Lee, 2002, Wannenes et al., 2008) is 
fundamental in testosterone induced hypertrophy.  
 
5.1.3 Aims and Objectives 
 
Therefore in light of the literature discussed above, the aims of this chapter 
were to: (1) investigate the role the predominant pathway (androgen receptor vs. 
the IGF-I receptor) in mediating testosterones hypertrophic effects in CON and 
MPD cells using specific substrate competitors for AR and IGF-IR (flutamide and 
Picropodophyllin respectively) in the absence and presence of testosterone. (2) 
Investigate the role of testosterone in cells that display prior reductions in 
regeneration/aged phenotypes and the associated signaling compared with ‘un-
aged’ controls. It was initially hypothesized that: (i) The inhibition of the AR and 
IGF-I receptor would both be fundamental in testosterones induced increases in 
myotube differentiation and hypertrophy and; (ii) that aged cells (although may 
respond to testosterone, as alluded to in chapter 3), the impact of T would be 
dampened in aged cells verses un-aged controls.   
 
5.2 METHODOLOGY 
5.2.1 Cell Culture 
Mouse C2C12 skeletal muscle myoblasts (CON and PD; outlined in 2.4.2) were 
resurrected as described in section 2.6. Cells were cultured as detailed in section 
2.4, chapters 3 and 4. Cells at the time points of 0, 72 hrs and 7 days were fixed 
for immunocytochemistry (outlined in 2.10.2), isolated for RNA (outlined in 
2.10.2 and 2.11) and lysed for protein analysis (outlined in 2.9).  
 
5.2.2Cell Treatments 
All treatments were administered in DM described above (detailed in 2.7.6). 
The treatments comprised of a vehicle control (DMSO at a concentration of 
0.01%), testosteronet alone (100 nM), Flutamide (F) alone (40 μM), 
Picropodophyllin (PPP) alone (150 nM), co-incubations of the inhibitors with T 
(i.e. T + F, T + PPP) and finally all three (T + F + PPP). DMSO was used as the 
solvent for reconstitution of testosterone and inhibitors (detailed in 2.7), at the 
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same concentration as the vehicle (0.01%). For results and figure legends the 
following nomenclature will be used Control (DMSO), T, F, and PPP 
respectively. All treatments were added at 0 hrs and existing media was further 
supplemented at 72 hrs as outlined (chapter 2 sections).    
 
5.2.3 RNA Isolation 
6 well plates for each time point (0hrs, 72hrs and 7 days) were washed with 1 
ml per well of Phosphate Buffer Saline (PBS) and extracted for RNA by placing 
300 μl of TRIzolTM Reagent (Sigma, St Louis) in each well. Total RNA was 
extracted as outlined in 2.11.1. RNA concentration and purity were assessed 
through UV spectroscopy at ODs of 260 and 280 nM, using the Nanodrop 
spectrophotometer 3000 (outlined in 2.11.2).  
 
5.2.4 Real time, Reverse Transcriptase Polymerase Chain Reaction (rt-RT-
PCR) 
Seventy nanograms of RNA were taken from each sample and real time, 
reverse transcription polymerase chain reaction (RT-rt-PCR) was performed as 
detailed in 2.12.3. Primer sequences for genes of interest are shown in table 2.1 
and were checked for specificity according to 2.12.2. The relative mRNA 
expression of AR, myogenin, MyoD, IGF-IR and myostatin was quantified using 
the comparative Ct (
ΔΔ
ct) method against a reference gene of RP-IIb and calibrator 
of control treatment (after CON 0hrs in all experiments).  
 
5.2.5 Immunoblotting 
Samples were prepared as outlined in 2.13.2. Gels were made up of a 10% 
resolving gel and a 5% stacking gel. Samples were electrophoresed at 200 volts 
until the sample buffer tracking dye reached the bottom of the gel (detailed in 
2.13.4). The proteins were transferred to the nitrocellulose membrane for use in 
immunoblotting for 30 minutes (described in 2.13.5). The western blotting was 
performed based on manufacturer’s instructions (described in 2.13.7). Membranes 
were sealed in plastic bags containing primary antibodies (outlined in table 2.1) 
for total proteins and related phosphorylation sites of the following proteins: 
Akt(ser473), ERK1/2(Thr202/Tyr204), p70S6K(Thr389) at a concentration of 1:1000, the 
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AR (1:500) and GAPDH (loading control; 1:4000) were diluted in an antibody 
diluent liquid for 1 hour incubation at room temperature. Detection of proteins 
was achieved using enhanced chemiluminescence (ECL) with a West Pico 
Supersignal kit (Pierce, Rockford, IL, USA) as described in 2.13.8. It was 
observed that the total levels of Akt and p70S6K changed in some conditions, 
however this was not repeatable and variable (discussed in chapter 7). ERK1/2 
total protein was unchanged across the conditions (Fig 5.10 and 5.11). Therefore 
the phosphorylated proteins were assessed relative to the GAPDH that was 
unchanged between conditions. Although proteins (p-Akt, p-ERK1/2 and p-
p70S6K) were analyzed on separate membranes between cell types i.e. (CON vs. 
PD when mean ± S.D were calculated globally for the arbitrary units (following 
detection), these were found to be non-significant between cell types (e.g. p-
p70S6K 72hrs: CON 0.21 ± 0.18 vs. PD 0.17 ± 0.17; P=N.S.). Thus comparisons 
between cell types were enabled to be made. For the AR protein, the same 
exposure times were selected for densitometry analysis allowing for comparison 
between cell types.  
 
5.2.6 Immunocytochemistry  
Cells were fixed using the protocol detailed in 2.10.2. PBS (2ml/well) was 
added after removal of the methanol/acetone mix and plates were stored in 4
o
c 
until further analysis. Immunocytochemistry was performed as described in 
2.10.2. Myotubes were stained for desmin (intermediate filament found in skeletal 
muscle near Z line of sarcomeres) and defined as 3+ nuclei encapsulating a 
desmin positive structure so to rule out cells undergoing mitosis. A total of 30 
images per condition were captured on x20 oil magnification fluorescence 
microscope. Quantification of morphology was performed as outlined in 2.10.3. 
 
5.2.7 Statistical Analysis  
Experiments were performed in triplicate, with  separate repeats (n=3). Data 
are presented as Mean + S.D unless stated otherwise. Gene expression data was 
assessed using a mixed three-way factorial ANOVA for interactions between time 
(72hrs and 7 days), treatments (DM, T, F, PPP, T+F, T+PPP T+F+PPP) and cell 
types (CON and PD). Morphology data was assessed using an ANOVA for 
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interactions between time (72 hrs and 7 days), treatments and cell types. 
Bonferroni post hoc analyses were performed where main effects for treatment or 
cell type occurred. A one way ANOVA was performed for western blots analyses 
to compare the effect of treatments within each cell type at 72 hrs and 7 days. A p-
value of <0.05 was considered statistically significant. All statistical analyses 
were performed using SPSS version 19 and GraphPad Prism Software (detailed in 
section 2.15).   
 
5.3 RESULTS  
5.3.1 Testosterone administration enhances hypertrophy in control myoblasts 
and cells displaying aged phenotypes.  
 
Myotubes were stained for desmin (Fig 5.1-5.4) to allow for the quantification 
of hypertrophic variables addressed in previous chapters (3 & 4). In CON cells, 
testosterone significantly increased myotube diameter after 72 hrs (CON DM 
16.18 ± 1.57 vs. CON+T 19.04 ± 2.07; P ≤ 0.05, Fig. 5.5A) and 7 days (CON DM 
16.34 ± 1.11 vs. CON+T 19.54 ± 1.77; P ≤ 0.05, Fig. 5.5A) administration. The 
enhanced myotube diameter was accompanied by significant increases in mean 
nuclei per myotube (72 hrs CON DM 3.38 ± 0.50 vs. CON+T 4.68 ± 0.92: 7 days 
CON DM 4.93 ± 0.92 vs. CON+T 6.80 ± 1.51; P ≤ 0.05, Fig 5.6A). After 72 hrs 
exposure, there was limited myotubes present in PD myoblasts for the various 
treatments, although the administration of testosterone significantly increased the 
myotube diameter (μm) in treated vs. un-treated PD myotubes (PD DM 13.40 ± 
0.47 vs. PD+T 17.57 ± 1.28; P ≤ 0.05, Fig. 5.5A) that were present.  
After 7 days, testosterone administration significantly increased myotube 
diameter (PD DM 15.52 ± 1.89 vs. PD + T 18.79 ± 2.10; P ≤ 0.05, Fig. 5.5A) in 
PD myoblasts compared to un-treated cells. Similar to CON myoblasts, the 
hypertrophic increase was accompanied by mean nuclei per myotube (PD DM 
4.14 ± 0.79 vs. PD+T 6.58 ± 1.54; P ≤ 0.05, Fig 5.6B). In terms of myotube 
number there were no significant differences between testosterone treated and un-
treated PD myoblasts (P=N.S). Between the two cell types (CON and PD), there 
were significant differences in myotube number and diameter (P ≤ 0.05) 
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confirming the impaired differentiation already observed in chapter 4 and 
previously published (Sharples et al., 2011, Sharples et al., 2012).  Interestingly, 
the magnitude of change in myotube diameter under a testosterone stimulus 
between CON and PD myoblasts was the same at 72 hrs (CON 15%; PD 23%) 
and 7 days (CON 16%; PD 17%) (Fig 5.5E). Similarly for nuclei per myotube a 
similar magnitude was observed between treated vs. untreated CON (27%) and 
PD (37%) myoblasts after 7 days culture. Indeed, these findings were reproduced 
in chapter 6 and highlight the ability of testosterone to rescue PD myoblasts to the 
hypertrophic level of basal CON myoblasts (in DM).       
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Fig 5.1 Representative microscope (x20) images for CON myotube morphology after 72 hrs 
culture. Myotubes were stained for desmin (B: red) and nuclei (B: green). Combined Light (A) and 
green images are presented too (D: last column). The presence of T resulted in larger myotubes 
compared to control conditions, with flutamide negating the increase in myotube size. 
Furthermore, T had positive effect on myotube size even in the presence of PPP.   
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Fig 5.2 Representative microscope (x20) images for CON myotube morphology after 7 days 
culture. Myotubes were stained for desmin (B: red) and nuclei (C: green). Combined Light (A) and 
green images are presented too (D: last column). The presence of T resulted in larger myotubes 
compared to control conditions, with flutamide negating the increase in myotube size and myotube 
number. Furthermore, T had positive effect on myotube size even in the presence of PPP, 
suggesting limited involvement of the IGF-I receptor in mediating T’s effect.    
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Fig 5.3 Representative microscope (x20 magnification) images for PD myotube morphology 
after 72 hrs culture. Myotubes were stained for desmin (B: red) and nuclei (C: green). Combined 
Light (A) and green images are presented too (D: last column). The presence of T appeared to 
reverse the aged phenotype as increases in myotube size were observed, yet flutamide negated the 
increase in myotube size. Furthermore, T had positive effect on myotube size even in the presence 
of PPP.   
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Fig 5.4 Representative microscope (x20 magnification) images for PD myotube morphology 
after 7 days culture. Myotubes were stained for desmin (red) and nuclei (green). Combined Light 
and green images are presented too (last column). The presence of T resulted in larger myotubes 
compared to control conditions, even in the presence of PPP.  However flutamide abrogated the 
increases in myotube size in PD myoblasts, highlighting a critical role of the AR in reversing the 
aged phenotype.  
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Fig 5.5. The effect of testosterone administration, along with co-incubations of flutamide and 
Picropodophyllin on myotube formation and hypertrophy. A) In CON cells, testosterone 
significantly increased myotube diameter at 72 hrs and 7 days exposure. The co-incubation of 
testosterone with Picropodophyllin did not abrogate testosterone increases in myotube diameter at 
either time point (*P ≤ 0.05) B) A similar trend occurred in PD myoblasts with testosterone 
treatment significantly increasing myotube diameter compared to un-treated cells (*P ≤ 0.05). The 
observed increases in testosterone induced hypertrophy continued at 7 days treatment (**P ≤ 0.05). 
The addition of Picropodophyllin had no effect on altering the observed increases in hypertrophy 
at either time point in PD myoblasts. C) The addition of PPP alone significantly reduced myotube 
number in CON myoblasts after 72 hrs (*P ≤ 0.05). Testosterone significantly increased myotube 
number after 7 days exposure (**P ≤ 0.001) in CON myoblasts, but the addition of 
Picropodophyllin abrogated this increase.  D) The myotube number at 7 days in PD myoblasts was 
increased with the co-incubation of testosterone and Picropodophyllin compared to untreated and 
Picropodophyllin treated cells (*P ≤ 0.001). E) The magnitude of change between testosterone 
treated CON (72 hrs 15%; 7 days 16%) and PD (72 hrs 23%; 7 days 17%) myoblasts in myotube 
diameter was the same, highlighting a similar intrinsic response to a testosterone stimulus.     
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5.3.2 The impact of flutamide and Picropodophyllin on testosterone-induced 
hypertrophy 
The addition of flutamide to both CON and PD myoblasts had an extensive 
detrimental effect on myotube formation at each time point as no quantifiable 
myotubes were observed (Fig 5.1-5.4). Testosterones function was rendered 
inactive in its ability to promote myotube formation and hypertrophy following its 
co-incubation with flutamide suggesting that the successful binding of 
testosterone to the AR is fundamental in these processes. Picropodophyllin (PPP) 
alone significantly decreased myotube number compared to DM conditions in 
CON myoblasts after 72hrs (CON DM 1.95 ± 0.86 vs. CON+PPP 1.18 ± 0.40; P ≤ 
0.05, Fig 5.5C). Although after 7 days there was still a mean decrease present 
with Picropodophyllin, this was not statistically significant (CON DM 3.27 ± 0.72 
vs. CON+PPP 2.80 ± 0.70; P=N.S, Fig 5.5C). The co-incubation of 
Picropodophyllin with testosteronet also abrogated the increase in myotube 
number after 7 days exposure (CON+T 4.73 ± 0.87 vs. CON+T+PPP 3.45 ± 0.60; 
P ≤ 0.05, Fig 5.5C).   
In terms of myotube diameter in CON cells, there was no significant effect at 
72 hrs and 7 days between treated and un-treated myoblasts (P=N.S, Fig 5.5A). 
The co-incubation of testosterone and Picropodophyllin still resulted in significant 
hypertrophic increases in myotube diameter along with testosteronet alone at each 
time point (72 hrs CON+T 19.04 ± 2.07 vs. CON+T+PPP 18.54 ± 1.45: 7 days 
CON+T 19.54 ± 1.77 vs. CON+T+PPP 19.23 ± 1.82; P=N.S, Fig 5.5A). 
Additionally, Picropodophyllin alone did not significantly alter mean nuclei per 
myotube in CON myoblasts after 72hrs and 7 days compared to DM treated cells 
(P=N.S., Fig 5.6A). The co-incubation of testosterone with Picropodophyllin did 
not abrogate the significant increases in mean nuclei per myotube with 
testosterone administration alone at each time point (72 hrs CON+T 4.68 ± 0.92 
vs. CON+T+PPP 3.86 ± 0.52: 7 days CON+T 6.80 ± 1.51 vs. CON+T+PPP 6.50 
± 1.22; P=N.S, Fig 5.6A).       
Similarly, Picropodophyllin addition resulted in no significant differences in 
myotube number for PD myoblasts compared to un-treated cells after 7 days 
exposure (P=N.S, Fig. 5.6B). A significant difference was detected between 
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Picropodophyllin and the co-incubation with testosterone group for myotube 
number (PD+PPP 2.29 ± 0.61 vs. PD+T+PPP 3.36 ± 0.50; P ≤ 0.01, Fig. 5.5D). 
For myotube diameter, the presence of Picropodophyllin was ineffective in 
preventing testosterone-induced hypertrophy in PD myoblasts after 72 hrs and 7 
days co-incubation (72 hrs PD+PPP 14.00 ± 0.10 vs. PD+T+PPP 18.06 ± 0.83: 7 
days PD+PPP 15.03 ± 1.14 vs. PD+T+PPP 19.87 ± 1.35; P ≤ 0.01, Fig. 5.5B). In 
addition, the co-incubation of Picropodophyllin with testosterone had no effect on 
abrogating the increases in mean nuclei per myotube with testosterone 
administered alone (PD+T 6.58 ± 1.54 vs. PD+T+PPP 5.85 ± 0.86; P=N.S, Fig 
5.6B). There were no significant differences observed between CON and PD 
treatments for PPP alone, T+PPP and T+F+PPP (no myotubes present) at either 
time point (P=N.S.). Overall, in terms of myotube morphology, it appears that 
testosterone-induced hypertrophy is not mediated via the IGF-I receptor in both 
cell types as testosterone still induced appropriate increases in myotube formation 
and hypertrophy in the presence of the IGF-IR inhibitor. The data suggests above 
that Testosterones effects are fully inhibited in the presence of flutamide, the AR 
inhibitor, in both cell types, providing initial evidence for the more predominant 
role of the AR in testosterone mediated myotube formation/differentiation and 
myotube hypertrophy verses the IGF-IR. This should however be viewed with 
some caution as PPP was not as effective alone on reducing the above parameters 
verses flutamide.  
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Fig. 5.6 Effect of testosterone treatment and AR/IGF-IR inhibitors (Flutamide/PPP respectively) 
on average nuclei per myotube in both CON and PD myoblasts. To note, AR inhibition resulted in 
all parameters measured being abolished in both cell types. Additionally, between CON and PD 
cells, there were no significant differences in PPP alone, T+PPP and T+F+PPP treatments at either 
time point. A) Testosterone significantly increased the mean nuclei observed in each myotube after 
72 hrs, with Picropodophyllin negating the observed increase in CON myoblasts (*P ≤ 0.05). After 
7 days, testosterone treatment continued to increase myotube nuclei content, with co-incubation of 
Picropodophyllin (**P ≤ 0.05) B) After 7 days in PD myoblasts, testosterone treatment 
significantly increased myotube nuclei content with Picropodophyllin co-incubation having no 
effect on these parameters measured compared to un-treated cells (*P ≤ 0.05).   
 
5.3.3 The effect of testosterone administration on Androgen receptor protein 
levels. 
A testosterone dose (100 nM) was sufficient to increase androgen receptor 
protein levels in both CON and PD myoblasts for each time point. In CON 
myoblasts, although not statistically significant, testosterone increased AR protein 
levels alone and even with co-incubation of Picropodophyllin after 72 hrs 
(CON+T 18 ± 6%; CON T+PPP 13.5 ± 4.5% vs. CON DM 7 ± 2%; P=N.S. Fig. 
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5.7) and 7 days (CON+T 15 ± 7%; CON T+PPP 12 ± 3% vs. CON DM 6 ± 1%; 
P=N.S. Fig. 5.7). The presence of AR protein with flutamide administration alone 
seemed to be completely abolished on first inspection on both 72 hrs and 7 day 
blots (Fig. 5.7A and 5.7B respectively). However, this was not statistically 
significant across all three experimental repeats. Testosterone in the presence of 
flutamide increased AR vs. flutamide alone (72 hrs CON T+F 5 ± 0% vs. CON F 
1 ± 0%; 7 days CON T+F 3 ± 0.5% vs. CON F 1 ± 0%; P=N.S.) but again this 
was not significant. It was interesting that in the testosterone plus IGF-IR inhibitor 
(PPP), AR total protein was seemingly restored back to basal levels suggesting 
that testosterone administration (similar to T alone) (72 hrs CON T 18 ± 6% vs. 
CON T+PPP 13.5 ± 4.5%; 7 days CON T 15 ± 7% vs. CON T+PPP 12 ± 3%; 
P=N.S.) induces increases in AR that is not dependant on IGF-IR/signaling.  
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Fig 5.7 The effect of testosterone and co-incubations treatment on total AR protein levels in 
CON myoblasts after 72 hrs (A) and 7 days (B). Values presented as Mean ± S.E.M. Although not 
statistically significant, the presence of T appeared to increase total AR abundance even in the 
presence of PPP. This was however abrogated with the introduction of flutamide.  
 
In the PD myoblasts, testosterone significantly increased the AR protein 
levels, even in the presence of Picropodophyllin after 72 hrs (PD+T 41 ± 2%; PD 
T+PPP 44 ± 11% vs. PD DM 11 ± 6%; P ≤ 0.05, Fig. 5.8) and 7 days (PD+T 42 ± 
2%; PD T+PPP 52 ± 5% vs. PD DM 6 ± 1%; P ≤ 0.05 Fig. 5.8) administration. 
Flutamide significantly abrogated testosterone increases in AR protein levels after 
72hrs (PD+T 41 ± 2%vs. PD T+F 3 ± 2%; P ≤ 0.05, Fig.5.8) and 7 days (PD+T 
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42 ± 2% vs. PD T+F 3 ± 2%; P ≤ 0.05, Fig. 5.8). Furthermore, the presence of 
flutamide in combination with testosterone and Picropodophyllin, decreased AR 
protein levels compared to testosterone incubated with Picropodophyllin (72hrs 
PD T+PPP 44 ± 11% vs. PD T+F+PPP 10 ± 2%: 7 days PD T+PPP 52 ± 5% vs. 
PD T+F+PPP 14 ± 7%; P ≤ 0.05, Fig. 5.8) at both time points. Together with 
morphological findings these data provide evidence that testosterone increases AR 
total protein and this increase is abrogated in the presence of flutamide but not 
PPP, again suggesting an important role for AR and not the IGF-IR/associated 
signalling in testosterones impact on the morphological parameters measured in 
CON and PD cells.  
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Fig 5.8 The effect of testosterone and co-incubations treatment on total AR protein levels in 
PD myoblasts after 72 hrs (A) and 7 days (B). Values presented as Mean ± S.E.M. A) Testosterone 
treatment significantly increased AR protein level, even in the presence of Picropodophyllin for 
PD myoblasts (*P < 0.05). Flutamide administration inhibited testosterone increases in AR protein 
levels. B) Testosterone treatment significantly increased AR protein level, even in the presence of 
Picropodophyllin (*P < 0.05). The presence of flutamide abrogated these increases in AR protein 
levels under a testosterone stimulus.  
 
It was interesting that between cells that display prior reductions in myotube 
formation/hypertrophy after 72 hrs there were no significant differences between 
basal CON and PD myoblasts for AR total protein expression (CON DM 7 ± 2% 
vs. PD DM 11 ± 6%; P=N.S, Fig 5.9A). However, there was a significant increase 
in AR in testosterone treated PD myoblasts verses CON treated cells (PD T 41 ± 
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2% vs. CON T 18 ± 6%; P ≤ 0.05) after 72 hrs culture. It is also worth noting this 
larger increase in AR with testosterone in the PD cells verses CON cells was also 
shown when in the presence of IGF-IR inhibitor (PPP) (PD T+PPP 44 ± 11% vs. 
CON T+PPP 13.5 ± 14.5%; P ≤ 0.05, Fig 5.9A). At 7 days, Testosteronet also 
induced a larger increase in AR PD verses CON myoblasts (PD T 42 ± 2% vs. 
CON T 15 ± 7%; PD T+PPP 52 ± 5% vs. CON T+PPP 12 ± 3%; P ≤ 0.05, Fig 
5.9B).  These observations provide evidence towards a heightened response in PD 
myoblasts to testosterone stimulated increases in AR protein expression which 
may contribute to the rescuing of the aged phenotype back to control cells in basal 
conditions as reported above.  
 
 
Fig 5.9 Comparison between total AR levels in CON and PD myoblasts exposed to 
testosteronet alone and in combination with Picropodophyllin after 72 hrs (A) and 7 days (B). A) 
Testosterone significantly increased AR levels in PD myoblasts vs. CON myoblasts after 72 hrs 
(*P ≤ 0.05). These increases in AR remained in the PD cells co-incubated with picropodophyllin 
compared to the same treatment in CON cells (**P ≤ 0.05). B) At 7 days culture, the same pattern 
was evident, where by Testosteronet alone (*P ≤ 0.05) and co-incubated with picropodophyllin 
(**P ≤ 0.05) significantly increased AR levels compared the same treatments in CON myoblasts. 
Values presented as Mean ± S.E.M.   
 
5.3.4 Impact of testosterone and inhibitor administration on downstream 
IGF-I signalling proteins.  
  Supplementary to assessing the androgen receptor protein levels with a 
testosterone stimulus and inhibitors, downstream proteins of IGF-I signalling 
(Akt, ERK1/2 and p70S6K) were investigated. Despite the IGF-IR being 
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seemingly un-important in testosterones impact on morphology shown above, 
downstream signaling to IGF-IR has been shown to be increased with T 
administration in the literature therefore  warranting further investigation 
(Basualto-Alarcón et al., 2013, Serra et al., 2011, White et al., 2012, Wu et al., 
2010a). Especially as i.e. p70s6K is fundamental in protein synthesis in 
hypertrophy (Baar and Esser, 1999, Bodine et al., 2001, Mitchell et al., 2013) and 
hypertrophy occurs in the presence of T in the present studies.  
 For ERK1/2 phosphorylation, the presence of testosterone and flutamide 
co-incubation treatments significantly reduced levels at both 72 hrs (CON DM 30 
± 6% vs. T+F 3 ± 2%; T+F+PPP 5 ± 2%; P ≤ 0.05, Fig. 5.10) and 7 days (CON 
DM 20 ± 8% vs. T+F 3 ± 2%; T+F+PPP 1 ± 0%; P ≤ 0.05, Fig. 5.10). There were 
no alterations in total ERK1/2 protein levels in any of the treatments at either time 
point. In the PD myoblasts, testosterone was ineffective in significantly increasing 
ERK1/2 phosphorylation at either time point. However there was a trend towards 
the presence of flutamide being detrimental towards ERK1/2 phosphorylation 
after 72 hrs and 7 days exposure, however this was non-significant (P=N.S., Fig. 
5.11). Between cell types, there were no significant differences in ERK1/2 
phosphorylation basally, as reported originally in Sharples et al. (2011) or for all 
other treatments in the present study at either time point.  
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Fig 5.10 The effect of exogenous testosterone and co-incubations on total and phosphorylated 
ERK1/2 in CON myoblasts after 72 hrs (A) and 7 days (B) exposure. A) The presence of flutamide 
was detrimental in ERK1/2 activation (*P<0.05). Exogenous testosterone did not significantly 
alter ERK1/2 activation levels.  B) Similar to 72 hrs, at 7 days flutamide administration continued 
to be detrimental for ERK1/2 phosphorylation (*P < 0.05). There were no alterations in total ERK 
protein at either time points.  There were no differences between cell types (CON vs. PD) for any 
time point/condition.  
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Fig 5.11 The effect of exogenous testosterone and co-incubations on total and phosphorylated 
ERK1/2 in PD myoblasts after 72 hrs (A) and 7 days (B) exposure. A) There were no statistically 
significant alterations in with any treatment after 72 hrs, although all flutamide conditions 
displayed a trend towards reduced ERK1/2 activation. B) At 7 days the presence of flutamide was 
significantly detrimental for ERK1/2 phosphorylation (*P < 0.05). There were no alterations in 
total ERK protein at either time points.    
  
 In CON cells, after 72 hrs there were significant reductions in 
phosporylated Akt with the presence of flutamide in treatments (CON DM 93.5 ± 
0.5% vs. F 24.5 ± 19.5%; T+F 19 ± 17%; T+F+PPP 33 ± 11.5%; P ≤ 0.05, Fig. 
5.12). The presence of testosterone had no effect on Akt phosphorylation at either 
time points in CON cells (P=N.S.). After 7 days administration, there were no 
statistically significant alterations with any of the treatments, notably an increase 
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in phosphorylated Akt with Picropodophyllin (P=N.S., Fig. 5.12), although this 
was non-significant. In comparison, a testosterone stimulus applied to the PD 
myoblasts lead to observed increases in Akt phosphorylation (although not 
statistically significant), after 72hrs exposure. These increases after testosterone 
administration were also present with the co-incubation of Picropodophyllin, yet 
the presence of flutamide significantly reduced Akt phosphorylation (PD T+PPP 
72.5 ± 10.5% vs. F 6 ± 5%; T+F 8.5 ± 5%; T+F+PPP 10.5 ± 5.5%; P ≤ 0.05, Fig. 
5.13). At 7 days, the increases in Akt phosphorylation with a testosterone stimulus 
were no longer present. However, the presence of flutamide was still detrimental 
to Akt phosphorylation (PD DM 93 ± 4% vs. F 9 ± 4%; T+F 7 ± 5%; T+F+PPP 1 
± 1%; P ≤ 0.05, Fig. 5.13).  Between cell types, there were significant differences 
in Akt phosphorylation for basal treatments in CON and PD myoblasts, where 
there was a significant reduction after 72 hrs in PD myoblasts (CON DM 93.5 ± 
0.5% vs PD DM 37.5 ± 19.5; P ≤ 0.01). However at 7 days, Akt phosphorylation 
was significantly increased in PD myoblasts compared to basal CON cells 
highlighting a delayed response and may explain the delay in fusion within this 
cell type (PD DM 93 ± 5 vs. CON DM 23 ± 5; P ≤ 0.001). For all other treatments 
between the cell types, no significant differences were observed at either time 
point.    
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Fig 5.12 The effect of testosterone administration and co-incubations on phosphorylated Akt 
in CON myoblasts after 72 hrs (A) and 7 days (B). After 72 hrs (A), flutamide presence 
significantly reduced Akt phosphorylation compared to un-treated CON myoblast (*P< 0.05). 
Exogenous testosterone had no impact on alterations in Akt phosphorylation. At 7 days (B), there 
were no statistically significant alterations in phosphorylated Akt in PD myoblasts. Values 
presented as Mean ± S.E.M.   
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Fig 5.13 The effect of exogenous testosterone and co-incubations on phosphorylated Akt in 
PD myoblasts after 72 hrs (A) and 7 days (B). After 72 hrs (A), exogenous testosteronet alone 
increased Akt phosphorylation (although not statistically significant). The co-incubation of 
testosterone and Picropodophyllin significantly increased phosphorylated Akt levels which were 
reduced in the presence of flutamide (*P< 0.05). At 7 days (B), the presence of flutamide 
significantly reduced the levels of phosphorylated Akt in PD myoblasts (*P < 0.05). Values 
presented as Mean ± S.E.M.   
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Fig 5.14 Comparison between Akt phosphorylation in basal and testosterone treated 
myoblasts after 72 hrs (A) and 7 days (B). A) Akt phosphorylation was significantly reduced in 
PD myoblasts compared to basal CON cells after 72 hrs (*P ≤ 0.01). B) After 7 days culture 
phosphorylated Akt increased in basal PD myoblasts compared to CON cells (*P ≤ 0.007), 
highlighting a delayed response in Akt signalling within the PD cell type. Values presented as 
Mean ± S.E.M.   
 
Finally, p706SK was investigated. In CON and PD myoblasts, testosterone 
had no significant effect on p70S6K phosphorylation after 72 hrs or 7 days 
treatment. After 72hrs the presence of flutamide alone, and in co-incubations with 
testosterone and and combined (T+F+PPP) significantly decreased 
phosphorylation levels compared to basal conditions (CON DM 38 ± 14% vs. F 
7± 4%, T+F 3± 2%; T+F+PPP 4± 3%; P ≤ 0.05, Fig. 5.15). After 7 days 
treatment, the pattern for flutamide administration being detrimental on p70S6K 
phosphorylation was still evident, although not statistically significant in CON 
cells. In PD myoblasts, the presence of flutamide was detrimental to p70S6K 
phosphorylation at both exposure points, although not statistically significant 
(P=N.S., Fig. 5.16). Between cell types, there were no significant differences in 
p70S6K phosphorylation observed for all treatments at either time point. 
 
Overall, the alterations in protein signalling provide evidence towards that a 
functional AR receptor is required for normal myotube formation and hypertrophy 
in control and age phenotypic myoblasts, as flutamide reduces these parameters 
with associated reductions in phosphorylation of ERK, Akt and p70S6K. 
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Inhibition of the IGF-IR (although reducing ERK and Akt acutely after 15 mins in 
chapter 4) by 72 hrs had little impact on the downstream signaling molecules 
assessed here (indeed Akt actually increased, non-significantly, with PPP in CON 
and PD myoblasts at 72hrs, perhaps as a delayed response following inhibition at 
earlier time points). Importantly, testosteronet alone itself had little impact on 
increasing these signaling proteins (except for Akt in PD myoblasts, which is a 
further investigated in chapter 6). Overall suggesting the requirement of a 
functional androgen receptor for testosterone induced adaptation and not IGF-IR 
or associated signaling.  
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Fig 5.15 The effect of testosterone administration and co-incubations on phosphorylated p70S6K 
in CON myoblasts after 72 hrs (A) and 7 days (B) exposure. A) The presence of flutamide was 
significantly detrimental to p70S6K activation compared to un-treated myoblasts (*P < 0.05)   B) 
There were no statistically significant alterations detected at 7 days.  Values presented as Mean ± 
S.E.M.   
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Fig 5.16 The effect of exogenous testosterone administration and co-incubations on total and 
phosphorylated p70S6K in PD myoblasts after 72 hrs (A) and 7 days (B) exposure. At both time 
points, no statistically significant alterations were observed between treatments, although the 
inclusion of flutamide in the cell culture media appeared to have a detrimental effect. Values 
presented as Mean ± S.E.M.   
 
Chapter 5: Testosterone acts via the AR and not the IGF-I receptor in Control and 
Aged myoblasts  
122 | P a g e  
 
5.3.5 Effects of testosterone administration on gene transcripts in control and 
PD myoblasts. 
 Gene transcripts (mRNA) were analyzed to determine the impact of 
treatments on important genes involved in muscle differentiation and hypertrophy 
in both CON and PD myoblasts. Testosterone significantly increased myogenin 
mRNA expression in both CON (DM 75.86 ± 12.67 vs. T 108.36 ± 18.34; P ≤ 
0.001, Fig 5.17A) and PD (DM 27.03 ± 3.02 vs. T 34.05 ± 5.03; P ≤ 0.05, Fig 
5.17B) myoblasts after 72 hrs exposure. After 7 days exposure, the observed 
increases in myogenin with testosterone treatment were no longer present in either 
cell type (P=N.S.). In basal conditions, CON cells had significantly higher 
expression of myogenin after 72 hrs compared to PD myoblasts (CON DM 75.86 
± 12.67 vs. PD DM 27.03 ± 3.02; P ≤ 0.01, Fig. 5.17), with this effect not 
observed at 7days (P=N.S, Fig 5.16). The observations with testosterone 
administration increasing myogenin expression support the evidence detailed in 
chapter 4 and importantly, show that such treatment can exert a positive effect in 
cells displaying an ageing phenotype. Gene transcripts for MyoD, Igf1 receptor 
and myostatin, the administration of testosterone had no impact in either cell type 
(P=N.S). In PD myoblasts, testosterone treatment significantly reduced AR 
mRNA levels after 72 hrs exposure (DM 4.07 ± 2.04 vs. T 1.28 ± 0.05; P ≤ 0.001, 
Fig. 5.18B), which is opposite to the observations at the protein level above (Fig 
5.8).  
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Fig 5.17 Impact of exogenous testosterone and AR (Flutamide/F) /IGF-IR 
(picropodophyllin/PPP) inhibitor co-incubations on MyoD and myogenin mRNA transcripts in 
CON and PD myoblasts after 72 hrs and 7 days. A) Picropodophyllin alone significantly increased 
MyoD levels after 72 hrs (*P < 0.05). At 7days, the presence of flutamide reduced MyoD 
expression levels in CON myoblasts (**P < 0.01) B) In PD myoblasts, testosterone had no impact 
on MyoD levels at either time point. The presence of flutamide significantly reduced expression 
levels after 72 hrs (*P < 0.01) and 7 days (**P <0.01). C) Testosterone treatment significantly 
increased myogenin expression levels in CON myoblasts after 72hrs (*P < 0.001). The presence of 
flutamide significantly reduced testosterone induced increases in myogenin (*P < 0.001). The 
presence of PPP did not significantly reduce increases in myogenin under a testosterone stimulus 
after 72 hrs culture. D) In PD myoblasts, testosterone administration increased myogenin levels (P 
< 0.05) compared to un-treated cells. This observation was abrogated by the presence of flutamide 
and Picropodophyllin (*P < 0.05). At 7 days, there were no increases in myogenin expression with 
testosterone, however the presence of flutamide resulted in reduced levels (**P < 0.01)   
 
 
5.3.6 Flutamide administration significantly impacted on gene transcription 
levels  
The presence of flutamide alone had a significant impact on genes 
investigated within the current chapter for both cell types. Specifically, flutamide 
was detrimental for transcripts involved in muscle differentiation (MyoD and 
myogenin). For MyoD mRNA expression, In CON cells, significant reductions 
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compared to DM conditions were observed with the presence of flutamide after 7 
days exposure (CON DM 1.88 ± 0.73 vs. F 0.12 ± 0.07; T+F 0.10 ± 0.06;  
T+F+PPP 0.78 ± 0.18; P ≤ 0.01, Fig 5.17C). A similar pattern occurred in the PD 
myoblasts after 72hrs (PD DM 1.48 ± 0.42 vs. F 0.13 ± 0.11; T+F 0.24 ± 0.13; 
T+F+PPP 0.34 ± 0.10; P ≤ 0.01, Fig 5.17D) and 7 days (PD DM 1.88 ± 0.48 vs. F 
0.16 ± 0.08; T+F 0.12 ± 0.07; T+F+PPP 0.21 ± 0.04; P ≤ 0.01, Fig 5.17D) 
exposure with treatments including flutamide for MyoD mRNA expression.  
After 7 days exposure, myogenin expression was significantly decreased in 
CON cells compared to basal treatments (CON DM 69.07 ± 13.15 vs. F 2.84 ± 
0.11; T+F 2.06 ± 0.33; T+F+PPP 6.99 ± 1.54; P ≤ 0.01, Fig. 5.17A). The 
reduction (~95%) in myogenin with flutamide completely inhibited CON 
myoblast fusion. Additionally, the detrimental effect with flutamide 
administration on myogenin expression was observed in PD myoblasts after 72 
hrs (PD DM 34.05 ± 5.03 vs. F 0.30 ± 0.11; T+F 1.44 ± 1.14; T+F+PPP 1.83 ± 
0.91; P ≤ 0.01, Fig. 5.17B) and 7 days (PD DM 56.04 ± 8.50 vs. F 1.02 ± 0.08; 
T+F 1.60 ± 0.73; T+F+PPP 1.39 ± 0.10; P ≤ 0.01, Fig. 5.17B) exposure.  
Between cell types, PD myoblasts appeared to be more susceptible to 
flutamide treatment than CON cells. MyoD expression was significantly reduced 
in PD myoblasts administered with flutamide compared to the same condition in 
CON myoblasts (PD+F 0.13 ± 0.11 vs. CON+F 1.81 ± 0.12; P ≤ 0.05) after 72 hrs 
culture, although this phenomenon was no longer present after 7 days culture. A 
similar trend for MyoD expression was observed in both testosterone plus 
flutamide (PD T+F 0.24 ± 0.13 vs. CON T+F 3.14 ± 0.17; P ≤ 0.05) and 
picropodophyllin (PD T+F+PPP 0.34 ± 0.10 vs. CON T+F+PPP 3.05 ± 0.64; P ≤ 
0.05) co-incubations after 72 hrs culture. Furthermore, the alterations in myogenin 
expression, supports the increased susceptibility of PD myoblasts to flutamide 
administration. Myogenin expression was significantly decreased after 72 hrs in 
PD myoblasts with flutamide compared to CON treated myoblasts (PD+F 0.30 ± 
0.11 vs. CON+F 65.95 ± 19.37; P ≤ 0.05). This pattern was further observed at 72 
hrs in treatments where flutamide was present (PD T+F 1.44 ± 1.14 vs. CON T+F 
53.98 ± 16.97; PD T+F+PPP  1.83 ± 0.91 vs. CON T+F+PPP 56.68 ± 13.65; P ≤ 
0.05). Overall, the presence of flutamide completely abolishes MyoD and 
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myogenin expression after 72 hrs and 7 days in CON and PD myoblasts, factors 
which are fundamental in the fusion of myoblasts.     
 
Fig 5.18 The effect of testosterone administration and inhibitor co-incubations on androgen 
receptor (AR) and IGF-I receptor (IGF-IR) gene transcripts in CON and PD myoblasts after 72 hrs 
and 7 days. A) Testosterone co-incubated with flutamide significantly increased AR mRNA 
expression levels after 72hrs in CON myoblasts (*P < 0.001). This effect was significantly reduced 
after 7 days (**P < 0.002). B) In PD myoblasts, there significant reductions in AR expression with 
testosteronet alone and the presence flutamide after 72 hrs (*P < 0.001). At 7 days, the addition of 
flutamide alone and co-incubated resulted in AR expression remaining decreased (**P < 0.001).  
C) In CON myoblasts, flutamide significantly reduced IGF-IR expression (*P < 0.05) and 
Picropodophyllin significantly increased IGF-IR levels at the same time point (**P < 0.001). 
There were no observed alterations at 7 days exposure.  D) Flutamide significantly reduced IGF-IR 
expression after 72 hrs in PD myoblasts compared to un-treated cells (*P < 0.003). The presence 
of flutamide, after 7 days treatment, resulted in significant reductions in IGF-IR expression 
compared to basal conditions (**P < 0.01).     
 
 In CON cells, AR expression was significantly reduced when co-incubated 
with testosterone after 7 days exposure (CON DM 2.76 ± 1.69 vs. T+F 0.49 ± 
0.32; P ≤ 0.002, Fig. 5.18A). To note, the administration of Picropodophyllin 
significantly increased AR mRNA expression after 72hrs exposure (CON DM 
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2.76 ± 1.69 vs. PPP 4.35 ± 1.09; P ≤ 0.001, Fig 5.18A). In the PD myoblasts, both 
the presence of testosterone and flutamide significantly reduced AR mRNA after 
72hrs (PD DM 4.07 ± 2.04 vs. T 1.28 ± 0.05; F 1.44 ± 0.99; T+F+PPP 2.79 ± 
1.37; P ≤ 0.001, Fig. 5.18B). For 7 days, the presence of flutamide in treatments 
significantly reduced AR expression (PD DM 5.42 ± 2.46 vs. F 0.59 ± 0.27; T+F 
0.87 ± 0.51; T+F+PPP 1.70 ± 0.21; P ≤ 0.001, Fig. 5.18B).  
The Igf1 receptor was significantly reduced with flutamide administration 
after 72 hrs exposure in CON cells (CON DM 1.96 ± 0.26 vs. F 0.85 ± 0.63; P ≤ 
0.05, Fig 5.18C). The addition of Picropodophyllin significantly increased Igf1 
receptor expression in CON cells at 72 hrs (CON DM 1.96 ± 0.26 vs. PPP 0.95 ± 
0.42; P ≤ 0.001, Fig. 5.18C), highlighting a possible negative feedback loop. The 
presence of flutamide significantly reduced Igf1 receptor expression in PD 
myoblasts after 7 days exposure (PD DM 1.65 ± 0.69; F 0.62 ± 0.33; T+F 0.47 ± 
0.18; T+F+PPP 0.57 ± 0.14; P ≤ 0.001, Fig 5.18D). Furthermore, testosterone co-
incubated with Picropodophyllin decreased IGF-I receptor mRNA expression 
after 7 days (PD DM 1.65 ± 0.69 vs. T+PPP 0.90 ± 0.14; P ≤ 0.001, Fig. 5.18D). 
Overall, the presence of flutamide had a significantly detrimental impact on IGF-I 
and androgen receptors in both cell types. Overall, testosteronet alone or in 
combination had very little impact on these receptors at the mRNA transcript 
level.  
Finally, as myostatin has recently been shown to be responsive to androgens 
(Dubois et al., 2014) the observations in myotube morphology with flutamide 
administration may be explained by the alterations in myostatin mRNA levels. 
The presence of flutamide significantly increased myostatin expression after 7 
days exposure in CON myoblasts (CON DM 2.78 ± 1.32 vs. F 8.30 ± 0.85; T+F 
7.44 ± 0.52; T+F+PPP 6.01 ± 2.52; P ≤ 0.001, Fig. 5.19A). Although not 
significant, there were trends for myostatin increased levels with the presence of 
flutamide after 72 hrs in CON myoblasts. Similarly in PD myoblasts, treatments 
containing flutamide increased myostatin expression at both time points, although 
not statistically significant. After 72 hrs, flutamide co-incubated with testosterone 
significantly increased myostatin expression in PD myoblasts (PD DM 3.83 ± 
1.17 vs. T+F 11.39 ± 2.49; P ≤ 0.001, Fig. 5.19B). In this experiment, testosterone 
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and Picropodophyllin had no impact on myostatin expression in either cell type. 
There were significant differences in myostatin expression between basal CON 
and PD myoblasts after 7 days culture (CON DM 2.78 ± 1.32 vs. PD DM 8.99 ± 
0.47; P ≤ 0.01). Myostatin has been observed to be detrimental in myotube size 
and inhibiting muscle differentiation, thus potentially explaining the lack of 
myotube formation in the current chapter (Trendelenburg et al., 2009).  
 
 
Fig 5.19 The effect of testosterone administration and inhibitor co-incubations on myostatin 
mRNA levels in CON and PD myoblasts after 72 hrs and 7 days.  A) There were no statistically 
significant differences in myostatin levels between treatments in CON myoblasts after 72 hrs. At 7 
days, there were sizeable increases in myostatin levels with flutamide presence compared to basal 
conditions (*P < 0.001).  B) After 72 hrs, the co-incubation of testosterone and flutamide increased 
myostatin significantly compared to un-treated PD cells (P < 0.001). At 7 days, there were no 
statistically different changes between treatments in PD myoblasts.  C) There was a significant 
increase in myostatin mRNA levels after 7 days culture between basal CON and PD myoblasts (*P 
≤ 0.01).  
 
5.4 DISCUSSION 
  
This chapter sought to investigate the predominate pathway for mediating 
testosterone induced hypertrophy as commonly the AR and IGF-I pathway have 
been investigated independently (Serra et al., 2011, White et al., 2012, Wu et al., 
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2010a). The alterations in myotube morphology and protein signalling (discussed 
below) provide evidence towards a pivotal role for a functional androgen receptor 
being required in myotube formation and hypertrophy in control and aged 
phenotypic myoblasts and thus the original hypothesis for both AR and IGF-IR 
being pivotal in testosterone induced hypertrophy was rejected.  
Secondly, the effect of testosterone administration in rescuing an ageing 
phenotype at the cellular level using a model of cells displaying impaired 
regeneration and hypertrophy was investigated. The observations in this chapter 
provide novel insights into the ability of exogenous testosterone to enhance 
impaired hypertrophy and rescue an ageing phenotype confirming our original 
hypothesis. Testosterone administration has been utilized in clinical populations 
where muscle wasting is present (Casaburi et al., 2004, Bhasin et al., 2000, Sinha-
Hikim et al., 2006, Atkinson et al., 2010). Furthermore, the mechanisms which 
may be involved in the hypertrophic effect of testosterone were addressed.    
 
5.4.1 Exogenous testosterone administration rescues an ageing phenotype via 
the androgen receptor and Akt 
Similar to the observations observed in Chapter 1, exogenous testosterone had 
a hypertrophic effect on C2C12 muscle cells highlighted by increases in myotube 
diameter and myonuclear accretion. In the current chapter, testosterone was able 
to rescue an ageing phenotype as increases in hypertrophic variables were 
observed such as myotube diameter. The positive effect of a testosterone stimulus 
on myotube morphology in CON and MPD myoblasts was accompanied by 
heightened myogenin expression, similar  results in chapter 1 and previous 
literature (Lee, 2002, Wannenes et al., 2008). At the transcriptional level, 
exogenous testosterone had little impact on other genes investigated. Although 
AR mRNA was significantly down-regulated in the PD myoblasts after 72 hrs 
culture, opposing the increased alterations observed in total AR protein following 
testosterone. At the protein level, testosterone significantly increased androgen 
receptor levels in PD myoblasts, even in the presence of the IGF-I inhibitor 
(Picropodophyllin). The AR increases in PD myoblasts were significantly greater 
compared to testosterone stimulated CON myoblasts and provide evidence 
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towards the rescuing of the ageing phenotype via the androgen receptor. This was 
accompanied via increases in myogenin, plus when the AR was inhibited 
alterations in MyoD occurred, providing evidence towards the morphological 
changes observed.  
Recently, Serra and colleagues (2011) highlighted the role of IGF-I signalling 
in mediating the effects of testosterone on skeletal muscle mass. The authors 
noted that a testosterone stimulus was mediated via IGF-IR signalling. The 
inhibition of IGF-IR was achieved through small interference RNA compared to 
the current chapter which utilized a substrate competitor inhibitor 
(Picropodophyllin). Contrary to the findings of Serra et al, (2011) we observed 
testosterone induced hypertrophy in both cell types even in the presence of the 
IGF-I receptor inhibitor, supported by the findings of Wu et al. (2010a). The most 
recent evidence has alluded to the potential role of Akt/mTOR signalling in 
testosterone induce hypertrophy (Basualto-Alarcón et al., 2013, White et al., 
2012) and it has been proposed a functional IGF-I receptor is not required for 
skeletal muscle hypertrophy in-vivo (Spangenburg et al., 2008). Within the 
current chapter, mean increases in downstream IGF—IR signaling (Akt 
phosphorylation) were apparent in the PD myoblasts only with testosterone 
administration after 72 hrs culture, an observation that continued even in the 
presence of the IGF-IR inhibitor (PPP), suggesting a direct activation of Akt 
independently of upstream IGF-IR. PD myoblasts also had basally reduced 
phosphor Akt at key time points in differentiation (72 hrs) verses control 
myoblasts and therefore Akt may be a mediating target for the testosterone 
mediated rescue in differentiation of the ageing phenotype myoblasts. The role of 
testosterone and Akt was investigated in chapter 6.  
 
5.4.2 The critical role of the androgen receptor in skeletal muscle 
hypertrophy  
The androgen receptor (AR) has been observed to be important in skeletal 
muscle development and muscle differentiation (Wannenes et al., 2008), as the 
knockout of muscle-specific AR results in reduced muscle mass and strength 
(MacLean et al., 2008). In the present chapter, flutamide (AR antagonist) 
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administration alone was detrimental to myotube formation in both CON and PD 
myoblasts. The presence of flutamide significantly impacted on Akt, ERK1/2 and 
p70S6K activation in both cell types which provides evidence towards the 
reduced protein synthesis required for differentiation and hypertrophy (Adi et al., 
2002, Baar and Esser, 1999, Jones et al., 2001, Rommel et al., 2001). 
Furthermore, the presence of flutamide abrogated testosterone induced 
hypertrophy in both cell types, even with Picropodophyllin co-incubation, 
supporting AR in being a critical pathway for muscle hypertrophy under a 
testosterone stimulus.  
Finally, the alterations in gene transcripts may provide an explanation for the 
impact of flutamide and thus an AR mechanism. In both CON and PD myoblasts 
with the presence of flutamide, there was a significant increase in myostatin 
levels. Myostatin has been observed to be a negative regulator of muscle mass and 
more specifically inhibit muscle differentiation and myotube size (Amthor et al., 
2004, McCroskery et al., 2003, Trendelenburg et al., 2009). Although in 
testosteronet alone had no impact on myostatin levels in the current chapter, in 
other chapters (3 and 6), a testosterone stimulus was observed to reduce myostatin 
levels. Recently Braga and colleagues (2012),  reported the effects of testosterone 
on TGF-β signalling (pathway detailed in 1.4.4) where testosterone stimulation of 
muscle proliferation and differentiation occurred due to inhibition of this pathway 
via follistatin up-regulation. Furthermore, Dubois and colleagues (2014) have 
highlighted the androgen receptor as a direct target for myostatin expression 
through using a satellite-cell specific AR knockout mice. Therefore, in relation to 
the current chapter, the inhibition of the AR may have contributed towards 
increased myostatin levels as the receptor has previously been observed to 
regulate follistatin levels, a factor that inhibits the TGF-β family member, 
myostatin (Amthor et al., 2004, Singh et al., 2009).  
 
 
5.4.3 Chapter Summary 
 
In summary, this chapter has highlighted the impact of testosterone in rescuing 
an ageing phenotype with cells displaying impaired regeneration and hypertrophy. 
Importantly, the results provide evidence towards the mechanisms for testosterone 
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induced hypertrophy, where in the presence of testosterone a functional androgen 
receptor seems fundamental in regulating appropriate myoD, myogenin and 
myostatin expression in the control of myotube differentiation and hypertrophy. 
The increases in androgen receptor protein levels in PD myoblasts under a 
testosterone stimulus highlight the responsiveness of aged myoblasts to a 
hypertrophic stimulus which may partly explain the use of testosterone as an 
effective clinical treatment in muscle wasting disease. Finally, myotube 
hypertrophy occurred in both cell types with testosterone administration even in 
the presence of an IGF-I receptor inhibitor suggesting a limited role of the IGF-IR 
and associated signaling in testosterones mediated increases in differentiation and 
hypertrophy.  Testosterone did appear however to increase Akt phosphorylation in 
cells that show a prior impaired regenerative capacity (PD) only. Therefore in the 
final chapter (6) the downstream target Akt will be investigated to provide more 
insight into whether its activity is directly involved in mediating a testosterone 
stimulus and rescuing an ageing phenotype observed in the present chapter.
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6. THE ROLE OF AKT IN TESTOSTERONE-INDUCED 
HYPERTROPHY IN AGED PHENOTYPE MYOBLASTS 
 
6.1 INTRODUCTION 
 
Recent studies suggest testosterone induced hypertrophy may be mediated by 
the AR and Akt/mTOR/p70S6K pathway as recent evidence has observed 
activation of this particular pathway through a testosterone stimulus (Basualto-
Alarcón et al., 2013, White et al., 2012). It is worth noting that the present study 
suggests that inhibition of the IGF-IR using Picropodophyllin, albeit only 
knocking down associated IGF-I signaling (Akt/ERK) by 60% and 40% 
respectively, did not impact on testosterone ability to induce myotube 
differentiation and hypertrophy. However, Akt was only significantly elevated 
with testosterone in the cells that display a prior aged phenotype (PD) vs. control 
cells, even in the presence of the IGF-IR inhibitor, suggesting that Akt could be 
directly activated by testosterone administration, independently of upstream input 
from the IGF-IR. The study by White and colleagues (2012) utilized an both an 
animal castration model and the C2C12 muscle cell line to address the impact of 
androgen availability on the aforementioned signalling pathway (the AR was not 
considered within this particular study). Loss of testosterone in the animal model 
resulted in significantly reduced skeletal muscle mass which was accompanied by 
reductions in Akt phosphorylation, GSK3, PRAS40 and FoxO3a (all Akt targets). 
Furthermore, administration of testosterone (5-500 nM) induced activation of Akt 
in C2C12 muscle cells with 24hrs exposure. Complementary to these findings, 
Basualto-Alarcón et al. (2013) observed an increase Akt phosphorylation after 15 
minutes testosterone (100 nM) stimulation. The present data, as eluded to above, 
from chapter 5, suggests that Akt is not significantly increased with testosterone 
in control cells but only increased in aged cells and PD cells show a reduction in 
Akt basally at 72hrs verses un-aged controls. Therefore, it appears that Akt seems 
to be fundamental in testosterones action in aged cells even when the IGF-IR is 
inhibited (chapter 5). This interaction, if not by IGF-IR, maybe mediated by 
myostatin, where increases in myostatin has been liked with directly inhibiting 
Akt (Dubois et al., 2014, Léger et al., 2008, Morissette et al., 2009), and in the 
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present study we see an increase in myostatin mRNA and corresponding decrease 
in pAkt when AR’s (via flutamide) action is inhibited and the protein level of AR 
is low (chapter 5). As myostatin has recently been shown to be transcriptionally 
regulated by AR (Dubois et al., 2014) the role of testosterones action in the ability 
to 1) restore regeneration in aged myoblasts via increasing Akt (chapter 5) and 
reducing myostatin (present chapter) maybe the important mechanism of action 
for testosterones restoration of myotube differentiation and hypertrophy in aged 
cells.   
In order to investigate this we cultured control and PD cells in the presence of 
T and T +/- LY294002 a PI3K/Akt inhibitor and measured the impact on 
myoblast/myotube morphology and transcriptional regulators of differentiation 
and hypertrophy (myogenin, mTOR, AR and myostatin). We hypothesized that by 
inhibiting PI3K/Akt, testosterone’s ability to restore differentiation and 
hypertrophy in PD cells only would be negated.  
 
6.2. MATERIALS AND METHODS 
6.2.1 Cell Culture 
Mouse C2C12 skeletal muscle myoblasts (CON and PD; outlined in 2.4.2) were 
resurrected as described in 2.6 and cultured as outlined in 2.4.1. Cells at the time 
points of 0, 72 hrs and 7 days were fixed for morphological analysis (outlined in 
2.10), isolated for RNA (outlined in 2.14.2 and 2.11).  
 
6.2.2 Cell Treatments 
All treatments were administered in DM described above. The treatments 
comprised of a vehicle control (DMSO at a concentration of 0.01%), 
Testosteronet alone (T) 100 nM (Tocris Bioscience, Bristol, UK), PI3K inhibitor 
(LY) 5 μM (LY294002- Calbiochem, Middlesex, UK), 100 nM T + 5 μM LY. 
DMSO was used as the solvent for T reconstitution at the same concentration as 
the vehicle (0.01%). For results and figure legends the following nomenclature 
will be used DMSO, T, LY and T + LY respectively. All treatments were added at 
0 hrs and existing media was further supplemented at 72 hrs. The inhibitor, LY at 
a dose of 5 μM has been extensively shown to be highly specific and effective in 
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C2C12 cells in inhibiting PI3K and downstream Akt (Al-Shanti et al., 2011, 
Coolican et al., 1997, Frost et al., 2009, Lee, 2009, Li et al., 2005a, Zeng et al., 
2012).  
 
6.2.3 RNA Isolation 
6 well plates for each time point (0hrs, 72hrs and 7 days) were washed with 
1ml per well of Phosphate Buffer Saline (PBS) and extracted for RNA by placing 
300μl of TRIzolTM Reagent (Sigma, St Louis) in each well. RNA extraction and 
quantification was performed as stated in chapter 3,4 and 5.  
 
6.2.4 Reverse Transcription Quantitative Real Time Polymerase Chain 
Reaction (rt-qRT-PCR) 
Seventy nanograms of RNA were taken from each sample and real time, 
reverse transcription polymerase chain reaction (RT-rt-PCR) was performed as 
detailed in 2.12.3. Primer sequences for genes of interest are shown in table 2.1 
and were checked for specificity according to 2.12.2. Analysis was performed as 
detailed in Chapter 3, 4 and 5.   
 
6.2.5 Morphological Analysis 
Following media aspiration and 2 × PBS washes (1 ml/well), cells were fixed 
by adding 1 ml methanol/acetone (1:1) to 1 ml PBS in each well in a drop-wise 
manner and incubated for 10 mins RT. Following aspiration, 2 ml methanol and 
acetone (1:1) were added to each well and incubated for a further 10 mins. Finally 
PBS (2ml/well) was added after removal of the methanol and acetone mix and 
plates were stored at 4
o
C until further analyses. This fixing process allows nuclei 
to become discernible under light microscopy alone, without the need for 
additional nuclear staining. Quantification was performed as outlined in 2.10.3 
and chapter 4. 
 
6.2.6 Statistical Analyses  
Experiments were performed  separate times (n = 3) in triplicate. Data are 
presented as mean + S.D. Morphology data at 72 hrs were assessed using a (2×2) 
mixed two-way factorial ANOVA (GraphPad Software, Inc., San Diego, USA) 
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for interactions between cell type (PD, CON) and treatments (DMSO, T). LY and 
T+LY treatment were excluded from the aforementioned analysis, as there were 
no observable myotubes at 72 hrs in these conditions. Morphology data at 7 days 
were assessed using a (2×4) mixed two-way factorial ANOVA for interactions 
between cell type (PD, CON) and treatments (DMSO, T, LY and T + LY). Gene 
expression data were assessed using a (2×2×4) mixed three-way factorial 
ANOVA for interactions between cell type (PD, CON), time (72 hrs and 7 days) 
and treatments (DMSO, T, LY and T + LY). Bonferroni post hoc analyses were 
performed where main effects for treatment or cell type occurred, without a 
significant interaction between treatment and cell type. If significant interactions 
were present, independent t-tests were conducted to confirm statistical 
significance between variables of interest. Furthermore, paired-sample t-tests were 
undertaken for variable of interests within cell type and treatment. Myonuclear 
Accretion (fusion index) measures were analysed using Chi Square to investigate 
whether myotube categories (3-4 nuclei or 5+ nuclei) differed from one another 
based on treatment exposure. A P-value of ≤ 0.05 was considered to represent a 
statistically significant difference.  
 
6.3. RESULTS  
 
6.3.1 Exogenous T treatment increases myotube hypertrophy in both CON 
and PD cells  
The administration of exogenous DMSO, T, LY, T+LY to CON and PD cells 
brought about morphological changes in differentiation (Figs 6.1 & 6.2). Firstly, 
it is important to mention that in support of previous observations showing 
reductions in differentiation in PD vs. CON cells (Sharples et al., 2011) as well as 
chapter 4 and 5; a significant difference for mean myotube diameter at 72 hrs was 
again observed in the present study (CON 17.32 ± 2.56 vs. PD 14.58 ± 2.66, P = 
0.01, Fig. 6.3A), supporting the ageing phenotype observed previously in PD cells 
(Sharples et al., 2011, Sharples et al., 2012) as well as in chapter 4 and 5. 
Importantly, in the present study, T administration appeared to increase 
hypertrophy (myotube diameter) in both cell types. Statistical analyses confirmed 
the morphological observations in Fig. 6.1 and 6.2 and revealed that a T-stimulus 
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significantly increased myotube diameter in both CON and PD cells after 72 hrs 
(CON+T 21.02 ± 1.89 vs. CON 17.32 ± 2.56; PD+T 18.29 ± 3.08 vs. PD 14.58 ± 
2.66, P = 0.01, Fig. 6.3A) and 7 days (CON+T 22.03 ± 2.65 vs. CON 17.50 ± 
2.38; PD+T 20.49 ± 1.99 vs. PD 15.70 ± 1.59, P = 0.01, Fig. 6.3A) compared with 
non-treated cells, respectively. 
 
Fig 6.1 Representative light microscope images (x10 magnification) of treatments (DMSO, T, 
LY, T+LY) exposed to the CON cell type after 72 hrs and 7 days. The presence of T increased 
myotube number and size after 72hrs and 7 days culture. The presence of LY abrogated the 
hypertrophic effects of T.  
 
Importantly, the magnitude of change between both cell models in 
response to T administration and compared with their respective baseline controls 
was not significantly different at either time points, with T increasing myotube 
diameter in both PD (+25% and +23%) and CON (+21% and +20%) cells to the 
same extent after 72 hrs (Fig. 6.3A) and 7 days (Fig. 6.3C); respectively, 
confirming the findings in Chapter 5 where we showed T increasing myotube 
diameter in both PD (23% and 17%) and CON (15% and 16%) after 72 hrs  (Fig 
5.5E) and 7 days (Fig. 5.5E). Overall, this suggests that cells with a reduced 
differentiation phenotype have the same capacity to undergo hypertrophy in 
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response to exogenous testosterone administration as CON cells as previously 
reported in chapter 5. Furthermore, the addition of T significantly increased 
myotube number in CON cells (CON+T 2.90 ± 0.72 vs. CON 2.23 ± 0.68, P ≤ 
0.05, Fig. 6.3D) after 7 days exposure only (at 72 hrs although there were mean 
increases this was not statistically significant (P = N.S.)). There were no 
significant changes in myotube number in PD cells after 72 hours or 7 days 
exposure (P = N.S.). This suggests testosterone increases hypertrophy (myotube 
diameter) in both cells types; however, T only enhanced myotube number in CON 
cells at 7 days.  
  
Fig 6.2 Representative light microscope images (x10 magnification) of treatments (DMSO, T, 
LY, T+LY) exposed to the PD cell type after 72 hrs and 7 days. The administration of T was able 
to reverse the aged phenotype observed in PD myoblasts at both time points. The presence of LY 
negated the hypertrophic effect of T, suggesting the role of Akt in mediating the effects of T.  
 
Together with the changes in myotube diameter at both 72 hrs and 7 days, T 
significantly increased the mean number of nuclei per myotube in CON cells 
(CON 3.77 ± 0.86 vs. CON+T 4.98 ± 1.76, P ≤ 0.001, Fig. 6.3B) at 72 hrs and at 7 
days (CON 3.68 ± 0.67 vs. CON+T 4.91 ± 1.10, P ≤ 0.01, Fig. 6.3B). 
Furthermore, in the PD cells, a similar response was observed for nuclei/tube in 
the presence of T at 72 hrs (PD+T 4.27 ± 1.03 vs. PD 3.33 ± 0.71, P = 0.03, Fig. 
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6.3B), and 7 days (PD+T 5.18 ± 1.31 vs. PD 3.84 ± 0.71, P ≤ 0.001 Fig. 6.3B) 
exposure compared to non-treated cells. Interestingly, again there were similar 
magnitude increases in CON and PD cells in the presence of T vs. basal 
conditions at 72 hrs (24.3% CON vs. 22% PD) and 7 days (25.1% CON vs. 25.9% 
PD), confirming the observations in chapter 5. 
 
Fig 6.3 The effect of T-stimulus on CON and PD cells on various morphology variables after 
72 hrs and 7 days exposure. A) The effect of T-stimulus on mean myotube diameter for CON and 
PD cells after 72 hrs exposure. *Reduced mean myotube diameter between CON and PD cells (P ≤ 
0.01). **T-stimulus significantly increased mean myotube diameter vs. non-treated CON and PD 
(P ≤ 0.01). Dash line represents magnitude change in mean myotube diameter with T-stimulus, 
similar in both CON (+21%) and PD (+25%) cells. A similar pattern was observed at 7 days (CON 
+20%; PD +23%). B) The changes in mean nuclei per myotube at 72 hrs and 7 days with and 
without exogenous T administration. *T significantly increased mean nuclei per myotube in CON 
(+24%; P ≤ 0.001) cells after 72 hrs and 7 days (+25%; P ≤ 0.001) exposure vs. non-treated cells. 
**Furthermore T-treatment in PD cells increased mean nuclei per myotube after 72 hrs (+22%; P 
= 0.033) and 7 days exposure (+25%; P ≤ 0.001).  C) The effect of T in the presence of LY is 
attenuated for mean myotube diameter after 7 days culture. *The presence of LY significantly 
reduced the effect of T on myotube diameter (P ≤ 0.05) in CON cells. **A similar effect was 
observed in PD cells (P ≤ 0.05). ≠ Myotube diameter significantly remained reduced in PD vs. 
CON cells, similar to that observed at 72 hrs (see Fig. 2A) (P ≤ 0.05). Dash line represents 
magnitude change in mean myotube diameter with T-stimulus, similar in both CON (+20%) and 
PD (+23%) cells. It appears that T’s action on myotube hypertrophy requires the activity of the 
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PI3K/Akt pathway in both cell types. D) The effect of T and LY treatment on myotube number in 
CON and PD cells at 7 days. *T-treated CON cells significantly exhibited a greater number of 
myotubes compared to non-treated cells (P ≤ 0.05). **The addition of LY alone and in the 
presence of T significantly reduced the number of myotubes compared to T-treated CON cells (P ≤ 
0.05). ***In PD cells, LY alone significantly reduced myotube number (P ≤ 0.01) at 7 days, with 
all other treatments showed no significant effects. 
 
6.3.2 PI3K/Akt inhibitor (LY) inhibits testosterone-induced increases in 
differentiation and hypertrophy for CON and PD cells  
The presence of LY inhibitor alone led to a lack of differentiation with no 
quantifiable myotubes being present in both CON and PD cells at 72 hrs (Fig. 6.1 
& 6.2). As highlighted above; the addition of T significantly increased 
differentiation shown by enhanced myotube number in CON cells (CON+T 2.90 ± 
0.72 vs. CON 2.23 ± 0.68, P ≤ 0.05, Fig. 6.3D) after 7 days exposure. The 
presence of LY co-incubated with T significantly reduced the effect on myotube 
number (CON+T+LY 2.21 ± 0.56 vs. CON+T 2.90 ± 0.72, P ≤ 0.05, Fig. 6.3D). 
LY alone was also able to reduce myotube number vs. T treatment (CON+LY 
1.77 ± 0.65 vs. CON+T 2.90 ± 0.72, P ≤ 0.05, Fig 6.3D) and non-treated controls 
(2.23 ± 0.68, P ≤ 0.01, Fig 6.3D). Interestingly, T in the presence of the LY 
inhibitor was unable to restore differentiation, shown by non-significant 
differences with LY alone conditions (P = N.S.) and non-treated CON cells (Fig. 
6.3D). These observations highlight that Ts increase in myotube number in CON 
cells, as previously observed, is blunted in the presence of the LY inhibitor; 
returning differentiation back to basal levels. As previously highlighted there were 
no significant changes in myotube number after T administration in PD cells. 
However, LY alone was able to reduce myotube number vs. T treatment (PD+LY 
1.89 ± 0.80 vs. PD+T 2.35 ± 0.69, P ≤ 0.05, Fig 6.3D) and non-treated controls 
(PD 2.26 ± 0.53, P = 0.05, Fig 6.3D). Overall, T’s action appears to require the 
activity of the PI3K/AKT pathway in order to differentiate in both CON and PD 
myoblasts.  
Following these observations for indices of differentiation we next wished to 
ascertain the impact of T in the presence of the PI3K inhibitor (LY) on myotube 
hypertrophy. At 7 days, as previously highlighted above, the addition of T 
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significantly increased myotube diameter in CON and PD cells (Fig. 6.3C). The 
presence of LY co-incubated with T significantly reduced the effect on myotube 
diameter in both CON (CON+T+LY 17.49 ± 2.21 vs. CON+T 22.03 ± 2.65, P ≤ 
0.05, Fig. 6.3C) and PD cells (PD+T+LY 17.10 ± 2.40 vs. PD+T 20.49 ± 1.99, P 
≤ 0.05, Fig. 6.3C). LY alone was also able to reduce myotube diameter vs. T 
treatment in CON cells (CON+T 22.03 ± 2.65 vs. CON+LY 17.7 ± 2.91, P ≤ 0.05, 
Fig 6.3C). Similar observations were observed in PD cells (PD+T 20.49 ± 1.99 
vs. PD+LY 15.83 ± 2.53, P ≤ 0.05, Fig 6.3C). Interestingly, T was unable to 
restore myotube diameter in the presence of the LY inhibitor shown by non-
significant differences with LY alone conditions in CON cells and non-treated 
CON cells (P = N.S, Fig. 6.3C). The same observations were mirrored in PD cells 
where T was unable to restore myotube diameter in the presence of the LY 
inhibitor shown by non-significant differences with LY alone conditions in PD 
cells (P = N.S, Fig. 6.3C). Overall, this shows that T’s observed increases in 
hypertrophy was blunted in the presence of the LY inhibitor returning myotube 
diameter back to basal levels in both cell types.  
 
6.3.3 T-treatment enhancement in differentiation and hypertrophy is 
accompanied by increases in cell fusion 
 To address the effects of the various treatments on cell fusion, myonuclear 
accretion was calculated. The administration of T resulted in a greater percentage 
of myotubes expressing 5+ nuclei for both CON (CON+T 67.9% vs. CON 32.1%, 
  
 = 32.99, P ≤ 0.05) and PD cells (PD+T 67.2% vs. PD 32.8%,   
 = 20.58, P ≤ 
0.05) compared to untreated cells after 7 days exposure (Fig 6.4A & 6.4B 
respectively). Furthermore, the addition of LY with T treatment reduced the 
percentage of myotubes expressing 5+ nuclei back to similar levels of LY-alone 
treated cells (CON+T+LY 28.1% vs. CON+LY 15.2%,   
 = 2.53, P = N.S; 
PD+T+LY 37.5% vs. PD+LY 21.6%,   
 = 3.4, P=N.S, Fig 6.4A & 6.4B 
respectively). In accordance with these observations, there was no significant 
difference in total nuclei counts for all treatments in either cell type at both time 
points (P = N.S). There was however a significant interaction between cell type as 
the PD cells had a significantly higher total nuclei count (P ≤ 0.05) compared to 
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CON cells at both time points, a finding confirmed previously by Sharples et al. 
(2011), who highlighted a continued proliferation at the expense of exiting the cell 
cycle in G1 and differentiating.  
 
 
Fig 6.4 The effect of T and LY treatment on fusion index in CON (A) and PD (B) cells after 7 
days exposure. T-treatment significantly increased the percentage of myotubes expressing 5+ 
nuclei in both cell types (P ≤ 0.05). The co-incubation of T and LY reduced the percentage of 5+ 
multi-nucleated myotubes back to similar levels of un-treated cells in both cell types at the same 
time point.   
 
6.3.4 Expression of myogenin mRNA increases after T-administration in both 
PD and CON cells 
There was a significant difference in myogenin transcript expression levels 
between CON and PD cells after 72 hrs (CON 191.51 ± 12.84 vs. PD 48.58 ± 
8.14, P ≤ 0.001, Fig. 6.5A) and 7 days exposure (CON 128.36 ± 27.11 vs. PD 
59.22 ± 4.57, P ≤ 0.001, Fig. 6.5A). Whilst still remaining significantly different, 
the expression of myogenin significantly increased in both CON and PD cells 
when treated with T (CON+T 222.18 ± 36.63 vs. CON 191.51 ± 12.84; PD+T 
67.00 ± 5.35 vs. PD 48.58 ± 8.14, P ≤ 0.05, Fig. 6.5A) after 72 hrs. The increase 
in myogenin mRNA expression also continued at 7 days in PD treated cells (PD + 
T 74.15 ± 8.13 vs. PD 59.22 ± 4.57, P ≤ 0.001, Fig. 6.5A), yet there was no 
difference in myogenin mRNA expression at this time point between non-treated 
and T-treated CON cells. However, absolute levels of myogenin transcript 
expression were basally significantly higher (shown above) in CON treated cells 
verses PD treated (CON+T 131.46 ± 24.53 vs. PD+T 67.00 ± 5.35, P = 0.001) 
cells at 7 days. The presence of LY, significantly reduced myogenin expression 
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after 72 hrs exposure in CON cells (CON+LY 134.38 ± 16.13 vs. CON 191.51 ± 
16.00, P ≤ 0.05 Fig. 6.5A), with no reductions being observed in PD cells at the 
same time point. Furthermore, LY alone had no effect on myogenin mRNA 
expression after 7 days culture in either cell type (P = N.S Fig. 6.5A). 
 
Fig 6.5 The effect of T-stimulus on transcript mRNA expression for myogenin (A), mTOR (B) 
and myostatin (C) in CON and PD cells. A) The effect of T-stimulus on myogenin mRNA 
expression levels after 72 hrs exposure. *T-stimulus significantly increased myogenin expression 
in CON and PD cells compared to non-treated cells (P ≤ 0.05). **The presence of LY with T 
treatment significantly attenuated T’s effect in CON cells (P ≤ 0.05). ***T exposure continued to 
increase myogenin mRNA in PD cells after 7 days culture, even in the presence of LY (P ≤ 0.05). 
B) Changes in mTOR mRNA expression with various treatments to CON and PD cells after 7 days 
culture. *CON+T and **CON+T+LY significantly increased mTOR expression vs. CON untreated 
cells (P ≤ 0.05). ***There was a significant difference in mTOR expression between CON+LY and 
CON+T+LY (P ≤ 0.001). Additionally there was a significant difference in mTOR expression 
between untreated CON and PD cells in 7 days culture. There were no changes in PD cells with 
the same treatments at either time points. C) The effect of T-stimulus on myostatin mRNA 
expression after 7 days exposure. *T significantly reduced myostatin expression in the PD treated 
cells after 7 days (P ≤ 0.01). **LY alone significantly reduced myostatin levels (P ≤ 0.01) at 72 hrs 
and 7 days. ≠ Plus with the addition of T to LY, this reduction was heightened (P ≤ 0.01) 
compared to non-treated PD cells.  
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T in the presence of LY inhibitor significantly attenuated myogenin expression 
after 72 hrs when compared with T alone in both cell types (CON+T 222.18 ± 
36.63 vs. CON+T+ LY 146.09 ± 24.58, P ≤ 0.05; PD+T 67.00 ± 5.35 vs. 
PD+T+LY 56.04 ± 11.50, P ≤ 0.05, Fig. 6.5A). At 7 days, there were no 
significant changes for any treatment conditions in CON cells (P = N.S for all 
comparisons) for myogenin expression. However in PD cells, T further enhanced 
myogenin expression significantly, even when administered in the presence of LY 
(PD 59.22 ± 4.57 vs. PD+T+LY 69.93 ± 3.98, P ≤ 0.05; PD+LY 57.04 ± 9.22 vs. 
PD+T+LY 69.93 ± 3.98, P ≤ 0.05, Fig. 6.5A). Thus, T caused an increase in 
myogenin expression in both cells types, whether LY was present or absent. This 
may suggest at the molecular level at least, that T elevates myogenin expression, 
independently of PI3K/Akt, but appears to be not sufficient enough to rescue 
morphological differentiation/hypertrophy in PD cells.  
 
6.3.5 Testosterone increases mTOR expression in the presence of PI3K 
inhibitor in CON cells   
The expression of mTOR did not change after 72 hrs in either cell type (CON 
0.97 ± 0.08 vs. PD 0.97 ± 0.12, Fig. 6.5B). After 7 days exposure, T 
administration alone significantly increased mTOR mRNA expression compared 
to CON non-treated cells (CON+T 121.08 ± 15.87 vs. CON 111.95 ± 19.36, P ≤ 
0.05 Fig. 6.5B). Furthermore, the treatment of T + LY significantly increased 
mTOR mRNA compared to LY alone (CON+T +LY 135.14 ± 16.08 vs. CON+LY 
112.70 ± 13.62, P ≤ 0.001, Fig. 6.5B) and untreated controls (CON+T +LY 
135.14 ± 16.08 vs. CON 111.95 ± 19.36, P ≤ 0.05). This highlights T 
administration increases in mTOR expression even in the presence of LY. In the 
PD cells, all treatments were without effect on mTOR expression at 7 days 
exposure (Fig. 6.5B).  However, at 7 days under basal conditions, CON cells 
displayed significantly higher mTOR expression than PD cells (CON 111.95 ± 
19.36 vs. PD 1.01 ± 0.10, P ≤ 0.05, Fig. 6.5B). 
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6.3.6 T-stimulus reduces negative muscle mass regulator myostatin in PD 
cells only  
Myostatin transcript expression was slightly elevated in PD cells after 72 hrs 
compared to CON, although these elevations were not statistically significant 
(CON 5.93 ± 1.87 vs. PD 7.63 ± 2.58, Fig. 6.5C). However, at 7 days, statistically 
significant observations were observed for increases in myostatin mRNA 
expression in PD cells compared to CON cells (PD 12.93 ± 4.69 vs. CON 4.57 ± 
1.20, P ≤ 0.001 Fig. 6.5C), confirming the findings in chapter 5. This novel 
finding suggests that under basal conditions, myostatin may block differentiation 
in these myoblasts and thus contribute towards reduced myotube hypertrophy. In 
CON cells, T treatments, LY alone or co-incubations of T+LY at 72 hrs did not 
alter myostatin mRNA expression (Fig. 6.5C). The presence of LY alone was the 
only treatment to significantly reduce myostatin mRNA expression after 72 hrs 
exposure to PD cells (PD+LY 4.27 ± 2.47 vs. PD 7.63 ± 2.58, P ≤ 0.01 Fig. 6.5C).  
At 7 days, there were no changes in myostatin mRNA expression in CON cells 
(CON 4.57 ± 1.20; CON+T 5.99 ± 1.40; CON+LY 4.32 ± 1.65; CON+T+LY 4.84 
± 1.01, Fig. 6.5C). However in the PD cells, T treatment significantly impaired 
elevations in myostatin expression compared to PD non-treated cells (PD + T 9.73 
± 2.56 vs. PD 12.93 ± 4.69, P ≤ 0.05, Fig. 6.5C). The reduction in myostatin 
transcript expression was significantly larger in magnitude with the addition of T 
with LY (-36%) in PD cells at the 7 day time point (PD + T + LY 3.47 ± 0.83 vs. 
PD 12.93 ± 4.69, P ≤ 0.01 Fig. 6.5C), yet similar effects were not observed in 
CON cells. However, the presence of LY alone also brought about reductions in 
myostatin expression (PD+LY 4.98 ± 2.25 vs. PD 12.93 ± 4.69, P ≤ 0.001, Fig. 
6.5C) and the reductions were similar to T+LY (P = N.S). Overall, suggesting 
both LY and testosteronet alone reduce myostatin expression in PD cells only. It 
therefore appears that T potentially reduces myostatin expression in aged PD cells 
only suggesting a potential mechanism that may explain the increase in 
differentiation/hypertrophy seen in this cell type, whereas in CON cells, the 
increases with T are independent of myostatin expression.   
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6.4 DISCUSSION 
The present chapter supports the findings in chapter 5, for testosterone in 
enhancing myogenic differentiation and myotube hypertrophy (Lee, 2002, Singh 
et al., 2003, Singh et al., 2009, Sinha-Hikim et al., 2003, Sinha-Hikim et al., 
2006, Wannenes et al., 2008). In the current chapter and chapter 5, testosterone 
was observed to rescue the ageing phenotype with increases in hypertrophic 
variables such as myotube diameter in the PD myoblasts. Enhanced myotube 
hypertrophy (chapter 5) in PD myoblasts was accompanied by increased Akt 
phosphorylation, for which the Akt/mTOR pathway has most recently been linked 
to mediating the effects of testosterone (Basualto-Alarcón et al., 2013, White et 
al., 2012). Thus the current chapter of work set out to inhibit Akt using 
LY294002, the results of which are discussed in more detail in section 6.4.1.    
Interestingly, testosterone improved hypertrophy (myotube diameter) to 
the same magnitude in both cell types at 72 hrs and 7 day time points, confirming 
the findings reported in chapter 5. Thus, despite PD cells having undergone 
multiple population doublings verses their controls, and therefore displaying a 
reduced basal differentiation capacity as previously described in Sharples et al. 
(Sharples et al., 2011, Sharples et al., 2012); testosterone was able to exert similar 
magnitude increases in myotube hypertrophy. Despite this interesting observation, 
testosterone was unable to fully restore differentiation (myotube number) to the 
level observed in untreated control cells at 7 days; perhaps suggesting 
testosterones predominant role in hypertrophy rather than differentiation in this 
model. Indeed in chapter 5, testosterone was not able to enhance myotube 
differentiation (unable to quantify myotube number) but did enhance hypertrophy 
in myotubes observed after 72 hrs culture. Furthermore, in line with previous 
findings, the current chapter and data presented in chapters 4 and 5,  the PD cells 
had reduced myogenin expression vs. CON cells (Sharples et al., 2011, Sharples 
et al., 2012), with the present chapter also supporting previous morphological and 
biochemical (reduced CK activity, marker of differentiation) findings (Sharples et 
al., 2011, Sharples et al., 2012), as myotube diameter was reduced in the PD cells. 
Overall, the findings in both chapters 5 and 6 further consolidate the use of these 
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cells as a representative model to investigate cellular and molecular mechanisms 
of aged (PD) phenotypes. 
 
6.4.1 The Impact of testosterone induced hypertrophy and Akt inhibition 
 
Importantly, testosterone mediated increases in myotube hypertrophy were 
potentiated via the PI3K/Akt pathway, where inhibition of this pathway in the 
presence of testosterone rendered the hormone unable to exert its potent influence 
on myotube hypertrophy in both cell types. This study supports previous work 
where the PI3K/Akt pathway has been implicated in testosterones action in L6 
myoblasts (Wu et al., 2010a) and human skeletal myoblasts (Serra et al., 2011) 
where the same PI3K inhibitor (LY294002) also reduced testosterone induced 
hypertrophy. Kovacheva and colleagues (2010) have also previously reported that 
Akt signalling downstream of PI3K was restored by testosterone administration in 
elderly mice. The present study further supports that testosterones action in 
myotube hypertrophy is mediated via PI3K/Akt pathway, especially where 
reductions in Akt activation have been previously reported in this model (i.e. 
lower in PD vs. CON) (Sharples et al., 2011). Indeed in chapter 5, Akt 
phosphorylation was significantly altered between basal CON and PD myoblasts 
after 72 hrs and 7 days (Fig 5.14), highlighted a delayed response in Akt 
signalling. Overall, these observations further suggest that the manipulation of this 
pathway by testosterone may be imperative for therapeutic restoration of muscle 
atrophy (Bodine et al., 2001).  
Interestingly, exogenous testosterone improved myogenin expression 
independent of the PI3K inhibitor (LY294002) suggesting testosterone-mediated 
activation of myogenin independently of the PI3K/Akt signalling pathway. 
Testosterone has previously been shown to increase myogenin in C2C12 cells (Lee, 
2002, Wannenes et al., 2008). Indeed, community-dwelling older men treated 
with grades doses of testosterone show increases in muscle fibre size 
accompanied by increased myogenin expression (Bhasin et al., 2005, Sinha-
Hikim et al., 2006). Despite this, testosterone induced increases in myogenin 
observed in the presence of PI3K inhibitor were unable to restore the 
differentiation/hypertrophy impinged by the PI3K inhibitor alone. Therefore, 
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suggesting that myogenin was not the main mechanism of action in testosterone-
induced increases in differentiation and hypertrophy. Despite this in chapter 5 
myogenin is severely reduced where androgen receptor function is inhibited via 
flutamide administration alone, suggesting functional AR is required for 
appropriate myogenin expression without testosterone. However, in chapter 5, 
there are also observed increases in AR protein levels under a testosteronet alone 
stimulus with increases in myogenin in CON cells in chapters 5 & 6. Therefore 
this suggests an association with testosterone, functional AR and myogenin 
expression. Absolute levels of myogenin were severely reduced in PD vs. CON 
cells with testosterone unable to rescue absolute myogenin expression levels in 
the cells that display an aged phenotype (PD’s) to those observed in untreated 
control cells. Thus, perhaps highlighting myogenin’s more pertinent role in 
differentiation (not hypertrophy) as testosterone was unable to restore absolute 
levels of myogenin and corresponding myotube numbers in PD cells verses 
untreated control levels.  
 
6.4.2 Possible involvement of mTOR in mediating Testosterone induced 
hypertrophy 
In addition, testosterone increased mTOR expression in CON cells at 7 
days, previously testosterone has been shown to increase mTOR phosphorylation 
in both L6 rat (Wu et al., 2010a) and in C2C12 (White et al., 2012) myoblasts. 
Indeed, mTOR mRNA expression in CON cells was increased in the presence of 
testosterone plus PI3K inhibitor (LY), perhaps suggesting an important role for 
testosterone in increasing mTOR independently of PI3K/Akt. Furthermore, White 
and colleagues (2012) also observed increases in mTOR phosphorylation with 
incremental doses of T in C2C12 cells, independently of Akt activation. However, 
mTOR expression was not increased in PD cells in the presence of testosteronet 
alone or in combination with the PI3K inhibitor suggesting impaired mTOR 
transcript expression in response to exogenous testosterone in the aged, reduced 
differentiation phenotype PD vs. control cells. Previously, it has been observed 
that reduced IGF-I transcript expression with corresponding reductions in Akt 
phosphorylation in PD myoblasts (Sharples et al., 2011) and in chapter 5 (Fig 
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5.14). As Akt is upstream of mTOR this suggests Akt may be involved in the 
reduction of mTOR observed between CON and PD myoblasts basally at 7 days. 
However, activity of mTOR was not directly assessed in the present chapter and 
warrants further investigation. 
 The observations towards mTOR expression may have implications 
towards the findings in chapter 5 and in the current chapter as myostatin over-
expression has previously been reported to down-regulate Akt/mTOR signalling 
(Amirouche et al., 2009) as well as the Akt/mTOR/p70S6K pathway inhibiting 
myostatin (Welle et al., 2009). Therefore the involvement of testosterone in 
stimulating mTOR may explain the reductions in myostatin in the current chapter, 
but also may explain the increases in myostatin with the inhibition of the AR, as 
flutamide treatments (chapter 5) resulted in significant reductions in Akt and 
p70S6K phosphorylation. However, the role in which mTOR interacts with AR, 
Akt and myostatin remains to be elucidated in this model. The combined 
observations in chapter 5 and 6, do provide evidence towards a cross talk between 
the AR and Akt/mTOR/p70S6K pathway with regards to myostatin regulation.  
 
6.4.3 Testosterone suppresses the myostatin levels in aged myoblasts  
Myostatin is a negative regulator of muscle mass in many species 
(Dominique and Gérard, 2006, McPherron et al., 1997, McPherron and Lee, 1997, 
Schuelke et al., 2004). There is evidence indicating that myostatin inhibits 
satellite cell activation, proliferation, and differentiation (Kawada et al., 2006, 
Sinha-Hikim et al., 2006, Wagner et al., 2005), possibly mediated through 
perturbation of Akt and mTORC1 signalling (Trendelenburg et al., 2009). 
Therefore reductions in myostatin, as previously observed with testosterone 
administration (Kawada et al., 2006), can enhance muscle mass regulation in 
muscle wasting diseases such as cachexia and sarcopenia (Liu et al., 2008, Siriett 
et al., 2006, Siriett et al., 2007). Interestingly, in the current chapter, myostatin 
mRNA expression was reduced in the presence of T in myoblasts expressing 
impaired differentiation, with observable increases in myotube hypertrophy. 
These reductions in myostatin mRNA under a testosterone stimulus support the 
observations in chapter 3. Interestingly, the inhibition of AR (through flutamide) 
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resulted in increases in myostatin expression (chapter 5). Additionally, Akt 
phosphorylation was up regulated with a testosterone stimulus in PD cells and 
down regulated in the presence of flutamide. Therefore the regulation of muscle 
hypertrophy under a testosterone stimulus appears to be controlled by AR, Akt 
and myostatin interactions. The reduction in myostatin mRNA expression at 7 
days with T treatment was accompanied by increases in myogenin mRNA 
expression in PD cells, which is supported recent literature highlighting 
myostatin’s role for inhibiting myogenic differentiation (Gao et al., 2013, 
McFarlane et al., 2011, Trendelenburg et al., 2009). Despite this, testosterone did 
not return absolute levels of myostatin expression to the low levels observed in 
the control cells. These observations suggest that although testosterone may 
reduce myostatin expression, it is not entirely responsible for the improved 
hypertrophy observed in the atrophic phenotype cells. Furthermore, the PI3K 
inhibitor (LY) alone also substantially reduced myostatin expression where there 
is a distinct lack of differentiation and hypertrophy. This is in contrast to recent 
studies where there was a reduction in the activity of Akt observed in the presence 
of exogenous myostatin in human myoblasts (Trendelenburg et al., 2009). 
Therefore, if myostatin was reduced, PI3K/Akt activity may be expected to 
increase. Although in chapter 5, the increased levels of myostatin expression with 
flutamide, occurred with reductions in Akt phosphorylation.  
 
6.4. Chapter Summary 
In this chapter, exogenous testosterone was able to increase hypertrophy in 
myoblasts with reduced differentiation potential (PD cells) to a similar magnitude 
as the control cells, confirming the findings in chapter 5. Testosterone induced 
myotube hypertrophy was mediated via the PI3K/Akt pathway, where inhibition 
of this pathway in the presence of testosterone rendered the hormone unable to 
exhibit its potent influence on myotube hypertrophy in both phenotypically aged 
and control cells. Similarly, in chapter 5, PD myoblasts were most responsive to 
testosterone stimulus highlighted by the significant increases in AR expression. 
Exogenous testosterone increased myogenin expression in both cell types. 
Myostatin expression was reduced in the presence of testosterone in aged cells 
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only. Overall, based on the observations in the current chapter and chapter 5, 
administration of testosterone shows strong potential to enhance hypertrophy in 
ageing myoblasts directly via the AR and alternatively through the PI3K/Akt 
pathway, that is not via upstream IGF-IR (as shown in chapter 5), but potentially 
through mTOR.
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7. GENERAL DISCUSSION  
The data collected and presented in this thesis provides evidence towards the 
mechanisms of action for testosterone induced hypertrophy, but most importantly 
the potential role for testosterone administration in preserving muscle mass from a 
cellular and molecular perspective. The ultimate goal of this research is to 
understand the mechanisms in skeletal muscle which are driven by a testosterone 
stimulus. Indeed, with testosterone administration in vivo, adverse events 
(discussed in section 7.3.2) can occur and thus understanding the mechanisms in 
skeletal muscle will aid in the advancement of tissue specific treatments in clinical 
populations where muscle wasting is present. The work undertaken in this thesis 
has identified molecular targets/pathways through which a testosterone stimulus is 
mediated and importantly provides evidence for the intrinsic ability of aged 
muscle cells to respond to this anabolic stimulus.   
Between the 1990’s to 2000’s, there has been extensive literature conducted 
highlighting the positive benefits of testosterone administration in various clinical 
populations such as Andropause (low testosterone levels). The major benefits 
centre on enhanced muscle mass. Recent studies have highlighted an increase in 
satellite cell number with testosterone administration, providing evidence how 
testosterone may interact with skeletal muscle and increase muscle growth. 
Human in vivo studies only allow for partial mechanistic questions to be 
addressed. More recently, in vitro studies have utilized various techniques to 
inhibit particular pathways and thus explore testosterone mechanisms in more 
detail. However evidence is lacking towards the role of potential pathways 
mediating a testosterone stimulus in skeletal muscle regeneration and ageing. 
Thus a deeper understanding of the regulation of the identified molecular targets 
in this thesis will, with future research, begin to enhance the progression of our 
understanding towards testosterone as a therapeutic treatment for muscle mass 
preservation.  
 
7.1 KEY FINDINGS 
Recent literature has addressed various pathways (AR, IGF-I/Akt/mTOR and 
TGF-β family etc) towards understanding the molecular and cellular mechanisms 
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which drive testosterone-induced muscle hypertrophy using in vitro cell culture 
(Basualto-Alarcón et al., 2013, Sculthorpe et al., 2012, Serra et al., 2011, White et 
al., 2012). However there is limited evidence which has addressed these proposed 
mechanisms in the context of ageing and muscle wasting (Serra et al., 2013). In 
light of this, an in vitro cell culture model was utilised which replicates an ageing 
phenotype to address the ability of a testosterone stimulus to rescue/enhance 
myotube differentiation and hypertrophy. Prior to this however, both testosterone 
and inhibitor doses were characterised in C2C12 muscle cells to be used in later 
experiments, assessing molecular and cellular targets e.g. myotube number, mean 
nuclei per myotube, diameter etc.  These initial experiments provided an inhibitor 
dose for androgen receptor and IGF-I receptor. The administration of flutamide 
(40μM) significantly reduced myotube hypertrophy and differentiation in cells 
expressing hypertrophic CON and atrophic (PD) phenotypes. The detrimental 
effect was accompanied by alterations in gene transcripts for muscle 
differentiation, IGF-I and the androgen receptor itself. In the instance of 
Picropodophyllin administration, a 150nM dose had a negative effect on muscle 
differentiation. Although low levels of AR protein have previously been observed 
in the literature within the C2C12 muscle cell line (Altuwaijri et al., 2004, Lee, 
2002), inhibiting the AR appeared to have catastrophic effects on morphological 
and transcriptional markers of differentiation and hypertrophy, eluding to the 
importance of a functional AR in myotube formation and hypertrophy in skeletal 
muscle (Mitchell et al., 2013, Sheppard et al., 2011).    
The data presented in this thesis, supports the role for testosterone  in 
enhancing myogenic differentiation and myotube hypertrophy (Lee, 2002, Singh 
et al., 2003, Singh et al., 2009, Sinha-Hikim et al., 2003, Sinha-Hikim et al., 
2006, Wannenes et al., 2008) but more importantly, shows the capacity to 
improve hypertrophy and myonuclear accretion in a previously established model 
displaying impaired differentiation and hypertrophy similar to that of atrophic 
phenotypes such as ageing (Sharples et al., 2011, Sharples et al., 2012). 
Interestingly, testosterone improved hypertrophy (myotube diameter) to the same 
magnitude in both cell types (chapter 5 and 6). Thus, despite PD cells having 
undergone multiple population doublings vs. their controls, and therefore 
Chapter 7: General Discussion  
153 | P a g e  
 
displaying a reduced basal differentiation capacity as previously described in 
Sharples et al. (2011, 2012); testosterone was able to exert similar magnitude 
increases in myotube hypertrophy. 
The mechanisms which regulate testosterone induced hypertrophy were 
investigated within the ageing phenotype (PD model). The role of the androgen 
receptor, IGF-I receptor (chapter 5) and Akt (chapter 6) were addressed as they 
have all be proposed to have a role in mediating testosterone’s anabolic effect 
(Basualto-Alarcón et al., 2013, Serra et al., 2011, White et al., 2012). 
Testosterone significantly up-regulated androgen receptor expression in cells 
displaying an ageing phenotype, even in the presence of the IGF-I receptor being 
inhibited. Thus it appears even in an ageing phenotype, the responsiveness to a 
testosterone stimulus remains and is not IGF-I receptor mediated. Interestingly, 
AR inhibition alone resulted in increases in myostatin levels which may explain 
the lack of myotube formation (Braga et al., 2012, Trendelenburg et al., 2009). 
Additionally testosterone was observed to decrease myostatin levels in the aged 
cells and thus may have contributed to enhancing myotube hypertrophy. Finally, 
the inhibition of Akt (upstream of mTOR pathway) lead to testosterone induced 
myotube hypertrophy being diminished, lending support to role of the Akt/mTOR 
pathway (White et al., 2012). Interestingly, mTOR mRNA expression increased 
even in the presence of LY294002 under a testosterone stimulus and thus 
testosterone may directly activate mTOR signalling directly (discussed in more 
detail below 7.3.1). In light of these mechanistic observations, a proposed figure 
of testosterone’s mechanism of action is detailed below (Fig 7.1):   
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Fig 7.1 Proposed mechanisms for testosterone induced myotube hypertrophy in rescuing an 
ageing phenotype. Testosterone action appears to be mediated via the Akt/mTOR pathway and via 
the androgen receptor which ultimately lead to reduced myostatin levels. Therefore, this signalling 
cascade, triggered by testosterone, provides a net positive balance for myotube hypertrophy to 
occur.   
 
7.2 LIMITATIONS TO THE PRESENT WORK 
In chapter 4, the use of Picropodophyllin to inhibit the IGF-I receptor may not 
have been fully effective as only a 60% and 40% approx. reduction in IGF-I 
downstream (Akt and ERK ½ respectively) signalling was observed. Of course, 
the dose selected for experiments was based on the dose response experiment 
performed where reductions in myotube morphological parameters was observed. 
Indeed, the dose used was higher than doses previously implemented within C2C12 
muscle cells (Deldicque et al., 2007, Galluzzo et al., 2009). Effectively the 
limitation lies within the nature of the inhibitor as it acts as a substrate competitor 
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to compete for binding to the receptor and thus reduced tyrosine kinase activity 
(Duan et al., 2009, Girnita et al., 2004). Thus although a high dose was 
implemented, there may have still been some residual activation of the IGF-I 
receptor.  
In chapter 5, the total protein levels for Akt and p70S6K were only completed 
for n=1. However, between treatments the totals appeared to be effected by each 
treatment. Ideally replicates (n=3) for the proteins would have been produced and 
thus the phosphorylated proteins could have been analysed relative to total levels 
instead of GAPDH, as was performed in the chapter. Furthermore, previous 
studies have addressed testosterone induced signalling after 12 hrs (Basualto-
Alarcón et al., 2013) and 24hrs (White et al., 2012) and thus the time points (72 
hrs and 7 days) in the current thesis may have not captured all the protein 
signalling involved in testosterone induced hypertrophy.  
Finally, the mechanistic work presented in this thesis has been performed 
within cell culture models. The adoption of muscle cells lines vs. primary human 
culture to address cell behaviour may facilitate different responses to androgen 
treatment between primary cultures and cell lines with myoblast proliferation and 
differentiation capacity impacting on variation in mechanisms observed (Serra et 
al., 2011). Even the comparison between muscle cells of the same species is 
difficult with varying androgen-responsiveness in varying muscle itself (De 
Naeyer et al., 2014, Johansen et al., 2007, Kadi et al., 2000). Culture systems are 
commonly monolayer, yet within the body, cell-cell and cell-matrix interactions 
occur within a 3-D environment. The role of the vascular network in skeletal 
muscle is another factor which limits current monolayer and 3D culture. Another 
limit is the lack of various other cell types, such as fibroblasts and motor neurons, 
which may play a role in skeletal muscle androgen-responsiveness (Mosler et al., 
2012, Serra et al., 2011). Overall, the mechanistic work presented provides an 
initial start point for subsequent studies (discussed below).   
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7.3 FUTURE DIRECTIONS 
 
7.3.1 Testosterone as a “kick starter” in muscle hypertrophy 
Recent evidence in vitro has suggested testosterone enhances mTOR 
activation in contributing towards muscle hypertrophy (Basualto-Alarcón et al., 
2013, Wu et al., 2010a) and increases at the mRNA level were observed in 
chapter 6. In the ageing muscle of elderly men, mTOR and its downstream targets 
have been observed to be reduced in activation by -30 to 50% (Cuthbertson et al., 
2005) compared to young counterparts. Furthermore, there is a reduced response 
in muscle contraction-induced mTOR signalling in aged models (Drummond et 
al., 2008, Fry et al., 2011, Parkington et al., 2004). The inhibition of mTOR 
through rapamycin has been observed to inhibit muscle protein synthesis 
(Drummond et al., 2009a). Therefore subsequent future studies may look to 
investigate the interaction between Testosterone and mTOR in the context of 
ageing, as testosterone-induced hypertrophy appears to be dependent on upon 
mTOR activation (Wu et al., 2010a, White et al., 2012).  
In Chapter 6, mTOR expression in CON cells was increased in the 
presence of testosterone plus PI3K inhibitor (LY) (albeit mRNA expression and 
not protein activity), other studies have shown that mTOR activation can occur 
via signals independent of canonical IGF-I/Akt, via a pathway involving 
phospholipase D, phosphatidic acid and a downstream regulator Rheb (ras 
homologue enriched brain) (Anthony et al., 2000a, Anthony et al., 2000b, 
Hornberger et al., 2006, Sun et al., 2010). Redd 2 may also be important in 
inhibiting mTOR via the tuberous sclerosis 1 (TSC1) and 2 (TSC2) complex 
(DeYoung et al., 2008). As mTOR mRNA expression is increased in CON vs. PD 
cells, testosterone increases mTOR expression in CON cells which is blunted in 
PD cells at 7 days, and mTOR transcript expression is still increased with 
testosterone even the presence of PI3K/Akt inhibitor it begs the question as to the 
role of testosterone in regulating phospholipase D, phosphatidic acid, Rheb and 
Redd2 and their subsequent interaction with mTOR. Especially in light of recent 
data where following mechanical overload Redd2 is reduced to enable mTOR to 
initiate p70S6K activity, which is involved in protein synthesis and hypertrophy, a 
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process that is impaired in the elderly (Drummond et al., 2009b) who have 
impaired regenerative capacity.  
Testosterone supplementation has been observed to increase satellite cell 
number in young and elderly individuals (Sinha-Hikim et al., 2003, Sinha-Hikim 
et al., 2006). In aged mice, there were observed increases in satellite cell 
activation (PCNA marker) with testosterone treatment compared to aged match 
controls (Kovacheva et al., 2010). A factor to consider is that the satellite cell 
provides the predominant location for androgen receptor expression (Chen et al., 
2005, Sinha-Hikim et al., 2004). Within type II muscle fibres, satellite cell content 
in elderly individuals has been observed to be reduced (Verdijk et al., 2007) and 
an overall decline in satellite cell number is observed (Sajko et al., 2004, Kadi et 
al., 2004). Indeed, in this thesis, data points towards testosterone induced 
hypertrophy being driving by myoblast fusion (heightened myogenin expression 
similar to human observations (Sinha-Hikim et al., 2006)) via the androgen 
receptor. Thus, as the AR has most recently been correlated as a marker of muscle 
hypertrophy (Mitchell et al., 2013), it seems pertinent that future studies may 
focus more on the role of the AR in the context of ageing and satellite cell 
activation through primary cell culture or clinical human studies.  
 
7.3.2 Hormone based therapies for muscle wasting with age 
Testosterone replacement therapy in males has been observed to increase 
skeletal muscle mass and strength in various clinical populations (e.g. sarcopenia) 
(Bhasin et al., 2005). Despite potential benefits, adverse events (such as 
haemoglobin/hematocrits alterations and prostate cancer where muscle wasting is 
observed) can occur with such treatment (Bhasin et al., 2005). Therefore, 
maximizing the muscle-specific benefits of testosterone administration is highly 
important and such future enhancements will stem from understanding the 
mechanisms of hormonal action in skeletal muscle. Recent literature, including 
work presented in this thesis, suggests the cross talk between the androgen 
receptor and Pi3K/Akt/mTOR cell signalling pathway in mediating effects of 
testosterone (Basualto-Alarcón et al., 2013, White et al., 2012).  
Importantly, testosterone administration is also unfavorable for female 
patients, therefore in post-menopausal females HRT (oestrogen/progesterone) is 
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administered as an alternative. Interestingly, similar to testosterone, HRT has been 
observed to elicit skeletal muscle strength gains and to enhance regeneration in 
humans (Ronkainen et al., 2009, Sipila et al., 2001, Taaffe et al., 2005). However, 
empirical data is sparse and it has only been alluded to that oestrogen specifically 
creates a pro-anabolic skeletal muscle environment (Velders and Diel, 2013), 
where reductions in inflammatory factors such TNF-α and NF-Kβ have been 
observed (Ghisletti et al., 2005). However, mechanistically how both testosterone 
and/or oestrogen/progesterone (HRT) may influence the chronically inflamed 
skeletal muscle niche remains to be elucidated, especially in relation to 
mechanisms of action.(Lach-Trifilieff et al., 2014, Watt et al., 2010)(Lach-
Trifilieff et al., 2014)(Watt et al., 2010)(Bhasin et al., 2006, Bhasin and Jasuja, 
2009, Dalton et al., 2011) 
 
7.4 CONCLUSION 
The work described in this thesis has detailed potential mechanisms towards 
testosterone induced hypertrophy through the utilization of an in vitro cell model 
which mimics an ageing phenotype. These observations provided evidence 
towards the impact testosterone administration can have on preserving muscle 
mass. The positive effect of testosterone on rescuing cells displaying impaired 
regeneration was accompanied by increases in AR protein, myogenin expression 
plus the involvement of Akt/mTOR signaling, independently of the IGF-IR 
appeared to be pivotal in mediating the effects of testosterone. AR inhibition 
alone resulted in interesting results which future studies may look to investigate 
regarding muscle hypertrophy. This thesis provides evidence towards unravelling 
key cellular and molecular mechanisms of testosterone regulation, for which the 
potential to harness the un-refutable power of this hormone in order to implement 
interventions for sarcopenia and muscle wasting diseases is pertinent. 
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9. APPENDIX 
 
9.1 APPENDIX 1 
 
Table 9.1 Raw CT values obtained for Myogenin, AR, IGF-I and myostatin transcripts. These 
data were used to construct Fig 3.5 
 
 Sample Myogenin 
mean CT 
AR mean 
CT 
IGF-I 
mean CT 
Myostatin 
mean CT 
RP2 mean 
CT 
72 hrs DM 21.93 29.71 20.23 26.09 20.19 
 50 nM T 21.01 29.78 20.29 26.16 19.84 
 500 nM T 21.30 29.46 20.14 25.84 19.54 
       
7 days DM 22.47 30.66 20.24 25.01 20.59 
 50 nM T 22.38 31.47 20.91 24.13 21.40 
 500 nM T 22.76 31.59 20.96 25.44 21.40 
  
 
 
 
9.2 APPENDIX 2 
 
Table 9.2 Raw CT values obtained for Myogenin, AR and IGF-I transcripts in CON and PD 
myoblasts treated with and without flutamide (F). These data were used to construct fig 4.3. 
 
 Cell type Treatment Myogenin 
mean CT 
AR mean 
CT 
IGF-I 
mean CT 
RP2 mean 
CT 
72 hrs CON DM 16.39 22.47 17.71 17.11 
  40 μM F 17.24 23.47 18.21 17.09 
 PD DM 18.28 21.32 19.11 16.17 
  40 μM F 21.91 21.85 20.48 16.90 
       
7 days CON DM 16.41 22.85 16.01 16.42 
  40 μM F 17.99 21.70 17.42 16.75 
 PD DM 17.19 19.90 17.66 16.09 
  40 μM F 22.27 22.75 19.15 16.59 
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9.3 APPENDIX 3 
 
Copy of peer reviewed journal article including data from chapter 6 (Deane et al., 
2013). 
 
Title: Impaired Hypertrophy in myoblasts is improved with testosterone administration 
 
Journal: The Journal of Steroid Biochemistry and Molecular Biology 
 
Issue: 138 
 
Pages: 152-161 
 
See Overleaf 
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